¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2024/5/13 ¤U¤È 08:56:10
²Ä 6636 ½g¦^À³
|
¥Í§Þ¤½¥q¬ãµoªº²£«~昰¾aÁ{§É¼Æ¾Úµw¹ê¤O¡A¤£¬O¥Î¤@ª½¹ª§jªº¡AÁ{§É¼Æ¾Ú¬OÄYÂÔ²z©Êªº§e²{¡AÁ{§É¼Æ¾Ú¥s¦n¡AªÑ»ù«o¤£¥s®y¡A¦æ±¡Á`¬O¦bµ´±æ¤¤ ½Ï¥Í¡A¥Ø«e¥u¯à@¤ßµ¥«Ý¥¨¤jÅܧ½ªº¨ÓÁ{¡C
¬ù¿«・¾H´¶¹y¡ã ¤HÌÁ`¬O°Ý§Úþ¸Ì±¡ªp·|Åܦn¡A¥i¬O³o¬OÓ¿ù»~ªº°ÝÃD¡C¥¿½Tªº°ÝÃD¬O¡Gþ¸Ìªº±¡ªp³ÌÁV¿|¡H¥¿½Tªº¶R¤J®É¶¡¬O¦b´dÆ[±¡ºü³ÌÄY«ªº®É¨è¡A¨º¼Ëªº¸Ü¡A¤j³¡¤Àªº°ÝÃD³£¯à¸Ñ¨M¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2024/5/13 ¤U¤È 02:25:06
²Ä 6635 ½g¦^À³
|
§Ú¤ñ¸û´dÆ[¡A
¤½¥q¥u·|§j¡A«o®³¤£¥X¦¨ÁZ¡A ¦pªG¼Æ¾Ú¦n¡A¬°¦óªÑ»ù·|¤@¦A©³¡A «Ü¦h¤jªºªk¤H±µÄò¥X³õ¡A ³sì©lªÑªF·s¥[©Y¥DÅv°òª÷²H°¨¿ü¤]«ùªÑÄò´î¡A
·s¥[©Y¬F©²¤£¤ä«ù·s¥[©Y²£·~¶Ü¡A
´N¬O¦]¬°¤@¦A³Q°ä§Ë¡A ¯T¨Ó¤F¥Î¤Ó¦h¦¸¤F¡AµL®Ä¤F¡A
³oCEO·µû¦n¶Ü¡A¥h±´Å¥«Kª¾¡A
³s¤@ª½¹ª§jªº¤Ñ©R¤j¡A¤]®ø¥¢¤£¨£¤F |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2024/5/12 ¤U¤È 04:10:40
²Ä 6634 ½g¦^À³
|
¸É¥R»P§ó¥¿ TREK-AD ¥D¥´600mg ¥|¶g£¸°w Âùª¼¸ÕÅç ¹êÅç²Õ¡þ¹ï·Ó²Õ 60¤H ¡þ60¤H 1¡þ1
TREK-DX 400mg ¨C¶g£¸°w Âùª¼¸ÕÅç
¹êÅç²Õ¡þ¹ï·Ó²Õ 50¤H ¡þ25¤H 1¡þ2
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2024/5/12 ¤U¤È 03:48:44
²Ä 6633 ½g¦^À³
|
Eblasakimab »P Dupilumab ¦b²§¦ì©Ê¥Ö½§ª¢¥@¬ö¤j¹ï¹ï¨M
eblasakimab¥¼¨Ó·|»PDupilumab¶i¤JÄvª§¡A¾é¸Ñ¹ï¤âªº¼Æ¾ÚÅܦ¨«Ü«¡A参·Ó¤½¥qªñ¤½§i´Á¼Æ¾Ú¡A¦A参¦ÒDupilumab¦b·s^®æÄõÂå¾Ç´Áµoªíªº¤T´ÁÁ{§É¼Æ¶i¦æ¤ñ¸û¡A ¥Ø«e¥X¨Óªº¼Æ¾Ú¦³22¤H¡A ÀHµÛ®É¶¡±À¶i¦¬®×¤H¼Æ ·|¶V¨Ó¶V¦h¡A¨ÖÁʩαÂÅv½Í§P ·|¶V¨Ó¶V¶¶§Q¡A²¦³º¦b¾ÇªÌ±M®a²´¤¤¤£¥²µ¥¨ì¦~©³¥þ³¡¼Æ¾Ú¤½§i´N¯à¹w¦ô¡A§_«h¤S«ç¯à·í¾ÇªÌ±M®a¡A¥t¥~ȱoª`·Nªº¬O¦¬®×EASI¤À¼Æ¤j©óµ¥©ó18¤Àªº¼Æ¾Ú¤ñITT¼Æ¾Ú¨Óªº«G²´¡A·íTREK-DX¦¬®×¼Ð·Ç´£°ª¨ìEASI¤À¼Æ¤j©óµ¥©ó18¤À¡A¥¼¨Ó¤½§iªº¼Æ¾ÚªÖ©w·|¤ñITT¼Æ¾Ú¨Óªº§ó«G²´¡A·íTREK-DX Àø®Ä¶V¦n¡A¨ÖÁʤè¹ïTREK-AD ªº¤T´ÁÁ{§É¦¨¥\¾÷²v´N¶V¦³«H¤ß¡A¨ÖÁʩαÂÅv»ù½X´N·|©Ô°ª¡A³o¬O£¸³s¦êªº¤¬°ÊÃö«Y¡C
°t¦XTREK-AD ¨C¤ë£¸°wªº¤è«K©Ê»P¦w¥þ©Ê¡Aªº½TTREK-AD»PTREK-DX 昰¥Û¤¤ÂÃ¥É
TREK-AD 400mg ¨C¶g£¸°w ¹êÅç²Õ¡þ¹ï·Ó²Õ 2 ¡þ1
¥H¤U¥HSOLO1 ¨â¶g¤@°w¬°¨Ò¡ASOLO1¼Æ¾Ú ¤ñSOLO2¦n£¸¨Ç¡A «n¼Æ¾Ú¦p¤U Dupilumab¤T´ÁÁ{§É ³]p Primary End Point vIGA 0 ©Î1 Key Secondary End Point EASI- 75
Dupilumab SOLO1¬ã¨s
Dupilumab ¨â¶g¤@°w¨ì²Ä16¶g ¹F¨ì vIGA score 0 or 1
¹ï·Ó²Õ 23¡þ224¤H 10% ¹êÅç²Õ 85¡þ224 38¢H
eblasakimab ITT¨ì²Ä16¶g ¹F¨ì vIGA 0 ©Î1
¹êÅç²Õ 66.7% 10¡þ15
¹ï·Ó²Õ 14.3% 1¡þ7
eblasakimab ¨ì²Ä16¶g EASI¤j©óµ¥©ó18¤À¹F¨ì vIGA 0 ©Î1
¹êÅç²Õ 75% 9¡þ12
¹ï·Ó²Õ o % o ¡þ3
Dupilumab ¨â¶g¤@°w¨ì¨ì²Ä16¶g ¹F¨ìEASI-75
¹êÅç²Õ115¡þ224 51¢H ¹ï·Ó²Õ 33¡þ224 15%
eblasakimab ITT ¨ì²Ä16¶g ¹F¨ì EASI-75
¹êÅç²Õ 73.3% 11¡þ15
¹ï·Ó²Õ14.3% 1¡þ7
eblasakimab ¤j©óµ¥©ó18¤À ¨ì²Ä16¶g ¹F¨ì EASI-75
¹êÅç²Õ 83.3% 12¡þ15
¹ï·Ó²Õ o % o ¡þ7
Dupilumab¨â¶g¤@°w¨ì²Ä16¶g ¹F¨ìEASI-90
¹ï·Ó²Õ 17¡þ224 8¢H ¹êÅç²Õ80¡þ224 36¢H
eblasakimab ITT ¨ì²Ä16¶g ¹F¨ì EASI-90
¹êÅç²Õ 60% 9¡þ15
¹ï·Ó²Õ14.3% 1¡þ7
eblasakimab EASI¤À¼Æ ¤j©óµ¥©ó18¤À ¨ì²Ä16¶g¹F¨ìEASI -90
¹êÅç²Õ 66.7% 8¡þ12
¹ï·Ó²Õ o % o ¡þ3
Dupilumab¨â¶g¤@°w¨ì²Ä16¶g ¹F¨ì IPP-NRS
¹êÅç²Õ - °§C51% ¹ï·Ó²Õ - °§C26%
Dupilumab¤j©óµ¥©ó 4 point improvement in PP-NRS
¹êÅç²Õ 87¡þ 213 41%
¹ï·Ó²Õ 26¡þ212 12 %
eblasakimab ITT¨C¶g¤@°w¨ì²Ä16¶g IPP-NRS°§C
¹êÅç²Õ - °§C53.8% 7¡þ13
¹ï·Ó²Õ - °§C14.3% 1¡þ7
eblasakimab EASI¤À¼Æ ¤j©óµ¥©ó18¤À ¨ì²Ä16¶gPP-NRS°§C
¹êÅç²Õ -°§C 60% 6¡þ 10
¹ï·Ó²Õ °§C0 % 0¡þ3
¥H¤WºÉ¤ß¾ã²z¤À¨É¡A¦pªG¦³¿ù½Ð§ó¥¿ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2024/5/10 ¤U¤È 10:29:38
²Ä 6632 ½g¦^À³
|
¬õ¹Ð¤j ¥´¦r¥´¨ì²´ªá¡Aeblasakimab TRED-DX¥Ø«e¼Æ¾Úªº½T·|µ¹Regeneron pharmaceuticals ±a¨Ó·¥¤jÀ£¤O¡A¦]¬°¨Ì¾Ú¤½¥q¤ÀªRdupilumab¡A¥i¥Hªø´ÁÀò±oº¡·NªºÀø®Ä¬ù¤G¦¨¡A³o¤K¦¨ªº¥«³õ¤]°÷¤j¤F¡A³o¤£¬O¦Y³½§À³½°©ÀY¡A昰¦Y£¸±ø³½ ªº¤K¦¨¤j¥÷ÃB¡A¤j®a¤£n¦Û§Ú³] |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2024/5/10 ¤U¤È 10:02:41
²Ä 6631 ½g¦^À³
|
¸É¥R¿òº| ITT vIGA 0 ©Î1 ¹êÅç²Õ 66.7% 10¡þ15 ¹ï·Ó²Õ 14.3% 1¡þ7 EASI ¤j©óµ¥©ó18¤À vIGA 0 ©Î1
¹êÅç²Õ 75% 9¡þ12 ¹ï·Ó²Õ o % o ¡þ3 |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2024/5/10 ¤U¤È 09:42:57
²Ä 6630 ½g¦^À³
|
eblasakimab TREK-DX ¬ã¨s ¤¤ë¥÷²³ø¤w¸g¥ý§iª¾¼Æ¾Ú¤F¡A¥i¥H参¾\¡A
eblasakimab TREK-DX ¬ã¨s¤¤ 22 ¦W±wªÌªº¶§©Ê¤¤´Á¼Æ¾ÚÅã¥Ü¡A»P¥ý«eªº¥Íª«»s¾¯²§¦ì©Ê¥Ö½§ª¢ (AD) ¬ã¨s¬Û¤ñ¡AÅã¥Ü¤F«e©Ò¥¼¦³ªºÀø®Ä¼Æ¾Ú¡G¨C¶g±µ¨ü 400mg eblasakimabªvÀøªºdupilumab¸g¾ú¹LªºAD±wªÌ¤¤¡A ITT EASI-75 ¹êÅç²Õ 73.3% 11¡þ15 ¹ï·Ó²Õ14.3% 1¡þ7
EASI ¤j©óµ¥©ó18¤À EASI-75 ¹êÅç²Õ 83.3% 12¡þ15 ¹ï·Ó²Õ o % o ¡þ7
ITT EASI-90 ¹êÅç²Õ 60% 9¡þ15 ¹ï·Ó²Õ14.3% 1¡þ7
EASI ¤j©óµ¥©ó18¤À EASI-90 ¹êÅç²Õ 66.7% 8¡þ12 ¹ï·Ó²Õ o % o ¡þ3
ITT EASI-100 ¹êÅç²Õ 20% 3¡þ15 ¹ï·Ó²Õ 0% 0¡þ7
EASI ¤j©óµ¥©ó18¤À EASI-100 ¹êÅç²Õ 25% 4¡þ15 ¹ï·Ó²Õ o % o ¡þ7
ITT PP-NRS ¹êÅç²Õ - 58.9% ¹ï·Ó²Õ- 14.3%
EASI ¤j©óµ¥©ó18¤À PP NRS ¹êÅç²Õ - 61.2% ¹ï·Ó²Õ +1.5 %
ITT 4 point improvement in PP-NRS ¹êÅç²Õ - 53.8% ¹ï·Ó²Õ -14.3%
EASI ¤j©óµ¥©ó18¤À 4 point improvement in PP NRS ¹êÅç²Õ - 60% ¹ï·Ó²Õ - 0%
³oÓ¹êÅç昰¥H¨Ï¥Î¹LDupilumab ¤ÏÀ³¤£¨¬¡A©Î°Æ§@¥Î¤Ó¤j¡A©Î¸gÀÙ¦Ò¶q¡A¦A¨Ï¥Î¨C¶g±µ¨ü 400mg eblasakimabªvÀøªºdupilumab¸g¾ú¹Lªº¯f±w¡Aªñ´Á¼Æ¾Ú£¸¦A½·s¡Aªº½T¥O¤HÅå³Y¡A¬Û«H·|¹ïDupklumab±a¨ÓÀ£¤O¡C ¦p§Ú©Ò¹w´Á£¸¼Ë¤½¥q·|¤T¤£¤®É¤½§i³Ì·s¼Æ¾Ú¡C
¥H¤W¤À¨É ¶È¨Ñ参¦Ò
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GROGER588910148151 |
µoªí®É¶¡:2024/5/10 ¤U¤È 07:38:58
²Ä 6629 ½g¦^À³
|
¹ï©óDupilumabªvÀø¥¢±ÑªºAD±wªÌ¸Ó¿ï¾ÜBaricitinibÁÙ¬Oeblasakimab ?
¥i¥H¾î¦V¹ï¤ñÀu¦H©Ê: 2022.9.29- Baricitinib(JAK§í¨î)ªvÀø¹ï dupilumab ªvÀø¤ÏÀ³¤£¨¬ªº²§¦ì©Ê¥Ö½§ª¢±wªÌ¡Gº¦¸¨C¤é¹ê½îµ²ªGonlinelibrary.wiley.com/doi/full/10.1002/jvc2.64 |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¬õ¹Ð¦³¹Ú10150039 |
µoªí®É¶¡:2024/5/10 ¤U¤È 01:58:57
²Ä 6628 ½g¦^À³
|
ASLAN Pharmaceuticals ¤½§G 2024 ¦~²Ä¤@©u°]°È·~ÁZ¨Ã´£¨Ñ¤½¥q³Ì·s°ÊºA 2024 ¦~ 5 ¤ë 9 ¤é¤W¤È 7:00 ¬ü°êªF³¡®É¶¡
eblasakimab TREK-DX ¬ã¨s¤¤ 22 ¦W±wªÌªº¶§©Ê¤¤´Á¼Æ¾ÚÅã¥Ü¡A»P¥ý«eªº¥Íª«»s¾¯²§¦ì©Ê¥Ö½§ª¢ (AD) ¬ã¨s¬Û¤ñ¡AÅã¥Ü¤F«e©Ò¥¼¦³ªºÀø®Ä¼Æ¾Ú¡G¨C¶g±µ¨ü 400mg eblasakimabªvÀøªºdupilumab¸g¾ú¹LªºAD±wªÌ¤¤¡A60.0%¹F¨ì¤F EASI-90¡]¦Ü¤Ö16 ¶g«á¡AÀã¯l±¿nÄY«µ{«×«ü¼Æ(EASI) µû¤À°§C¤F90%¡A66.7% ªºvIGA µû¤À¹F¨ì0 ©Î1¡]¥Ö½§³z©ú©Î´X¥G³z©ú¡^¡A¦Ó¦w¼¢¾¯²Õ±wªÌ¦¹¤ñ¨Ò¬°14.3%¡C
¥xÁ޽Фj¥i§_¤ÀªR¼Æ¾Ú |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2024/5/3 ¤W¤È 10:06:00
²Ä 6627 ½g¦^À³
|
ASLAN ªº Æ[°·®É¨è
ASLAN ±NÀò±o1200 ¸U¬ü¤¸ªº¹w¥I´Ú¡A¨Ã¦b¹F¨ìTREK-AD 2b ´Á¸ÕÅç¼Æ¾ÚŪ¥X©MÁ{§É¬ã¨s³ø§i ¥æ¥Iªº¬Y¨Ç¹w¥ý°Ó©w±ø¥ó«á¡A¦³¸ê®æ±qZenyaku Àò±oÃB¥~ªº300 ¸U¬ü¤¸¡A³Ì°ª¥i¹F2950¸U¬ü¤¸ ¶}µo¨½µ{¸O©M°ª¹F 9,400 ¸U¬ü¤¸ªº°Ó·~¨½µ{¸O¡C Zenyaku ±N®Ú¾Úeblasakimabªº²b¾P°âÃB ¦V ASLAN ¤ä¥I¨â¦ì¼Æªº¯S³\Åv¨Ï¥Î¶O( Roalty)¡A¦Ê¤À¤ñ³Ì°ª¥i¹F 20%¡C®Ú¾Ú³\¥i¨óijªº±ø´Ú¡A Zenyaku ±Nt³deblasakimab¦b¤é¥»ªº©Ò¦³¶}µo©M°Ó·~¤Æ¬¡°Ê¡C Zenyakup¹º©ó2024¦~¤W¥b¦~ ¦b¤é¥»±Ò°Êeblasakimabªº¤@´Á¬ã¨s¡C ( ¤é¥»ÃÄ«~¥«³õ¦û¤ñ¦Ê¤À¤§5 ¬ü¼Ú¤¤¦û¤ñ³Ì°ª )
¨Ì¾Ú¤W¤å Ó¤Hµû½× : ÁÙ¥¼°Ó·~¤Æ 9,400 ¸U¬ü¤¸ªº°Ó·~¨½µ{¸O¡C Zenyaku ±N®Ú¾Úeblasakimabªº²b¾P°âÃB ¦V ASLAN ¤ä¥I¨â¦ì¼Æªº¯S³\Åv¨Ï¥Î¶O( Roalty)¡A¦Ê¤À¤ñ³Ì°ª¥i¹F 20% ³oÓ³¡¤À¥Ø«eÁÙ®³§G¤£¨ì
1 Zenyakup¹º©ó2024¦~¤W¥b¦~¦b¤é¥»±Ò°Êeblasakimabªº¤@´Á¬ã¨s 2 ¦b¹F¨ìTREK-AD 2b ´Á¸ÕÅç¼Æ¾ÚŪ¥X©MÁ{§É¬ã¨s³ø§i¥æ¥Iªº¬Y¨Ç¹w¥ý°Ó©w±ø¥ó«á¡A ¦³¸ê®æ±qZenyaku Àò±oÃB¥~ªº300 ¸U¬ü¤¸¡A³Ì°ª¥i¹F2950¸U¬ü¤¸¶}µo¨½µ{¸O 3 TREK-AD 2b±Ò°Ê¤T´ÁÁ{§É®É ¦³¾÷·|®³¨ìÃB¥~ªº300 ¸U¬ü¤¸»P2950¸U¬ü¤¸¶}µo¨½µ{¸O¤¤ªº³¡¥÷¸êª÷
4 ¦X²z±À½×n®³¨ì¶}µo¨½µ{¸O¤¤ªº³¡¥÷¸êª÷¤½¥q¥²»Ý¦b6¤ë3¤é«e±Ò°Ê¤T´ÁÁ{§É
5 ¤]¦³¥i¯à¦pªoºj©Ò¨¥:¦pªG¯uªº¯à©µ´Á¡A¥NªíASLNµ¹¤FNasdaq¥i¦æ©Ê«Ü°ªªºp¹º (©µ´Á180¤Ñ)
6 ¥i¦æ©Ê«Ü°ªªºp¹º·|¬O»PZenyakuªº¥ý«e¬ù©w, ªñ´Á¦A¬ù©w ©Î¬O¥t¦³¦X§@¹ï¶H ???
¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò
§¹¾ãª© ASLAN Pharmaceuticals »P Zenyaku Kogyo µ¦²¤©Ê±ÂÅv¨óij:
ASLAN Pharmaceuticals »P Zenyaku Kogyo ´N Eblasakimab ¦b¤é¥»ªº¶}µo©M°Ó·~¤Æ ¹F¦¨µ¦²¤©Ê±ÂÅv¨óij 2023 ¦~ 6 ¤ë 22 ¤é
ASLAN ±NÀò±o°ª¹F 1500 ¸U¬ü¤¸ªº¹w¥I´Ú©Mªñ´Á¥I´Ú¡A¥H¤Î°ò©ó¶}µo©M°Ó·~¨½µ{¸OªºÃB¥~ °ª¹F 1.235 »õ¬ü¤¸ªºÃB¥~¸êª÷¡A¥H¤Î³Ì°ª 20% ªº¤À¼h¾P°â¯S³\Åv¨Ï¥Î¶O( Roalty)
¤é¥»»â¥ýªº¥Ö½§¯f¾Ç©M¸~½F¾Ç»sÃĤ½¥q Zenyaku Kogyo p¹º©ó 2024 ¦~¤W¥b¦~¦b¤é¥»±Ò°Ê eblasakimabªº 1 ´Á¬ã¨sASLAN°w¹ï¤¤««× AD ±wªÌ¶i¦æªºeblasakimab¥þ²y TREK-AD 2b ´Á ¬ã¨sªº¥Dn¼Æ¾Ú¹wp±N©ó 2023 ¦~ 7 ¤ëªìµo¥¬
¥[¦{¸t°¨¤N¡B·s¥[©Y©MªF¨Ê¡A2023 ¦~6 ¤ë22 ¤é¡]Àô²y³q°TªÀ¡^¡XASLAN Pharmaceuticals ¡]¡§ASLAN¡¨¡A¯Ç´µ¹F§JªÑ²¼¥N½X¡GASLN¡^¬O¤@®aÁ{§É¶¥¬q¡B±Mª`©ó§K¬Ì¾Çªº¥Íª«»sÃĤ½¥q¡A P¤O©ó¶}µo³Ð·sÀøªk¨Ó§ïÅܤH̪º¥Í¬¡±wªÌ©M¤é¥»»â¥ý»sÃĤ½¥qZenyaku Kogyo Co., Ltd. ¡]¡§Zenyaku¡¨¡^¡]¨p¤H±±ªÑZenyaku Holdings Co., Ltd.¡]¡§Zenyaku Holdings¡¨¡^ªº¤l¤½¥q¡^ ¤µ¤Ñ«Å¥¬Ã±¸p¾Ô²¤³\¥i¨óij¡A±Â¤©Zenyaku ¿W®aÅv§Q¦b¤é¥»²§¦ì©Ê¥Ö½§ª¢¡]AD¡^©M©Ò¦³¨ä¥L¾AÀ³¯gªºeblasakimab ¡C
ASLAN ±NÀò±o1200 ¸U¬ü¤¸ªº¹w¥I´Ú¡A¨Ã¦b¹F¨ìTREK-AD 2b ´Á¸ÕÅç¼Æ¾ÚŪ¥X©MÁ{§É¬ã¨s³ø§i ¥æ¥Iªº¬Y¨Ç¹w¥ý°Ó©w±ø¥ó«á¡A¦³¸ê®æ±qZenyaku Àò±oÃB¥~ªº300 ¸U¬ü¤¸¡A³Ì°ª¥i¹F2950¸U¬ü¤¸ ¶}µo¨½µ{¸O©M°ª¹F 9,400 ¸U¬ü¤¸ªº°Ó·~¨½µ{¸O¡C Zenyaku ±N®Ú¾Úeblasakimabªº²b¾P°âÃB ¦V ASLAN ¤ä¥I¨â¦ì¼Æªº¯S³\Åv¨Ï¥Î¶O¡A¦Ê¤À¤ñ³Ì°ª¥i¹F 20%¡C®Ú¾Ú³\¥i¨óijªº±ø´Ú¡AZenyaku ±Nt³deblasakimab¦b¤é¥»ªº©Ò¦³¶}µo©M°Ó·~¤Æ¬¡°Ê¡C Zenyakup¹º©ó2024¦~¤W¥b¦~¦b¤é¥»±Ò°Ê eblasakimabªº¤@´Á¬ã¨s¡C
Zenyaku ¦b¤é¥»¥Ö½§¯f¾Ç©M§K¬Ì¾Ç¾AÀ³¯g¤è±¾Ö¦³Â×´Iªº²£«~¶}µo¡BºÊºÞ©M¦æ¾P±M·~ª¾ÃÑ¡C §@¬°¥þ²y»â¥ý»sÃĤ½¥qªºªø´Á¦X§@¹Ù¦ñ¡AZenyaku¦b¤é¥»¥«³õ¾P°â Rituxan ®¡]§Q§´©õ³æ§Ü¡^¡A ¨Ã¦b¤é¥»¶i¦æ©Ò¦³Á{§É¶}µo¡C Zenyaku ¤w¦¨¥\Àò±o¤é¥»ºÊºÞ¾÷ºc§åã Rituxan ®ªº¥t¥~ 11 ºØ¾AÀ³¯g¡A¥]¬A¦hºØ¸~½F¾Ç©M¥Ö½§¯f¾Ç¾AÀ³¯g¡A¨ä¤¤ 7 ºØ¬O¤é¥»¥«³õ¿W¦³ªº¡C
¡u§ÚÌ«D±`°ª¿³»P Zenyaku ¦X§@¡AZenyaku ¬O¤@®a»â¥ýªº¤é¥»»sÃĤ½¥q¡A¾Ö¦³¨ô¶VªºÁ{§É©M¥Í©R¶g´Á ºÞ²z±M·~ª¾ÃÑ¡C Zenyaku ¦b¶}µo·s«¬¥Íª«»s¾¯¡BÀò±oºÊºÞ³¡ªù§åã¥H¤Î¦b¤é¥»¦¨¥\°Ó·~¤Æ¥Ö½§¯fÀøªk ¤è±«Ø¥ß¤F¦¨¥\ªº°O¿ý¡A¡vASLAN Pharmaceuticals º®u°õ¦æ©x Carl Firth ³Õ¤h»¡¡C¡u¦b¤é¥»¡AAD ªºt¾á«Ü«¡A¦Ó¥BÁÙ¦b¤£Â_¼W¥[¡X¡X¦³ 500 ¸U¤H±w¦³³oºØ¯e¯f1¡AÁÙ¦³¼Æ¦Ê¸U¤H±w¦³¨ä¥L 2 «¬¯e¯f¡C ÀHµÛ§Ú̦b¥þ²y½d³ò¤º±µªñeblasakimabªº«á´Á¶}µo¡A¹ï§Ų́ӻ¡¡A§ä¨ì¹³ Zenyaku ³o¼Ëªº¦X§@¹Ù¦ñ «D±`«n¡A¥LÌ¥i¥H§Q¥Î¨ä¸gÅç¨Ó¥[³teblasakimab¦b¤é¥»ªº¶}µo¡C
Zenyaku Kogyo Á`µôÝ°õ¦æªø¾ô¥»¯E¤@ (Koichi Hashimoto)ªí¥Ü¡G ¡uÀHµÛ¤é¥»¤¤«×¦Ü««×AD ªº¥Í¬¡t¾á«ùÄò¥[«¡AÂå¥Í©M±wªÌ¹ï§ó¨ã³Ð·s¡B¦³®Ä©M«K§QªºªvÀø¤èªkªº»Ý¨D¤£Â_¼W¥[¡C ¡¨ ¡C ¡u§ÚÌ«Ü°ª¿³»P ASLAN ¦X§@¡AÂX¤j§Ú̪º¥Ö½§¬ì²£«~²Õ¦X¡Aeblasakimab¿W¯Sªº§@¥Î¾÷¨î¥H¤Î¦w¥þ¡B ¦³®Ä©M¤è«K¦aªvÀø¤¤«×¦Ü««× AD ªº¼ç¤O¡A¥Nªí¤F§Ú̪º«n©M¾Ô²¤©Ê¸É¥R¡CºÞ¹D¡C°ò©ó¨´¤µ¬°¤î ²£¥Íªº¿n·¥¼Æ¾Ú¡A§Ú̬۫Heblasakimab¦³¼ç¤O¦¨¬°¤é¥»¤@¬yªº AD ®t²§¤ÆÀøªk¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2024/5/2 ¤U¤È 11:32:43
²Ä 6626 ½g¦^À³
|
¥h¦~¤»¤ë ASLAN Pharmaceuticals »P Zenyaku Kogyo ´N Eblasakimab ¦b¤é¥»ªº¶}µo©M°Ó·~¤Æ¹F¦¨µ¦²¤©Ê±ÂÅv¨óij
±ø¥ó¦p¤U
ASLAN ±NÀò±o°ª¹F 1500 ¸U¬ü¤¸ªº¹w¥I´Ú©Mªñ´Á¥I´Ú¡A¥H¤Î°ò©ó¶}µo©M°Ó·~¨½µ{¸OªºÃB¥~°ª¹F 1.235 »õ¬ü¤¸ªºÃB¥~¸êª÷¡A¥H¤Î³Ì°ª 20% ªº¤À¼h¾P°â¯S³\Åv¨Ï¥Î¶O
¤é¥»»â¥ýªº¥Ö½§¯f¾Ç©M¸~½F¾Ç»sÃĤ½¥q Zenyaku Kogyo p¹º©ó 2024 ¦~¤W¥b¦~¦b¤é¥»±Ò°Êeblasakimabªº 1 ´Á¬ã¨s
µû½× ¤é¥»³o®a¤½¥q·|ÂX¤j¦X§@®×¡A À³¸Ó¬O¹ïÁ{§É¼Æ¾Úº¡·N¤~·|¦A¥X¸êÂX¤j¬ã¨s¦X§@¡A¨Ãû£°Ê£¸´ÁÁ{§É¡A«á±ÁÙ¦³1.235»õ¬ü¤¸ªº¶}µo»P°Ó·~®Èµ{ª÷nµ¹¤½¥q¡A¦b¤é¥»¾P°âÃB¦Ê¤À¤§20ªº Roalty nµ¹¤½¥q¡A¤»¤ë¤T¤é«e¦p¯à¨ú±oÃB¥~¸êª÷¡A¤½¥q¦M¾÷´N¸Ñ°£¡C
¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2024/5/2 ¤U¤È 10:24:12
²Ä 6625 ½g¦^À³
|
2023 ¦~ 6 ¤ë»P¤é¥»Zenyaku ¶}µo©M°Ó·~¤Æeblasakimabªº°Ó·~¨óij±NÂX¤j¦X§@ ( ³o¶µ¦X§@±N¥Ñ Zenyaku ¥X¸ê)
ASLAN Pharmaceuticals «Å¥¬ÂX¤j»P Zenyaku ªº¦X§@( ¤é¥»)¡A¥H¬ã¨s Eblasakimab »P ¨ä¥L¥Íª«»s¾¯¬Û¤ñ¸ûI«áªº¥Íª«¾Ç®t²§®ÄÀ³
·sªº¬ã¨s¦X§@±N±´¯Áeblasakimab ªº§@¥Î¾÷¨î»P°w¹ï²§¦ì©Ê¥Ö½§ª¢ (AD)¡Bdupilumab©Mlebrikizumab ªº¥Íª«Àøªk¤§¶¡ªº®t²§¡C
³o¨Çµo²{±N¥[²`¹ï³Ìªñµo²{ªº¥Íª«¾Ç°ò¦ªº²z¸Ñ¡A§Y¤@¨Ç AD ±wªÌ§Y¨Ï¹ï dupilumab ¤ÏÀ³¤£¨¬¡A ¤]¥i¯à¹ïeblasakimab²£¥Í¤ÏÀ³¡C
¦X§@ªº²Ä¤@³¡¤À±N«ÂI©ñ¦b¨üÅé¥Íª«¾Ç©M°Ê¤O¾Ç¡A¥H¬ã¨seblasakimab¤À¤Æ¼ç¤Oªº²ÓM©M¤À¤l°ò¦¡C ³o¶µ¤u§@±N¥Ñ Zenyaku ¸ê§U¡C
¥[¦{¸t°¨¤N©M·s¥[©Y¡A2024 ¦~5 ¤ë2 ¤é¡]Àô²y³q°TªÀ¡^- ASLAN Pharmaceuticals ¡]¯Ç´µ¹F§J¥N½X¡GASLN¡^¬O¤@®aÁ{§É¶¥¬q¡B±Mª`©ó§K¬Ì¾Çªº¥Íª«»sÃĤ½¥q¡AP¤O©ó¶}µo ³Ð·sÀøªk¨Ó§ïÅܱwªÌªº¥Í¬¡¡A¤µ¤Ñ«Å¥¬¥¦»P¨ä¦X§@¹Ù¦ñ Zenyaku Kogyo Co., Ltd. (Zenyaku) ñ¸p¤F¤@¶µ·sªº¬ã¨s¦X§@¨óij¡A¬°¤@¨t¦C¬ã¨s¶µ¥Ø«Ø¥ß®Ø¬[¡A·sªº¬ã¨s¦X§@±N±´¯Áeblasakimab ªº§@¥Î¾÷¨î»P°w¹ï²§¦ì©Ê¥Ö½§ª¢ (AD)¡Bdupilumab©Mlebrikizumab ªº¥Íª«Àøªk¤§¶¡ªº®t²§
¦b¥ý«eµoªíªº AD ±wªÌ§K¬Ì²ÓM©M¥Ö½§¬¡À˪ºÂà¤Æ¼Æ¾Ú1¤¤¡A¥ÎeblasakimabªýÂ_ IL-13 ¨üÅé (IL-13R)¦ü¥G¤ñªýÂ_IL-4 ¨üÅé(IL-4R) §ó¯à¦³®Ä¤U½Õµoª¢¼Ð°O¡C®Ú¾Ú·sªº¬ã¨s¦X§@¡A ASLAN©MZenyaku±N¶i¦æ¦X§@¬ã¨s¡A±´¯ÁIL-13©MIL-4¨üÅ骺¥Íª«¾Ç¡A¥]¬A¥Íª«»s¾¯ eblasakimab¡Bdupilumab©Mlebrikizumab¹ï¨CÓ¨üÅé¨È°òªº¼vÅT¡C
³o¶µ¬ã¨s¦X§@ªºµ²ªG±N¶i¤@¨B²`¤J¤F¸Ñ¹v¦V IL-13R »P IL-4R ªº®t²§¤Æ¨üÅé¥Íª«¾Ç¡C ³o¨Ç¬ã¨sÁÙ¥i¥H¸ÑÄÀ¦´ÁÁ{§É¬ã¨s¤¤¦beblasakimabªvÀø´Áµ²§ô«áÆ[¹î¨ìªº¯e¯fÄY« µ{«×¥Íª«¼Ð°O¡]¨Ò¦p TARC¡^ªºªø´Á§í¨î¡C³o¶µ·s¨óijÂX®i¤F ASLAN »P Zenyaku ©ó 2023 ¦~ 6 ¤ëñ¸pªºÃö©ó¦b¤é¥»¶}µo©M°Ó·~¤Æeblasakimabªº°Ó·~¨óij¡C
¡uEblasakimab¥i¯à¦¨¬°ªvÀø¶V¨Ó¶V¦h AD ±wªÌªº«n·sÀøªk¡A§ÚÌ«Ü°ª¿³ÂX¤j »P ASLAN ªº¦X§@¡A³z¹L§Q¥Î§Ú̪º¦yºÝ¬ã¨s³]¬I¡A¶i¤@¨B¤F¸ÑEblasakimab»P ¨ä¥L¥Íª«»s¾¯ªº°Ï§OI«áªº¬ì¾Çì²z¡C°ò©ó ASLAN ¨´¤µ¬°¤î²£¥Íªº±j¦³¤OªºÂà¤Æ ©MÁ{§É¼Æ¾Ú¡A§Ú̬۫Heblasakimab¨ã¦³¿W¯Sªº§@¥Î¾÷¨î¡A¥i¥H¬°±wªÌ´£¨Ñ¦w¥þ¡B ¦³®Ä©M¤è«Kªº AD ªvÀø·s¿ï¾Ü
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2024/4/27 ¤W¤È 11:43:00
²Ä 6624 ½g¦^À³
|
³o¤½¥q©{¦p¶BÄF¶°¹Î¡A
¥Xªº³ø§i½Ö«H¡A ¨S±Ï¤F¡A ªü¤TCEO¡A ·Ç³Æ¤U¥« |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gªoºj·Æ±¼10153108 |
µoªí®É¶¡:2024/4/27 ¤W¤È 09:20:47
²Ä 6623 ½g¦^À³
|
1.¥Ø«e¹ïASLN¨Ó»¡¡A³Ì«æ¢ªº¨Æ±¡¬O²bȤ£¨¬¡AªÑ²¼¦XªÑ¥u¯à´£¤ÉªÑ»ù¨ÃµLªk´£¤É²bÈ¡A©Ò¥H¥u¦³¨ú±o¸êª÷¤~¯à¸Ñ¨M²bÈ°ÝÃD¡C 2.³o¦¸trek-dx¤½§iªº¼Æ¾Ú¤w¬O¸Ñª¼«áªº¤F¡A¼Æ¾Ú¬Ý¦ü¤£¿ù¡A¦ý¥«³õ©l²×µLªk¤ÏÀ³¡A¦bªÃ«ù¥«³õ¬O¹ïªº±¡§Î¤U¡A¬Ý¨ÓÀ³¸Ó¬O¦³¤°»òt±¸ê°T¬O¤@¯ë¤HµLªkª`·N¨ìªº¡A¤£µM¥«³õ¤W³o»ò¦h±M·~§ë¸ê¤H«ç»ò·|¿ù¹LASLN ¡AªÑ»ù§C°g¤]¤£¬O¤@¤G¤Ñ¤F¡A¦Ü©óÀ£§C»ù®æ¦Y³fªº»¡ªk¡A°ò¥»¤W§¹¥þ¬Ý¤£¨ìÃÒ¾Ú¡A¨ì²{¦b³£ÁÙ¨S¦³«ùªÑ¶W¹L10%ªºªÑªF¥X²{¡A»ù®æ¤£¨ì0.5Ãø¹DÁÙÀ£ªº¤£°÷§C¡H 3.²z½×¤W²bȧﵽp¹ºÀ³¸Ó¬On¥i¦æ©Ê«Ü°ª¤~·|³QNasdaq±µ¨ü¡A¦ý¥H¥Ø«eª¬ªp¬Ý¤£¨ìASLN¨ã¦³¥ô¦óÄw¸ê¯à¤O¡A¦pªG¯uªº¯à©µ´Á¡A¥NªíASLNµ¹¤FNasdaq¥i¦æ©Ê«Ü°ªªºp¹º¡AÁ`¤§0603¨M©w¤FASLNªº¥Í¦º¡A¿N¤F³o»ò¦h¿ú´«¨Óe©µ´Ý³Ý¡A¥O¤H¤£³Ó®D¼N..... |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2024/4/23 ¤W¤È 10:23:29
²Ä 6622 ½g¦^À³
|
¦p©ú¤Ñ¤j©Ò»¡¡A³o¯uªº¬O³ÌµL¨}¾Þ§@ªü! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©ú¤Ñ¹L«á10151242 |
µoªí®É¶¡:2024/4/23 ¤W¤È 09:50:08
²Ä 6621 ½g¦^À³
|
¬Ý°_¨ÓÁÙ¨S¸Ñª¼´N¥²¶·¤U¥«¡A°£«DÄ~Äò¤À©îªÑ²¼¡A¦A¨ÓÓ6¦X1¡AªÑ»ù¤S·|¤W¤É¨ì2¶ô¦h¡AÄ~Äò¼µ¤U¥h¡AµM«á¦A¨ÓÓ¼W¸ê¼W¥[ªÑ¥»¡A¤S¥i¥HÄFÓ¤@¦~Åo |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2024/4/22 ¤U¤È 10:07:39
²Ä 6620 ½g¦^À³
|
ªGµM¤S¤½§i·s¼Æ¾Ú¡A¤ñ¤T¤ë¤½§iªº§ó¸Ô²Ó ¦]¬°¤H¼Æ¤Ö¼vÅTpÈ¡A³oÓµL¶Ë¤j¶®¡A ±M®a¬Ý¤F¤ß¤¤¦Û¦³©w¨£¡A¤j®a¥i¥H¤ñ¹ï£¸¤U¡A ¤µ¤Ñ¤½§i¼Æ¾ÚĶ¤å¦p¤U¡A¦³¿ù¦Û¦æ×¥¿¡C
ªº²×ÂI¡^¡C 66.7% (10/15) ªºeblasakimabªvÀø±wªÌªº vIGA µû¤À¬° 0 ©Î 1¡A¦Ó¦w¼¢¾¯²Õ¬° 14.3% (1/7) (p=0.0750)¡C ±µ¨üeblasakimabªvÀøªº±wªÌ®pÈ·kÄo¼Æ¦rµû¦ô¶qªí (PP-NRS) µû¤À¥§¡°§C 58.9% ¡A¦Ó¦w¼¢¾¯²Õ«h°§C 12.9% (p=0.0015)¡C°ò½uµû¤À¦Ü¤Ö 4 ªºeblasakimabªvÀø±wªÌ¤¤¦³ 53.8% (7/13) ªºPP-NRS µû¤À°§C 4 ¤À¡A¦Ó¦w¼¢¾¯²Õ¬° 14.3% (1/7) (p=0.2460)¡C ¦b¥ý«e¹ïdupilumab¤ÏÀ³¤£¨¬ªº 6 ¦W±µ¨üeblasakimabªvÀøªº±wªÌ¤¤¡A66.7% (4/6) ¹F¨ì EASI-90¡A66.7% (4/6) ¹F¨ì vIGA µû¤À 0 ©Î 1¡C
ªvÀø@¨ü©Ê¨}¦n¡A¨S¦³µo²{·sªº¦w¥þ°T¸¹¡C¬¡©Ê²Õ©Î¦w¼¢¾¯²Õ¤¤¨S¦³µ²½¤ª¢©Îµù®g³¡¦ì¤ÏÀ³ªº³ø§i¡C
°ò½u EASI µû¤À¬° 18 ©Î¥H¤Wªº¨È²Õ¸ê®ÆºKn
¦p¦P¥ý«e©Ò«Å¥¬ªº¡ATREK-DX ©Û¶Ò¼Ð·Ç©ó 2023 ¦~ 10 ¤ë¦¬ºò¡A¶È©Û¶Ò°ò½u EASI µû¤À¬° 18 ©Î¥H¤Wªº±wªÌ¡C³o¨Ç§óÄY®æªº¼Ð·Ç±N¦¨¬°¹wp¦b2024 ¦~©³¤½§Gªº³»½uŪ¼Æªº¤ÀªR°ò¦¡CÀø®Äµ²ªG¡G
±µ¨üeblasakimabªvÀøªº±wªÌªº EASI µû¤À¸û°ò½u¥§¡°§C 89.2% ¡A¦Ó¦w¼¢¾¯²Õ«h°§C 45.7% (p=0.0045)¡C 83.3% (10/12) ªºeblasakimabªvÀø±wªÌ¹F¨ì EASI-75¡A¦w¼¢¾¯²Õ¬° 0% (0/3) (p=0.0556)¡C 66.7% (8/12) ªºeblasakimabªvÀø±wªÌ¹F¨ì EASI-90¡A¦w¼¢¾¯²Õ¬° 0% (0/3) (p=0.1667)¡C 25% (3/12) ªºeblasakimabªvÀø±wªÌ¹F¨ì EASI-100¡A¦Ó¦w¼¢¾¯²Õ¬° 0% (0/3)¡]EASI-100 ¤£¬O¹w¥ý«ü©wªº²×ÂI¡^¡C 75.0% (9/12) ªºeblasakimabªvÀø±wªÌªº vIGA µû¤À¹F¨ì 0 ©Î 1¡A¦Ó¦w¼¢¾¯²Õ¬° 0% (0/3) (p=0.1111)¡C ±µ¨üeblasakimabªvÀøªº±wªÌPP-NRS µû¤À¥§¡°§C 61.2% ¡A¦Ó¦w¼¢¾¯²Õ«h¼W¥[ 1.5% (p=0.0004)¡C°ò½uµû¤À¦Ü¤Ö¬° 4 ªºeblasakimabªvÀø±wªÌ¤¤¦³ 60% (6/10) ªºPP-NRS µû¤À°§C¤F 4 ¤À¡A¦Ó¦w¼¢¾¯²Õªº¤ñ¨Ò¬° 0% (0/3) (p=0.2000)¡C ¤¤´Á¼Æ¾Ú±N´£¥æµ¹§Y±N¥l¶}ªº¬ì¾Ç·|ij¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2024/4/22 ¤U¤È 08:44:17
²Ä 6619 ½g¦^À³
|
ªoºj¤jªº¾á¼~¬O¦X²zªº¡A¤½¥q¯Ê¸êª÷ªº±¡ªp¤U¡A ±ÂÅv©Î¨ÖÁʽͧP¤£¯à¤Ó©T°õ¤v¨£¡AÁöµM¦³¥|¶g£¸°w¼ç¤O¡AÁö¦³»PDupilumab£¸¨M°ª¤UªººA¶Õ¡A ¦³¸êª÷¤~¯à¦s¬¡¡A¨ú±Ë¶¡»Ý¦Ò¼{§é°J¤è®×¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2024/4/22 ¤U¤È 07:49:06
²Ä 6618 ½g¦^À³
|
1¥»¤½¥q¦³¦Û¸Ó¨ç¥ó¤§¤é°_ 45 Ó¤é¾ä¤é¤º©Îª½¦Ü 2024 ¦~ 6 ¤ë 3 ¤éªº´Á¡A´£¥æ«·s¿í¦uªÑªFÅv¯qn¨Dªºp¹º¡C¦pªG¦¹Ãþp¹º³Q´£¥æ¨Ã±µ¨ü¡A¯Ç´µ¹F§J¥i¯à·|µ¹¤©¤½¥q¦Û¸Ó¨çµo¥X¤§¤é°_³Ì¦h 180 Ó¤é¾ä¤éªº©µ´Á¡A¥H«K¤½¥q«·s¿í¦u³W©w(¤]´N¬OÁÙ¦³180´Á¤Ñ¼e¡A¤j¬ù¦b10¤ë14¤é¥ª¥k)
2.2024 ¦~ 3 ¤ë¤w¤½§G¤FTREK-DX ¬ã¨sªºªì¨Bª¼¼Æ¾Ú¡C¦b¹ïTREK-DX ¬ã¨s¤¤±µ¨üªvÀøªº22 ¦W±wªÌªº¼Æ¾Ú¶i¦æ¼f¬d«á¡A45% (10/22) ªº±wªÌªºEASI µû¤À(EASI-90) ¦Ü¤Ö°§C¤F90%¡A50% (11/22) ªº±wªÌªºEASI µû¤À¦Ü¤Ö°§C¤F90%¡C¦b¥ý«e¹ïdupilumab¤ÏÀ³¤£¨¬ªº 9 ¦W±wªÌ¤¤¡A5 ¦W±wªÌ(56%) ¹F¨ìEASI-90¡A5 ¦W±wªÌ(56%) vIGA µû¤À¬°0 ©Î1¡CÂù¦b¦³¸g¾úªº AD ±wªÌ¸sÅédupilumab¡C¹wp§¹¾ã¸ê®Æ¶°¤¤ªº«Dª¼¸ê®Æ±N©ó 2024 ¦~©³µo§G
3.¤½§i22¤H¦û¤ñ¬ù¦Ê¤À¤§30,³o»ò«æ©ó¤½§i¼Æ¾Ú¡A»¡¤£©w6¤ë¦A¤½§i45¤H¼Æ¾Ú(¦û¤ñ¦Ê¤À¤§60¡^¡A9¤ë¦A¤½§i60¤H¼Æ¾Ú¡]¦û¤ñ¦Ê¤À¤§80¡^ ¥H¤W¦sÄݲq´ú¡A¤j®a·Q·Q´£¨Ñª`·N¨ì¨ÖÁʪ̦ʤÀ¤§60¦Ü 80ªº¼Æ¾Ú¡A¤w¸g¦³¥i«H«×¡AÂù¤è¥i¥H¨Ì¨ÖÁÊ ºD¨Ò´£¨ÑÂùűø¥ó»P¼Æ¾Ú¡A¤££¸©wµ¥¨ì¦¬§¹75¤H ¤~½Í¨ÖÁʮסC
4¤¤ë¤¤»Ýª`·N¦³¨S¦³§ó·s¦¬®×²{ªp¡A¦³§ó·s ©Î¼W¥[¼Ú¬w¦¬®×¦aÂI¡A³o¬O¦n²{¶H
¥H¤W¤À¨É ¦sÄÝÓ¤H¬ã§P¡A¶È¨Ñ参¦Ò |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gªoºj·Æ±¼10153108 |
µoªí®É¶¡:2024/4/20 ¤W¤È 11:47:29
²Ä 6617 ½g¦^À³
|
ASLN¬Q¤Ñ¤S¤½§i¤F¦¬¨ìNASDAQªº¤U¥«³qª¾¡A³o¦¸¬O2023¦~©³²bȧC©óUSD250¸U¡An¦b6/3«e´£¥æ¦X³WªºªÑªFÅv¯q´£¤Ép¹º¡A¬Ý¤F¤@¤U2023¦~©³ªÑªFÅv¯q¬OUSD-1330¸U¡Aµ¥©óªÑªFªº¿ú³£¤w¸g¿N¥ú¤F¡A¤â¤W²{ª÷³£¬OɨӪº¡A¥H¥Ø«e¨Ó¬Ý¥ú¬O2023¦~©³ªº¼Æ¦rn¹F¼Ð´NnÄw¥XUSD1580¸U¡A¦Ó¥B±µ¤U¨ÓÁÙ¦b«ùÄò¿N¿ú¡A2024Q1°²³]¤]¬Oªá¶OUSD2000¸U¡A¨º´NnÄw¥XUSD3580¸U¡A¦ýnÅýNASDAQ±µ¨üªºp¹º¡A«ç»ò¥i¯à¥un´ê¨ì2024Q1ªÑªFÅv¯q¹F¼Ð´N¦n¡A¦ý¥HASLN¥Ø«eªºÄw¸ê¯à¤O°ò¥»¤WÄw¤£¥X¿ú¤F¡A©Ò¥H°ò¥»¤W´N¥u¦³³Q¨ÖÁʩάO®³¨ì¤jµ§±ÂÅvª÷¤~¥i¥H¸Ñ¨M¡A¨S·Q¨ìASLNªº©R¹B·|´£«e¶}¼ú¡A³strek-dx¸òfast-aaªºµ²ªG¥X¨Ó³£¼µ¤£¨ì......
**¥h¦~ASLNªº°]³ø¤½¥¬¨Æ¥ó¬O¤G¤ë©³¡A³o¦¸©ì¨ì²{¦b¤~¤½§G¤j·§²v´N¬O·Q©µ«á¤U¥«ªº®É¶¡§a¡A¬Ý¤F¤@¤U°]³ø¡A²ÖpÁ«·l¤w¸g¨ì¤FUSD3.2»õ¡A¤w¸g¿N¤F³o»ò¦h¿ú¡A¦¨ªG¤~³o¼Ë¡A¯u¬OªA¤Fªü«i¡A±Mªø¬O¨ÖÁʪº½Í§P¤j®v¡A³oºÙ¸¹«D§A²öÄݤF |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gªoºj·Æ±¼10153108 |
µoªí®É¶¡:2024/4/18 ¤U¤È 02:05:15
²Ä 6616 ½g¦^À³
|
ADS¾ú¥v³Ì°ª52.195´N¬OÁÙì´î¸êªºµ²ªG¤F¡A´î¸ê«e³Ì°ªÀ³¸Ó¬O10¶ô¦h¡A©Ò¥H¥Î´î¸ê«á¨Ó¬Ý¼Ð·Ç¤ñ¸û¤@P¡A´N¬O¶^¤F99%¨S¿ù~ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2024/4/18 ¤U¤È 01:55:22
²Ä 6615 ½g¦^À³
|
¨È«Í±d³oÄêªÑ±q¥¼¹F¨ì52¤¸¡A
¨º¬O¦]¬°³sÄò´î¸ê³y¦¨ªº |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gªoºj·Æ±¼10153108 |
µoªí®É¶¡:2024/4/18 ¤W¤È 11:31:24
²Ä 6614 ½g¦^À³
|
¼ÖÆ[ªº¤H¥i¥HÄ~Äò¼ÖÆ[¡A¦ý²{¹ê´N¬O¦p¦¹¡A»¡¤@¤U¨Æ¹êÁÙn³Q»¡¬O§O¦³¥Î¤ß¬Ý°IªÑ»ù¡Aþ»Ýn¬Ý°I¡A¬Ý¤£¨ì±ÂÅv©Î¨ÖÁʶi«×¡AÄ~Äò¿N¿ú¡AªÑ»ù´N¬Oª½±µ¤U¥h¤Fªü¡A¥h½½Â¤å¡A¨º¨Ç©úÅã¼ÖÆ[ªº¹w´ú¡A¦Ü¤µþÓ¦³¹w´ú¦¨¥\?
©t¨àÃĤj¤]¬O¦Ñ·à¤Í¤F¡A³o¤@¸ô¨«¨Ó·Q¥²ÂIºw¦b¤ßÀY¡A½Í§P¤j®v´N¬O¤@ª½·dÄê¦ÑªÑªFªºÅv¯qªü¡A¬Ý¬Ý·íªìªºì©lªÑªF¡A±q²H°¨¿ü¡BÀq§J¤l¤½¥qµ¥¡A¨ì«á¨Óªºtang¡A²{¦b³£¤£¦b¤F¡A¦p¦¹¦³«e´º¸ò·ÓÅUªÑªFªº¤½¥q·|³o¼Ë?±q¥xªÑ¤W¥«¨ì²{¦b°ò¥»¤WªÑ»ù´N¬O¤@¸ô±Y¶^¡AADS¾ú¥v³Ì°ª52.195¨ì²{¦b0.5¤£¨ì¡A¶^´T¶W¹L99%¡A¤j·§¬O¸}¥Ö±Ù¤F¡A¦pªG¬O±q¥xªÑÂà´«¹L¨Óªº¦Ñ·à¤Í¡A«áÄò¨S¥[½Xªº¸ÜÀ³¸ÓÁ«·l¤]³£¶W¹L9¦¨¡AªÑ»ù½10¿³£ÁÙ¤£¤@©wÁÈ¿ú¡A¥u¯à«ü±æASLAN¦³©_ÂÝ¥X²{¤F¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2024/4/17 ¤U¤È 04:01:19
²Ä 6613 ½g¦^À³
|
°ò©ó¥ý«e´X¦¸½Í§P¤j®vªº¦¨ªG¡A´X¥G¬O¥HÄ묹¦ÑªÑªFªºÅv¯q¦¬³õ¡A©Ò¥H¥u¯à¹³¨â©¤³Ìªñ¤õ¬õªº¹q¼v©P³B°£¤T®`¡A½Í§P¤j®v¥ý¤U¥xªº¸Ü¡Aªü·à·d¤£¦n´N·|¤j½¨¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gªoºj·Æ±¼10153108 |
µoªí®É¶¡:2024/4/17 ¤W¤È 11:42:47
²Ä 6612 ½g¦^À³
|
ASLAN¤½§iªº³Ì·s¤½¥q¶i«×¡A°£¤FFarudodstat±q2024¦~¤¤¤S¨Ç·L©µ¿ð¨ì2024Q3¥~¡AÓ¤H»{¬°ÁÙ¦³¤GÓ«ÂInª`·N
1.Eblasakimab ¼Ú¬w¦¬®×¶}©l¤F¨S?clinical trail©|¥¼§ó·s¼Ú¬w¦¬®×¦aÂI¡A¤§«e¬O»¡¹wp2024Q2¶}©l¼Ú¬w¦¬®×¡A¦A¤£»°§Ö¶}©l¡ATREK-AD2024¦~©³¼Æ¾Ú¥Xªº¨Ó?
2.³o¬O§Ú»{¬°³Ì«nªº¤@ÂI¡AASLAN¥Ø«e¤½¥¬ªº¶i«×§ó·s¤w¸g¨S¦³´¦ÅS±b¤W²{ª÷¾lÃB¤Î¹wp²{ª÷¥i¨Ï¥Î¦Ü¦ó®É¡A¤§«e¬O¹wp¥i¥H¥Î¨ì2024¤U¥b¦~¡A¦ýºI¤î2023/12¤ë©³¡A±b¤W²{ª÷¥u³Ñ21.3M¡A¿N¿úªº³t«×¤ñ·Q¹³¤¤§Ö¡AÀ³¸ÓQ1²{ª÷´N¿N¥ú¤F¡A³o¤@¤è±Ë¬O¨S¬Ý¨ìASLAN°µ»¡©ú¡A¤£ºÞ¬O¥¼¨Ó¹wp¨p¶ÒÁÙ¬O¥t¦³³W¹º?
°ò©ó¥H¤W²{¹êªº¦Ò¶q¡AASLAN¯uªº¦³¦X§@¹ï¶H¥i¥H¶i¤J¤T´Á¡AÀ³¸ÓQ2´Nn·Ç³Æ¦X§@¶i¤J¤T´Á¤F¡A±ø¥ó§Y¨Ï¤£²z·Q¤]¥u¯à§]¤F¡A½Ö¥s½Í§P¤j®vª±¨ì¨S¿ú¨S©³®ð¤F©O?¤S©ÎªÌASLANÄ~Äò¦LªÑ²¼´«¶r²¼¡A¦ý¥H¥Ø«eªÑ»ù¨Ó¬Ý¡A¶Ò¸ê®Ä²v·¥¬°§C¸¨¡A¥u¯à»¡¹ï·à¤Í̪º¦n³B´N¬OASLAN¶Õ¥²Q2n¦³¤j°Ê§@¤F¡A¤£¥ÎWWµ¥ÔFAST-AA¸òTREK-DXªº¼Æ¾Ú¥X¨Ó¤F |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2024/4/16 ¤U¤È 11:06:11
²Ä 6611 ½g¦^À³
|
¢±¢¯¢±¢²¦~¡@²Ä¥|©u©M³ÌªñªºÁ{§É¶i®i«ÂI¡@¡@¡]FAST-AA ¬ã¨s²{¤w©Û¶Ò¤Fªñ 75% ¡^
2023 ¦~ 10 ¤ëeblasakimabªvÀø¤¤««× AD ªº2b ´Á TREK-AD ¬ã¨sªº·s¼Æ¾Ú¦b²Ä 32 ©¡ ¼Ú¬w¥Ö½§¯f¾Ç©M©Ê¯f¾Ç¦~·|¤Wªº³Ì·s¤fÀY³ø§i¤¤´£¥X¡C
2023 ¦~ 10 ¤ë¡AÁ|¿ì¤F¤@³õÃö©ó AD Á{§É¸ÕÅç©MªvÀø®æ§½ÅܤƪºÃöÁä·N¨£»â³S (KOL) ¬¡°Ê¡C ASLAN »P»â¥ýªºÁ{§É¬ã¨s²Õ´©M KOL Jonathan Silverberg¡]³ìªvµØ²±¹y¤j¾ÇÂå¾Ç»P°·±d ¬ì¾Ç¾Ç°|¡^©M April W. Armstrong¡]¥[¦{¤j¾Ç¬¥§üÁF¤À®Õ¡^Âå¾Ç³Õ¤h MPH¡]Âå¾Ç³Õ¤h MPH¡^ ¦@¦PÁ|¿ì¤F§ë¸êªÌ¬¡°Ê¡C¦b¦¹¦¸¬¡°Ê¤¤®i¥Üªº TREK-AD ¬ã¨s¤¤¹ï§óÄY«±wªÌ¡]°ò½u EASI 18 ©Î§ó°ª¡^ ªº·s¤ÀªR¤¤¡A¨C 4 ¶g±µ¨ü 600 ²@§J¨Ì¥¬©Ô§Æ³æ§ÜªvÀøªº±wªÌ¤¤¡A55.6% ªºEASIµû¤À¦Ü¤Ö°§C¤F75% ¡]EASI -75¡^¬Û¤ñ¤§¤U¡A¦w¼¢¾¯²Õªº±wªÌ¬°15.4%¡A¦bIGA 0/1 ¦w¼¢¾¯²Õªº±wªÌ¬°8.0%¡A ¹êÅç²Õ30.6% ªº±wªÌÀò±o¤F0 ©Î1 ¤À¡]³z©ú©Î´X¥G³z©úªº¥Ö½§¡^
2023 ¦~ 11 ¤ë¡Aº¦¸¦beblasakimabªº AD ¥H¥~¾AÀ³¯g¤¤´£¨Ñ¼Æ¾Ú¡C¦b¥Ö½§¬ìÃĪ«¶}µo°ª®p·|¤W¡A ASLAN³z¹LºC©Êªý¶ë©ÊªÍ¯f (COPD) ªº¤HÃþÂà¤Æ¼Ò«¬®i¥Ü¤Feblasakimab¦b AD ¥H¥~ªº¾AÀ³¯g¤¤ªº ¼ç¦b¥Î³~¡C¼Æ¾ÚÅã¥Ü¡Aeblasakimab¥i¦³®Ä°§C IL-4 ©M IL-13 ÅX°Êªº®ð¹D°ª¤ÏÀ³©Ê¡C
2023 ¦~ 12 ¤ë¡A´¦ÅS¤F¥¿¦b¶i¦æªºFarudodstatªvÀø´³¨r (AA)ªº 2a ´Á FAST-AA ¬ã¨sªºª¼ªk ¦w¥þ©Ê¼Æ¾Ú¡C¼Æ¾ÚÅã¥Ü¡A¨´¤µ¬°¤î¡A¤J²Õ±wªÌ¨S¦³¨xŦ©Î¨ä¥L¥Dn¦w¥þ°ÝÃD¡A³o¤ä«ù¤FFarudodstat »P²Ä¤@¥N§å㪺¤G²B¨Å²M»Ä²æ²B酶 (DHODH) §í¨î¾¯¬Û¤ñ¡A¦w¥þ©Ê¦³©Ò§ïµ½¡CFarudodstat¬O¤@ºØ °ª¿ï¾Ü©Ê¤fªA DHODH §í¨î¾¯¡A¦³¼ç¤O¦¨¬° AA ªº¤@¬yªvÀøÃĪ«¡C FAST-AA ¬ã¨s²{¤w©Û¶Ò¤Fªñ 75% ªº±wªÌ¡A¸Ó¬ã¨sªº¥Dn¤¤´Á¼Æ¾Ú¹wp±N©ó 2024 ¦~²Ä¤T©u´£¨Ñ¡C
2024¦~2¤ë¡A¨ú±o¼Ú¬w±M§Q§½¡]EPO¡^Ãö©ófarudodstatª«½è²Õ¦¨±M§Q¥Ó½Ðªº¦³§Q·N¨£¡C ¼Ú¬w±M§Q§½¾á¥ôFarudodstat¦h´¹«¬±M§Q¥Ó½Ðªº°ê»Ú¼f¬dû¡A¦pªG¦b°ê®a¶¥¬qÀò±o§åã¡A ±N§âFarudodstatªº¦³®Ä±M§Q«OÅ@©µªø¦Ü¦Ü¤Ö 2043 ¦~¡C
2024 ¦~ 3 ¤ë¡A«Å¥¬¤Feblasakimab»Pdupilumab¦b COPD ¤HÅé²Õ´¼Ò«¬¤¤¶i¦æªºÀY¹ïÀY¬ã¨sªº¿n·¥Âà¤Æ¼Æ¾Ú¡C ¦b¬ã¨s¤¤¡A¦b¬Û¦P¿@«×¤U¡A e blasakimab¦b§ïµ½®ð¹D¥\¯à©M¼W±j¤ä®ðºÞÂX±i¤è±¤ñdupilumabªí²{§ó¦n¡A
¬°eblasakimab§@¬° COPD ¥Íª«Àøªkªº¼ç¤O´£¨Ñ¤F¶i¤@¨B¤ä«ù¡C³o¨Ç¼Æ¾Ú¤w´£¥æµ¹§Y±N¥l¶}ªº¬ì¾Ç·|ij¡C 2024 ¦~ 3 ¤ë¡A¤½§G¤FTREK-DX ¬ã¨sªºªì¨Bª¼¼Æ¾Ú¡C¦b¹ïTREK-DX ¬ã¨s¤¤±µ¨üªvÀøªº22 ¦W±wªÌªº¼Æ¾Ú¶i¦æ¼f¬d«á¡A45% (10/22) ªº±wªÌªºEASI µû¤À(EASI-90) ¦Ü¤Ö°§C¤F90%¡A50% (11/22) ªº±wªÌªºEASI µû¤À¦Ü¤Ö°§C¤F90%¡C¦b¥ý«e¹ïdupilumab¤ÏÀ³¤£¨¬ªº 9 ¦W±wªÌ¤¤¡A5 ¦W±wªÌ(56%) ¹F¨ìEASI-90¡A5 ¦W±wªÌ(56%) vIGA µû¤À¬°0 ©Î1¡CÂù¦b¦³¸g¾úªº AD ±wªÌ¸sÅédupilumab¡C¹wp§¹¾ã¸ê®Æ¶°¤¤ªº«Dª¼¸ê®Æ±N©ó 2024 ¦~©³µo§G
¹wp§Y±N¨ì¨Óªº¨½µ{¸O ( °Ñ¦Ò2024 04 12 ¤½¥q°T®§ ¤½¥qºô¶¥þ±§ó·s )
¦b§Y±N©ó 2024 ¦~²Ä 2 ©u¥l¶}ªº¬ì¾Ç¤j·|¤W®i¥Ü¤Feblasakimab»Pdupilumab¦b COPD ¤HÅé²Õ´¼Ò«¬¤¤ªº ÀY¹ïÀY¬ã¨sªº¿n·¥Âà¤Æ¼Æ¾Ú
AA ªºfarudodstat 2a ´Á¬ã¨sªº¥Dn¤¤´Á¼Æ¾Ú¹wp±N©ó 2024 ¦~²Ä¤T©uµo§G (Ó¤Hµû½×¡G²Ä¤T©u 7 8 9¤ë §é¤¤ ¥H 8¤ëµo§G¾÷·|³Ì¤j)
eblasakimabªº TREK-DX ¸ÕÅ窺¥Dn¼Æ¾Ú¹wp±N©ó 2024 ¦~©³µo¥¬ ( Ó¤Hµû½×¡G¤w¸g¤½§G 22¤H/75¤H ¼Æ¾Ú ³£¥l¦¬¢Ó¢Ï¢á¢×18¤À¥H¤W ¤T¤À¤§¤G¦b¹êÅç²Õ ¼Æ¾ÚÀ³¦b¹w´Á¤¤ )
¿ï¾Ü¶}µo¦X§@¹Ù¦ñ¥H±Neblasakimab±À¶i AD ©M¨ä¥L¾AÀ³¯gªº 3 ´Á Á{§É ( Ó¤Hµû½×¡G§¹¦¨¤G´ÁªºÃĪ« ¤T´ÁÁ{§É¥i¥H©Ý®i¨ä¥L¾AÀ³¯gªº3´ÁÁ{§É ¡@´N¦n¹³Dupilumab °£¤F¶}µoAD¡@¥~¤]©Ý®i¨ä¥L¾AÀ³¯g)
¥H¤WÓ¤Hµû½×¡@¶È¨Ñ°Ñ¦Ò¡@¡@§¹¾ã¸ê°T½Ð°Ñ¦ÒApril 12, 2024 ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gªoºj·Æ±¼10153108 |
µoªí®É¶¡:2024/4/12 ¤U¤È 06:38:24
²Ä 6610 ½g¦^À³
|
°]³ø¥XÄl¡A¬Ý¨Ó¤T¤ë¯uªº¬O¿ú§Ö¿N¥ú¤F¡A¥u¯à§C»ù¦LªÑ²¼´«¶r²¼¡AºI¤î2023/12¤ë©³¡A±b¤W²{ª÷¥u³Ñ21.3M¡A¹ï¤ñ2023¦~Q4Á`¦@¿N¤F20.4M¡A±b¤W²{ª÷®Ú¥»¼µ¤£¨ìQ2¡A§Y¨ÏQ1¦LªÑ²¼´«¦^5M¡A¬Ý°_¨ÓÁÙ¬OªM¤ô¨®Á~¡A©Ò¥H»¡¹Ln¹M¤F¡A®É¶¡©ì¶V¤[¶V¤£§Q´N¬O³o¼Ë¡AÁ`¤§n¹À³Ìªñ¯uªº¦³¦X§@¹Ù¦ñ´Nn»°§ÖºV©w¤F¡A¤£µM´N¬OÄ~Äò¦LªÑ²¼¨Ó¼µ¡A¦ý§A¦U¦ì·Q¤@¤U¡AªÑ¥»¿±µÈ¨º»ò¦h¤~®³¨ì5M¡An¦L¨ì°÷¼µ¨ì¦~©³¡AªÑ¥»·|¿±µÈ¨ì¦h¤j§Ú¬O¤£´±·Q¹³°Õ¡AµM«á½Í¨ì²{ª÷¿N¥ú¡AAD¤T´ÁÁÙ»»»»µL´Á¡A¯uªº¬O½Í§P¤j®v¡I¡H«ô°Ucarl firth§Ö¨Ó¥´§ÚÁy¡A¦V·à¤ÍÌÃÒ©ú¦Û¤v¹ê¤O§a¡I |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2024/4/5 ¤U¤È 10:54:31
²Ä 6609 ½g¦^À³
|
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Eblasakimab in Male or Female Moderate-to-Severe Atopic Dermatitis Patients Previously Treated With Dupilumab
A TRED-DX ¥l¶Ò75¤H (¹êÅç²Õ50¤H 400mg QW ¹ï·Ó²Õ25¤H)
B ¯Ç¤J¼Ð·Ç¡G
≥18·³ªº¨k©Ê©Î¤k©Ê°Ñ»PªÌ Ä@·N¨Ã¥B¯à°÷¿í¦uªù¶E©M¬ã¨s¬ÛÃöµ{§Ç ¿zÀË«eºC©Ê AD ¤w¦s¦b¦Ü¤Ö 1 ¦~ °ò½u®É vIGA µû¤À≥3 °ò½u®É AD ¨ü²Ö BSA ≥10% ¿zÀË©M°ò½u®É EASI ≥18 ¹ï§½³¡¥Ö½èÃþ©T¾J (TCS) ©Î§½³¡¶t½Õ¯«¸gÁC»Ä酶§í¨î¾¯ (TCI) éw¤è®×ªvÀø AD ¤ÏÀ³¤£¨¬¡B¤£@¨ü©Î¸T§Òªº¯f¥v ©Ò¦³°Ñ»PªÌ¤§«e¥²¶·±µ¨ü¹L dupilumab ªvÀø¡A¥B²Å¦X¥H¤U±ø¥ó¤§¤@¡G
¦]µL¤ÏÀ³¡B³¡¤À¤ÏÀ³¡BÀø®Ä³à¥¢¦Ó°±¤î dupilumab ªvÀøªº°Ñ»PªÌ¥²¶·¥ý«e±µ¨ü¹L dupilumab ªvÀø¦Ü¤Ö 16 ¶g¡F ¥Ñ©ó¹ïÃĪ«¤£@¨ü©Î¤£¨}¨Æ¥ó (AE) ¦Ó°±¤î dupilumab ªvÀøªº°Ñ»PªÌ¥i¥H¶i¤J¬ã¨s¡AµL»Ý¨Æ¥ý±µ¨ü dupilumab ªvÀøªº®É¶¡ªø«×¡F ¦]¶O¥Î©ÎµLªkÀò±o dupilumab ©Î¥ô¦ó¨ä¥Lì¦]¦Ó°±¤î dupilumab ªvÀøªº°Ñ»PªÌ¥i¥H¶i¤J¬ã¨s¡AµL»Ý¨Æ¥ý±µ¨ü dupilumab ªvÀøªº®É¶¡ªø«×¡F
C ¦h¤¤¤ß¡BÀH¾÷¡BÂùª¼¡B¦w¼¢¾¯¹ï·Ó¡B¥¦æÁuÁ{§É¬ã¨s¡A¦®¦bµû¦ô eblasakimab ¹ï¥ý«e±µ¨ü dupilumab ªvÀøªº¤¤«×¦Ü««×²§¦ì©Ê¥Ö½§ª¢ (AD) °Ñ»PªÌªºÀø®Ä©M¦w¥þ©Ê¡C¬ã¨s¥]¬A 16 ¶µ¬ã¨s¶gªvÀø´Á©Mª½¦Ü²Ä24 ¶gªº8 ¶g°lÂÜ´Á¡C²Å¦X±ø¥óªº°Ñ»PªÌ±N³QÀH¾÷¤À°t¨ì2ÓªvÀø²Õ¤§¤@
2024¦~3¤ë ²³ø P25 2024 ¦~ 2¤ë¶i¦æ ªºªì¨Bª¼ªk¸ê®Æ¼f¬d¡A¥]¬A¨´¤µ¬°¤î¤J²Õªº©Ò¦³ 22 ¦W±wªÌ¡G17 ¦W±wªÌ§¹¦¨¤F 16 ¶gªºªvÀø´Á¡A 5 ¦W±wªÌ¦b¦¹¤§«e°±¤îªvÀø 45% ªº±wªÌªº EASI µû¤À (EASI-90) °§C¤F¦Ü¤Ö 90%¡A50% ªº±wªÌ¹F¨ì¤F vIGA µû¤À 16 ¶g«á¬° 0 ©Î 1¡]³z©ú©Î´X¥G³z©úªº¥Ö½§¡^
¦b¥ý«e¹ï dupilumab ¤ÏÀ³¤£¨¬ªº 9 ¦W±wªÌ¤¤¡A5 ¦W±wªÌ (56%) ¹F¨ì EASI-90 ¥B 5 ¦ì±wªÌ (56%) vIGA µû¤À¬° 0 ©Î 1 ªvÀø@¨ü©Ê¨}¦n¡A¥¼µo²{·sªº¦w¥þ°T¸¹¡C ¨S¦³µ²½¤ª¢©Îµù®gªº³ø§i²{³õ¤ÏÀ³
Ó¤Hµû¦ô: 5¤ëÓ¤¤¥ª¥k»Ý¦¬§¹³Ì«á¤@¦W¨ü¸Õ ( ªvÀø»P«áÄò°lÂܦ@24¶g (6Ó¤ë) ¦p¦¹¤~¯à¦b¦~©³¤½§iTRED-DX ¼Æ¾Ú
¦b¥ý«e¹ï dupilumab ¤ÏÀ³¤£¨¬ªº 9 ¦W±wªÌ¤¤¡A5 ¦W±wªÌ (56%) ¹F¨ì EASI-90 ¥B 5 ¦ì±wªÌ (56%) vIGA µû¤À¬° 0 ©Î 1 ( ¤½§i³o¤@¬q «Ü@¤H´M¨ý, ·Pı¤½¥q«H¤ß¤Q¨¬ TREK-DX ¬O TREK-AD ªº©µªøÁÉ)
TREK-DX ¸ÕÅç 2024 ¦~©³¤½§i Topline readout • ¿ï¾Ü¦X§@¹Ù¦ñ±N eblasakimab ±À¶i¨ìÁ{§É3 ´Á • 2024¦~¤¤´Á ¤½§iFarudodstat 2a ¶¥¬q ´Á ¤¤ Topline data • TREK-AD ¬ã¨sªº¶i¤@¨B¼Æ¾Ú±N¦b«n·|ij¤Wµoªí¨Ã®i¥Ü (eblasakimab ©M farudodstat)
¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gªoºj·Æ±¼10153108 |
µoªí®É¶¡:2024/3/26 ¤U¤È 05:25:17
²Ä 6608 ½g¦^À³
|
®Ú¾ÚSEC¸ê®Æ¡A¥Ø«e¤jªÑªF¤S¦h¥Ó³ø¤FINTRACOSTAL LLC(4.4%)¸òLIND GLOBAL FUND(5.7%)¡A³£¬O³o¤@¦¸ªº¨p¶Ò¹ï¶H¡AªÑ¥»¿±µÈ«á¥Ø«e¤w¸g¨S¦³«ùªÑ¶W¹L10%ªºªÑªF¤F¡A¥hª¦ª¦Â¤å¡A±q2023¦~7¤ë¸Ñª¼ªÑ»ù±Y¶^¡A¦³¨Ç¤@ª½¥D±i¥D¤O¦b¦Y³f¡A±q4.X±Y¨ì0.4¨ì²{¦b0.6X¡A®É¶¡¤w¸g¹L¤F§Ö9Ó¤ë¡A¦³½Ö§ä¨ì¦Y³fªº¥D¤O¤F¶Ü¡A¤p§Ì¸ê½è¾q¶w§ä¤£¤Ó¥X¨Ó³â¡AµM«á¹L¤F9Ó¤ëÁÙ¨S§ä¨ì¤H¤@°_±À¶i¤T´Á¡A§Ú¬Ý¤]¬O¤¿¦h¦N¤Ö.....
**°¸º¸À°¦Ñ·à¤Í§ó·s¤@¤USECªº¸ê®Æ¡A¤£µMSEC³o»ò¤Î®É¸ò·Ç½T³£¨S¤Hn¬Ý¡A³£¶]¥h¬Ý¤@¨Çºô¯¸µM«á¸£¸É¤@°ï¤p¼@³õXD |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥d¦b¥b¤s¸y10153098 |
µoªí®É¶¡:2024/3/18 ¤U¤È 10:43:25
²Ä 6607 ½g¦^À³
|
§CÀɼɺ¦¼É¶^ ³o¬O¤£¬O¥s¾_Ü¥ÏÃâªü...... |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2024/3/18 ¤U¤È 10:42:40
²Ä 6606 ½g¦^À³
|
§ó¥¿»P¸É¥R
Duplimab ¨âÓ¤T´ÁÁ{§É¡A¹êÅç²Õ»P¹ï·Ó²Õ¤H¼Æ¬ù²¤¬Û¦P¡A
TRED-DX¹êÅç²Õ»P¹ï·Ó²Õ¤H¼Æ¤ñ昰50¤H/25¤H¡A¦¬®×¹ï¶HEASI ¦Ü¤Ö18¤À¥H¤W¡A¥ÎÃÄ16¶g¡A³o22¤Hblinded data ·íµM¥ÎÃIJթâ¨ì¤H¼Æ·|¤ñ¹ï·Ó²Õ¦h¡C
¥t¥~¤½¥q°T®§¤¤¦³´£¨ì£¸¤p¬q@¤H´M¨ýªº¸Ü¡Aȱoª`·N ³o9¤H·|¤£·|´N¬O¹êÅç²Õ
9¦W±wªÌ¤¤¦b¥ý«e¹ï dupilumab ¤ÏÀ³¤£¨¬ªº±wªÌ¤¤¡A5 ¦W±wªÌ (56%) ¹F¨ì EASI-90¡A5 ¦W±wªÌ (56%) ¹F¨ì vIGA µû¤À¬° 0 ©Î 1¡C¨´¤µ¬°¤î¡AªvÀøªº@¨ü©Ê¨}¦n¡A¨S¦³µo²{·sªº¦w¥þ°T¸¹,¨S¦³µo²{µ²½¤ª¢¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2024/3/18 ¤U¤È 09:01:46
²Ä 6605 ½g¦^À³
|
eblasakimab ¥¼¨Ó¦³¾÷·|»PDupilumab¶i¤JÄvª§¡A¹ï¤âªº¼Æ¾ÚÅܦ¨«Ü«nªº«ü¼Ð¡AÃĪ«ªº¬ãµo¨S¦³§¹¬üªº³Ì¦n¡A¥u¦³¤£Â_³Ð·sªº§ó¦n
Dupilumab SOLO1¬ã¨s ¹F¨ì IGA score 0 or 1 ¹ï·Ó²Õ¤H¼Æ224¤H¤¤¦³23¤H(10%)¹F¼Ð
¹êÅç²Õ224¤H¨â¶g¤@°w¹F¨ìIGA score 0 or 1 ¦@85¤H( 38¢H)¹F¼Ð
¹êÅç²Õ224¤H¨C¶g¤@°w¹F¨ìIGA score 0 or 1 ¦@83¤H( 37¢H)¹F¼Ð
¹êÅç²Õ224¤H¨â¶g¤@°w¹F¨ìEASI-75 ¦@115¤H( 51¢H)¹F¼Ð
¹êÅç²Õ224¤H¨C¶g¤@°w¹F¨ìI EASI-75 ¦@117¤H( 52¢H)¹F¼Ð
EASI-90 ¹ï·Ó²Õ224¤H¤¤¦³17¤H 8¢H¹F¼Ð
¹êÅç²Õ224¤H¨â¶g¤@°w¹F¨ìEASI-90 ¦@80¤H( 36¢H)¹F¼Ð
¹êÅç²Õ224¤H¨C¶g¤@°w¹F¨ìEASI-90 ¦@74¤H( 33¢H)¹F¼Ð
Dupilumab SOLO2¬ã¨s
¹F¨ì IGA score 0 or 1 ¹ï·Ó²Õ¤H¼Æ236¤H¤¤¦³20¤H(8%)¹F¼Ð
¹êÅç²Õ224¤H¨â¶g¤@°w¹F¨ìIGA score 0 or 1 ¦@84¤H( 36¢H) ¹F¼Ð¡C
¹êÅç²Õ223¤H¨C¶g¤@°w¹F¨ìIGA score or 1 ¦@87¤H( 36¢H)¹F¼Ð
¹êÅç²Õ236¤H¨â¶g¤@°w¹F¨ìEASI-75 ¦@103¤H( 44¢H)
¹êÅç²Õ224¤H¨C¶g¤@°w¹F¨ìEASI-75 ¦@115¤H( 48¢H)¹F¼Ð
EASI-90 ¹ï·Ó²Õ236¤H¤¤¦³17¤H 8¢H¹F¼Ð ¹êÅç²Õ224¤H¨â¶g¤@°w¹F¨ìEASI-90 ¦@70¤H( 30¢H)¹F¼Ð
¹êÅç²Õ223¤H¨C¶g¤@°w¹F¨ìEASI-90 ¦@73¤H( 31¢H)¹F¼Ð
¥H¤U昰Dupilumabµoªí¦b·s^®æÄõÂå¾Ç´Á¥Z¨âÓ¤T´ÁÁ{§Éªº¹Ïªí¼Æ¾Ú
½Æ»s«á·j´M phase 3 trials of dupilumab versus placebo in atopic dermatitis nejm ©¹¤U§ä¨ì Results «ö¤U¥h¥i¥H§ä¨ì¹Ïªí1»P¹Ïªí2
¬ÛÃö°ò¥»¸ê®Æ»PÁ{§É¼Æ¾Ú¡AÀ³¦³ºÉ¦³¡C
¥»¦¸22¤H¥¼¸Ñª¼ªì¨B¤ÀªR¡A45%¹F¨ìEASI-90 10/22¡A¦Ê¤À¤§50¹F¨ìIGA score o/1 11/22¡A¨ä¤¤·|¦³¦h¤Ö¤H¨Ó¦Û¹ï·Ó²Õ¡A¥i¥H参¦ÒDupilumab SOLO1,SOLO2 ¨âÓ¤T´ÁÁ{§É¤¤ ¹ï·Ó²Õ¦bEASI-90,IGA score o/1¦û¤ñ¡A¥i¬Ý¥Xªì¨BºÝÙ¡A ¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò ¼Æ¾Ú¥H·s^®æÄõÂå¾Ç´Á¥Z¬°¥D
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2024/3/17 ¤U¤È 11:07:31
²Ä 6604 ½g¦^À³
|
SOLO1¹F¨ì vIGA 0 or 1 ¹ï·Ó²Õ¬ù¦b¦Ê¤À¤§10¡A¹êÅç²Õ¹F¨ìvIGA 0 or 1 ¬ù¦b¦Ê¤À¤§37~38 SOLO2¹F¨ìvIGA 0 or 1 ¹ï·Ó²Õ¬ù¦b¦Ê¤À¤§8¡A¹êÅç²Õ¹F¨ìvIGA 0 or 1 ¬ù¦b¦Ê¤À¤§36
¥»¦¸¤½§iªº22¤Hªì¨B¥¼¸Ñª¼¼Æ¾Ú昰 ¦³¦Ê¤À¤§50ªº¤H¹F¨ìvIGA 0 or 1 ±q¹L¥hdupilumab¨âÓ¤T´ÁÁ{§É¼Æ¾Ú¨Ó¬Ý¡A³o11Ó¤H¹F¼Ð¤¤¦³¦h¤Ö¤H昰¹ï·Ó²Õ¦P¼ËÃø«×¬Û·í°ª 50% (11/22) of patients achieved a vIGA score of 0 or 1 (clear or almost clear skin) after 16 weeks
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2024/3/17 ¤U¤È 10:37:20
²Ä 6603 ½g¦^À³
|
1ªoºj¤j«e«h¤À¨É¬O¥¿½Tªº¡A§Ú¿ù§â±µ¨üªvÀø22¤H¥þ³¡·í¬°¹êÅç²Õ¡A³oÓ昰blinded data,¦~©³¤½§iªº¤~¬Ounblind data ¡A¤]´N¬O¸Ñª¼ªº¼Æ¾Ú¡C 2¤½¥q¤½¥qªº^¤å¥þ¤å In a preliminary review of blinded data from 22 patients treated to date, 45% (10/22) of patients saw at least a 90% reduction in their EASI score (EASI-90) and 50% (11/22) of patients achieved a vIGA score of 0 or 1 (clear or almost clear skin) after 16 weeks. Topline unblinded data from the full dataset is expected at the end of 2024
3´N§Ú¦L¶H©Ò¤Î¡Adupilumab¨âÓ¤T´ÁÁ{§É SOLO1¹F¨ìEASI90 ¹ï·Ó²Õ¬ù¦b¦Ê¤À¤§8¡A¹êÅç²Õ¹F¨ìEASI90 ¬ù¦b¦Ê¤À¤§33~36 SOLO2¹F¨ìEASI90 ¹ï·Ó²Õ¬ù¦b¦Ê¤À¤§7¡A¹êÅç²Õ¹F¨ìEASI90 ¬ù¦b¦Ê¤À¤§30~31 ³o¦¸¤½¥q¤½§iªº22¤H¥¼¸Ñª¼ªºªì¨B¼Æ¾Ú¡A¹ï·Ó²Õn¦³¦Ê¤À¤§45ªº¨ü¸Õ¹F¨ìEASI90Ãø«×¬Û·í°ª¡A ¤j®a´N@¤ßµ¥«Ý¡Aµ¥«Ý¼Æ¾Ú»¡¸Ü¡C
¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gªoºj·Æ±¼10153108 |
µoªí®É¶¡:2024/3/17 ¤U¤È 07:43:36
²Ä 6602 ½g¦^À³
|
¥xÁÞ¤j³£»¡¦³¦h¤Ö¼Æ¾Ú»¡¦h¤Ö¸Ü¤F¡A§Ú´N¸É¥R¥H¤U´XÂI´N¦n¡G 1.¥»¦¸¨p¶Ò500¸UªÑ+»{ªÑÅvÃÒ500¸UªÑ¡A¨Ã¨S¦³³¬Âê´Á5¦~ªº°ÝÃD¡A»{ªÑÅvÃÒ5¦~¨ì´Á¬O«üµo¦æ«áÀH®É¥i¥H¥Î1¤¸ÁʶR¡A»{ªÑÅv5¦~«á¨ì´Á´N¥¢®Ä¤F¡A¨p¶Ò§¹ªÑ¥»¿±µÈ3¦¨¡A»{ªÑÅvÃÒ³£¦³¦æ¨Ï¡AªÑ¥»¿±µÈ6¦¨¡A¦pªG¨ÖÁÊ»ù®æ¤£ÅÜ¡AªÑ¥»¿±µÈ3~6¦¨µ¥©ó¨CªÑ»ù®æ¤Ö¤F25%~40%¡A§Ú¬O¤£»{¬°³o¥sªÑ¥»¼W¥[¤£¦h°Õ¡A°²³]10»õ¬ü¦¬ÁÊ¡AìªÑ¥»¤@ªÑ60¤¸¡A¿±µÈ«á·|¥u³Ñ24~45¤¸¡A³o¥u¬O²{¦³ªº¼Æ¾Ú³á¡AÁÙ¤£ºâ¤W¤§«á¦³¥i¯àÄ~Äò¼W¸ê... 2.³o¦¸TREK-DX¤½¥¬ªºªì´Á¼Æ¾Ú¬O¥¼¸Ñª¼¼Æ¾Ú¡A«üªº¬O³o22Ó§¹¥þ¤£ª¾¹D¹êÅç²Õ¸ò¹ï·Ó²Õªº¤À°t¡A©Ò¥H¥xÁÞ¤j§â³o22Ó³£ºâ¨ì¹êÅç²Õ¨ä¹ê¬O¿ù»~ªº¡A³o22ÓÀ³¸Ó¬O¹êÅç²Õ¹ï·Ó²Õ³£¦³¡An¸Ñª¼¤~·|ª¾¹D¦p¦ó¤À°t¡A©Ò¥HTREK-AD¤G´Á¸Ñª¼·|±Y·´¸òCNTB¤@¼Ë¡A¬Ý¨ìªì´Á¼Æ¾Ú³£Ä±±oÀø®Ä¶W¦n¡]¦]¬°³£¤ñ·Ó§ù¥²ª¢ªº¹ï·Ó²Õ¼Æ¾Ú¡^¡A«á¨Ó¸Ñª¼«á¤~µo²{ì¨Ó¹ï·Ó²Õ¦³§ïµ½ªº¤ñ¨Ò·¥°ª¡A¾ÉP¹êÅç²Õ¸ò¹ï·Ó²Õ®t¶Z¨S¦³©Ô¶}¡A©Î³\¦¬®×¼Ð·Çקï¥i¥H§ïµ½¡A¦ý§âªì´Á¼Æ¾Ú³£·í¦¨¹êÅç²Õ³o¼Ë·|¾ÉP»~§P¡A§O§Ñ¤FTREK-DX¤G´ÁªººGªp¡A¹ê»Úµ²ªGÁÙ¬O¥H¸Ñª¼¥X¨Ó¦A»¡§a... |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2024/3/17 ¤U¤È 03:43:33
²Ä 6601 ½g¦^À³
|
¥t¥~½Í¨ì¤Ñ©R¤jªº±ÂÅvª÷±À¦ô¡A§Ú»{¬°¬O¦X²zªº±À¦ô¡A´«¦¨£¸¯ë§ë¸ê¤H¤]·|¥Î¤½¥q±ÂÅvµ¹¤é¥»ªºª÷ÃB°£¥H¤é¥»ÃÄ«~¥«³õ¥«¦û²v¡A·íµM³o¬O·§²¤¦ôºâ¡A¤½¥q¥Ø«eµ¦²¤¦A昰±À¥X´³¨rÃĪ«¡A³oÓ¤G´Á¬ã¨sFAST-AA ¤TӤ륪¥k´Nn¤½§i¼Æ¾Ú¡A¥H´£°ª¤½¥q»ùÈ¡A³o¤äªÑ²¼¤W¤W¤U¤U¡AÅý§ë¸ê¤H¤ß¦Ç·N§N¡A¥Ø«eªÑ»ù§¹¥þ¨S¦³¤ÏÀ³À³¦³ªº»ùÈ¡A¯u¥¿·N¹Ï¤£©ú¡H¥u¦³®É¶¡¤~¯àµ¹¥Xµª®×¡A昰n§â´²¤áÄw½X¥þ§l¨«À£§C¶i³f¡A¦A¤j´T©Ô¤É¡A¦A«Å§G¨Ö©Î±ÂÅvª÷¡A¦Y¹¡³Ü¨¬¡A¥u¦³¤½¥q¬£¡A¤jªÑªF¡A¤jªº§ë¸ê¾÷ºc¤~ª¾¹D¡H¡H¡H
¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2024/3/17 ¤U¤È 01:45:57
²Ä 6600 ½g¦^À³
|
¤p©ú¤j ¹L«×¼ÖÆ[»P¹L«×´dÆ[³£¬O«D²z©Ê·Qªk¡A¦³¦h¤Ö¼Æ¾Ú»¡¦h¤Ö¸Ü¡A¤j®a·Q£¸·QTREK-DX »PTREK-AD 昰¤£¬O¬Û¤¬½÷¬M¡A¬Û¤¬±Ï´©¡ATREK-AD¤C¤ëªìªº¼Æ¾Ú¹ï·Ó²Õ¤ñ¹w´ÁÁÙ¦n¡A¸g¹L¦¸²Õ¸s¤ÀªR²×©ó§ä¨ì¦¬®×ÄY®æ¤~¯à¯u¥¿¤ÏÀ³¨â²Õªº®t¶Z¡ATREK-DX ©Û¶Ò75¦W¡A¥ß§Y§ó§ï¦¬®×¼Ð·Ç¡Aªì¨B22¤H¼Æ¾ÚÃÒ ©ú¨ä¥O¤HÅåÆvªºÀø®Ä¡A22¤H¥ÎÃIJÕ昰¤°»ò·N«ä¡A ³o¦¸¦¬®×75¤H¡A¹êÅç²Õ50¤H¡A¹ï·Ó²Õ25¤H 22¤H\50¤H¡A¤½§i¼Æ¾Ú±µªñ¦Ê¤À¤§45¡A§Ö£¸¥b¤F¡A³o¨Ç¨Ï¥ÎDuplicub ¨S®Ä©Î¬O°Æ§@¥Î©Î¬O¨ä¥L¦]¯ÀÂ÷¶}ªº¯f±w¡A³o¸sÃøªvªº¯f±w¨Ï¥ÎASLAN004 16¶g ¨C¶g400mg¾¯¶q²£¥Í¥O¤H ¦L¶H²`¨èªºÀø®Ä»P¦w¥þ©Ê¡ATRED-DX ÃÒ©úTRED AD¥ý«eªº°²³]¦¬®×ÁÍÄY®æªº¥¿½T©Ê¡A³o¬O£¸Ó±µ¤OÁÉ¡A«e±Áö±¼´Î¡A«á±°¨¤W°l»°¤W¨Ó¡AÀHµÛ¼Ú¬ü§ó§ï¦¬®×¤è¦¡¡A¦~©³¼Æ¾Ú¤£·|®t¤Ó¦h¡AÁÙ®t¦Ê¤À¤§55¥ÎÃIJռƾڡAÀR«Ý¦~¤¤»P¦~©³¼Æ¾Ú¡A ²{¦bÁ`¥«È¤~£¸¤d¦h¸U¬ü¤¸¡A¤£©ÈªÑ¥»¼W¥[£¸¨Ç¡A¤]¤£ª¾¹D¦³¦h¤ÖªÑn³¬Âꤦ~¡H¯u¥¿¼W¥[¤]¬O¦³¡AÀø®Ä»P¨ÖÁʩαÂÅv¤µÃB¤~¬O³Ì«nªº ¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2024/3/16 ¤U¤È 05:43:27
²Ä 6599 ½g¦^À³
|
¥xÁÞ¤j¡A
§A«Ü¥Î¥\¨Ã«O«ù¼ÖÆ[¡A
¦ý§ÚÁÙ¬O¤£¬Ý¦n¡AÁöµM§Ú¤]¤£½æªÑ¤F¡A´N·í½ä³Õ¿é嘞¡A
¸Ó¤½¥qªº¸Û«H¤£¨Î¡A¦h¦¸©ó¸Ñª¼µo¥¬¼ÖÆ[°T®§¡A
¸Ñª¼«á´N«æ³t¼É¶^¡A¹ï¤½¥qªº®ø®§§Ú¬O¤£·|¬Û«H¤F¡A
¦A»¡¦pªG¦³¤½¥q©Ò»¡¡ATREK-DX¸ÕÅ禳¦¨®Ä¡A ¡A ¦ÛµM·|¦³±M®a¬ã¨s¨ä¦¨®Ä¡A
¤½¥q¬°¦ó¥uº¦¤@¤Ñ´N«æµÛ½â½æªÑ²¼¨p¶Ò¡A
³o¤£²Å¦XÅÞ¿è¡A
¦Ó¥B¤Ñ©R¤j¤wÂ÷¶}¥»ª©¤@¦~¡A¤]³\¦¤w¥X²MªÑ²¼¡A
¥Lªº½×z¤]¤w¨Æ¹L¹Ò¾E¡A¦A¤Þz¥i¯à¤£©y¡A |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2024/3/15 ¤U¤È 09:08:12
²Ä 6598 ½g¦^À³
|
§ó¥¿ ¤Ñ©R¤j¥h¦~¤»¤ë¤G¤Q¤T¤é¹ïASLAN 004²§¦ì©Ê¥Ö½§ª¢±ÂÅv¹w¦ôÈ¡A¥Dn昰®Ú¾Ú¤é¥»ÃÄ«~¥«³õ ¦û¤ñ±À¦ô¥þ²y¥«³õ±ÂÅvª÷(¤£¥]¬AASLAN003¯Z¨r) ȱo¤j®a参¦Ò¡A¨º®ÉÔ©|¥¼¤½§GTREK-DX ¥O¤HÅåÆvªºªì¨B¼Æ¾Ú
¸É¥R 1 TREK-DX Àu²§ªºªì¨B¼Æ¾Ú¨Ó¦Û©óTREK-AD ªº¦¸±Ú¸s¤ÀªR, ¨Ã§Ö³t½Õ¾ã¦¬®×ÁͦVÄY®æ¼Ð·Ç ªºµ¦²¤(¼Ú¬ü¦P¨BÁͦVÄY®æ)TREK-DX »P EblasaKimab in Atopic Dermatitis TREK-AD ¦P¨BÁͦVÄY®æ¦¬®×
2 FAST-AA ¬ã¨s¡A¹wp¸Ó¬ã¨sªº¤¤´Áµ²ªG±N©ó 2024 ¦~¤¤¤½§G, ªÎ¤ô¤£¸¨¥~¤H¥Ð»°§Ö¥Ó½Ð±M§Q«OÅ@ (ªø¹F20¦~)
3 ASLAN Pharmaceuticals °õ¦æªø Carl Firth ³Õ¤h»¡¡C ¡u§ÚÌ«Ü°ª¿³¦¬¨ì¼Ú¬w±M§Q§½Ãö©ófarudodstatª«½è²Õ¦¨±M§Q¥Ó½Ðªº¥¿±ªì¨B·N¨£¡A¨Ã»{¥i§ÚÌ©Ò¦³ ªºÅv§Qn¨D§¡¨ã¦³·s¿o©Ê©M³Ð³y©Ê¡C¦pªG¦b°ê®a¶¥¬qÀò±o±ÂÅv¡A·s±M§Q±N§âfarudodstatªº±M§Q«OÅ@ ©µªø¦Ü¦Ü¤Ö2043¦~¡C³o±NÅãµÛ¼W±jfarudodstatªº°Ó·~¿W¦û©Ê¡A¬O§Ú̦b©Ò¦³ÃöÁä°Ó·~»â°ìfarudodstat ¥[±j ¥Ñ©ó´³¨r±wªÌ¥i¥ÎªºªvÀø¿ï¾Ü«Ü¤Ö¡A§Ú̪º¥Ø¼Ð¬O¬°±wªÌ´£¨Ñ¦w¥þ¦³®ÄªºªvÀø¿ï¾Ü¡C
¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2024/3/15 ¤U¤È 08:30:14
²Ä 6597 ½g¦^À³
|
¤Ñ©R¤j¥h¦~¤»¤ë¤G¤Q¤T¤é¹ïASLAN 004²§¦ì©Ê¥Ö½§ª¢±ÂÅv¹w¦ôÈ¡A¥un昰®Ú¾Ú¤é¥»Ãħ½¥«³õ¦û¤ñ±À¦ô¥þ²y¥«³õ±ÂÅvª÷¡A(¤£¥]¬AASLAN003¯Z¨r) ȱo¤j®a参¦Ò¡A¨º®ÉÔ©|¥¼¤½§GTREK-DX¥O¤HÅåÆvªº¼Æ¾Ú
¥H¤U¬O¤Ñ©R¤j¹w¦ô
ASLAN004 ¥þ²y±ÂÅv+§Q¼í¤§¹w¦ô
¤é¥»¦û¥þ²y¾P°â¬ù5%.,±ÂÅvª÷1.385 »õ¬ü¤¸.
¥þ²y±ÂÅvª÷¦ô 1.385/5%=27.7»õ¬ü¤¸----B
C=B-A=27.7»õ¬ü¤¸-7.8»õ¬ü¤¸(CSL¦¨¥»)=19.9»õ¬ü¤¸(¦©°£CSL¦¨¥»«á¤§§Q¯q)
¤@¤@¤@¤@¤@ASLN004 ¤§»ùÈ:¥þ²y±ÂÅvª÷ 19.9»õ¬ü¤¸ + 10% ¾P°â¤À¼í¤@¤@¤@¤@
⋯¡]¾P°â¤À¼í: 20%- 10%=10%(¦©°£CSL¦¨¥»¤§§Q¯q)
¥H¤W¥¼§tASLAN003ªº»ùÈ¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gªoºj·Æ±¼10153108 |
µoªí®É¶¡:2024/3/14 ¤U¤È 07:53:27
²Ä 6596 ½g¦^À³
|
³o¤@¦¸¬O¨p¶Ò500¸UªÑADS¡]¨p¶Ò»ù1¤¸¡^¦A¥[¤W500¸UªÑªº»{ªÑÅvÃÒ¡]»{ÁÊ»ù1¤¸¡^¡A»{ªÑÅvÃÒ5¦~«á¨ì´Á¡A»{ªÑÅvÃÒ´N¥b¶R¥b¬Û°e¤£¥t¦¬Åv§Qª÷ª½±µµ¹¨p¶Òªº¤H¤F¡AÁ`¦¬¤J¬°467.5¸U¬ü¤¸¡An¬O»{ªÑÅvÃÒ¥þ³¡¦æ¨Ï¡AªÑ¥»ª½±µ¿±µÈ6¦¨¥H¤W¡AÁ`¦¬¯qºâ967.5¸U¬ü¤¸¦n¤F¡A¦U¦ì»{¬°³o°Ï°Ï967.5¸U¬ü¤¸±Ï±o¤Faslan?¬JµM³oµ§¿ú¤w¸gµLÃö¥G¤j§½¡A¤S¬°¦ónÅýªÑ¥»¿±µÈ6¦¨¡H¡H¡H³o´N¬O©Ò¿×ªº¨ÖÁʤj®v¡H¡H¡H¡H |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2024/3/13 ¤U¤È 09:27:06
²Ä 6595 ½g¦^À³
|
«Ó°¶¤j»¡ªº¨S¿ù¡AªGµM¤Þ°_§ë¸ê¾÷ºc zacks investment research ªºª`·N ¥Zµn¤½¥q¤½§i¸ê°T¥þ¤å¡A¥i·j´M ASLAN (ASLN) Up 161% on Upbeat Initial Data From Eczema Study
March 12, 2024 ¡X 09:58 am EDT
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2024/3/13 ¤U¤È 08:53:29
²Ä 6594 ½g¦^À³
|
¦U¦ì·à¤Í¯u¬O¨üºÉ§é¿i¤F¡A
§ÚÓ¤H»{¬°¡A
¤½¥q¨p¶Ò5¦Ê¸UªÑ¡Aq»ù1¬üª÷¡A
¥æ©ö¤é3¤ë14¤é¡A¤¦~«á¤~¨ì´Á¡A
¥Ø«eªÑ»ù§C©ó1¤¸¡A¦pªG©ú¤Ñ¤´¯à¨Ì¬ù§¹¦¨¥æ©ö¡A
§Ú·Q¤½¥q¤§¥Øªº¡A¬OÅýªÑ»ù¦b6¤ë©³«eºû«ù¦b1¬üª÷¤§¤W¡A
ºû«ùÄ~Äò¦bNASDAQªº¥æ©ö¤è¦¡¡A
¨Ã¥Bª§¨ú¤@¨ÇÎA©µ´Ý³Ýªº®É¶¡¡A |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gªoºj·Æ±¼10153108 |
µoªí®É¶¡:2024/3/13 ¤U¤È 07:51:12
²Ä 6593 ½g¦^À³
|
¼ÖÆ[¥J¯uªº«Ü¼F®`¡A¥un·h¥X¥«³õ¼ç¤O«Ü¤j¡AµeÓ¤j»æ´N¥i¥H¹L¤é¤lªº·Pı¡A§Y¨ÏCOPD¡BAA¤G´Á®Ú¥»¤°»ò¨M©w©Êªºµ²ªG³£ÁÙ¨S¥X¨Ó´N¥i¥H±·¦¨³o¼Ë¡A¥t¥~ÁÙ¦³µêµLÄÆ´ùªº¥D¤OÀ£§CªÑ»ù¦Y³f»¡ªk¤]¬O¤@µ´¡A°ò¥»¤W«ùªÑ¶W¹L5%´Nn¥Ó³ø¤F¡A¨ì²{¦b³Ìªñ¥Ó³øªº¤]´NBVF,K2¸òUBS¡A³o¤G¤Ñ¶gÂà²v¤j·§¬ù180%¸ò90%¡A¦pªG³o´X¤Ñ¨S¦³¥Ó³ø«ùªÑ¶W¹L5%ªº·s¤jªÑªF¡A´Nª¾¹D¼ÖÆ[¥J̪º¥D¤O´N¬O¯º¸Ü¤@«h¡A¨ì©³þ¸Ì¨Óªº¼oª«¥D¤O³sÄò¤G¤Ñ¶gÂà²v³o»ò°ªÁÙ¦¬¤£¨ì¶W¹L5%Äw½X¡A¦Ó¥B¥HAslan¥«È1»õ¬ü¤¸¡]ªÑ»ù¬ù6¬ü¤¸¡^¨Ó»¡¡A5%¥«È¤]¤~500¸U¬ü¡A§ó¦óªp±q2024¦~1¤ë¥H¨Ó¡AªÑ»ùªø´Á¦b0.5¬ü¤¸¥ª¥k¡A5%«ùªÑ¤]¤~¤£¨ì50¸U¬ü¤¸¡A¨ì©³¬OþÓ¼oª«¥D¤O³s50¸U¬ü³£¶R¤£°_°Õ¡AÃø¤£¦¨³o°¶¤jªº¥D¤OnÀ£§C¨ì0.05Ä~Äò¦Y³f¡H |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G§_¨ì©³°Õ10148994 |
µoªí®É¶¡:2024/3/13 ¤U¤È 07:06:00
²Ä 6592 ½g¦^À³
|
m.investing.com/news/stock-market-news/aslan-pharmaceuticals-announces-5-million-offering-93CH-3334785 ¥i¥ß§Y¦æ¨Ï¡A¤¦~ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2024/3/13 ¤U¤È 02:32:58
²Ä 6591 ½g¦^À³
|
¥ý¤£ºÞªÑ»ù¤S¦^¨ììÂI ¦Ü¤Ö¶q¦³ª£¥X¨Ó¡AÅý¤j®aÃöª`¨ì´N¬O¦n¨Æ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GªL®õ10030886 |
µoªí®É¶¡:2024/3/13 ¤U¤È 01:47:47
²Ä 6590 ½g¦^À³
|
½Ð°Ý¦U¦ì¤j¤j
¬üªÑ¨p¶ÒªÑ²¼ ¦³³¬Âê´Á¶Ü¡H ¦³ªº¸Ü ¦h¤[¡H
½Ðª¾¹Dªº¤j¤j ½ç±Ð |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2024/3/13 ¤U¤È 01:09:30
²Ä 6589 ½g¦^À³
|
ªº½T´²¤áªº®zÂI´N¬O¬Ý¨£ªÑ»ù¶^ªº®ÉÔ·|¶°Å鮣·W½æ¥X«ùªÑ , ¤W¨R¤U¬~®É¤£°í©wªºÄw½X ³vº¥¸¨¤J¤jªÑªF¤â¤W, ¨ä¹ê´N¬O¥H¤j´Û¤p ( ¤jªÑªF¤â¤W¦³ªÑ²¼ ¤S¦³²{ª÷ ) µ¥¬y³qÄw§l¦¬¹L¥b®ÉªÑ»ù©Ô©ï°_¨Óªý¤OÅܤp ( ¯d¤Uªº´²¤á³£¬O°í©wªºÄw½X) ªÑ»ù¤~¦³¯u¥¿ªº¤W¤É
¤jªÑªFÁöµM¾Ô³NÆF¬¡¿W¥ß©Î¦X¤O©Ô©ïªÑ»ù µL©¹¤£§Q , ´²¤á¯u¥¿nÃö¤ßªº°£¤FªÑ»ù ¨ÖÁÊ»ù¥~¬O¾Ô²¤ªº¥¿½T ¤]´N¬O¤½¥q¶}µo²£«~¬O§_¨ã¦³Àø®Ä»P¦w¥þ©Ê ¶}µo²£«~ªººØÃþ»P¥«³õ¤j¤p , ¥»¦¸¶Ò¸ê500¸U¬ü¤¸¥Dn¥Î©ó ¸ê§U·sªº©M¨ä¥L¥¿¦b¶i¦æªº¬ãµo¬¡°Ê¡BÀç¹B¸êª÷©M¨ä¥L¤@¯ë¤½¥q¥Î³~, ¯à¶Ò¨ì¸êª÷³Ì«n ,¦³¸êª÷¤~¦³ «áºüªº¬ãµo, ·í²£«~½u¦h¤¸¤S¦³Ävª§¼ç¤O¥¼¨Ó³Q¨ÖÁÊ»ù¤~·|°ª, ´²¤á»P¨äÃö¤ßªÑ»ù¤£¦pÃö¤ß¨ÖÁÊ»ù
ÁÉ¿Õµá¡B¦A¥Í¤¸ ÀHµÛºC©Êªý¶ë©ÊªÍ¯fªºÂX±i¡A¾P°âÃB¥¼¨Ó¥i¯à¹F¨ì 20B ¬ü¤¸°ª®p , 2023¦~ ¬ù115.9 »õ¬ü¤¸ ( Dupixent global net sales soared by 33% to $11.59 billion in 2023)
¨Ì¾Ú¤½¥q¤½§i¼Æ¾Ú 63% ±µ¨ü dupilumab ªvÀøªº±wªÌ¦b 16 ¶g«á¥¼¯à¹ê²{³z©ú©Î´X¥G³z©úªº¥Ö½§ ¡]IGA µû¤À¬° 0 ©Î 1¡^¡Aªí¥Ü¥u¦³37¢Hªº¯f±w¹F¼Ð¡A¹F¼Ð¤¤¤S¦³£¸¥bµLªk¦b±µ¤U¨Ó36¶gºû«ù³z©ú©Î ±µªñ³z©úªº¥Ö½§¡A¤]´N¬O»¡¥u¦³¦Ê¤À¤§18.5ªº¯f±w¨Ï¥Îdupilumab¯à¯u¥¿ªº¹F¨ìIGAµû¤À¹F¨ì0©Î1¡A ¦Ê¤À¤§81.5ªº¯f±w¨Ï¥ÎÀø®ÕµLªkªø´Á¹F¨ìIGAµû¤À¹F¨ì0©Î1,³o¬O£¸Ó«Ü¤j¥¼³Qº¡¨¬ªº»Ý¨D¡A ¤]¬Oeblasakimab ¤d¸üÃø³{ªº¾÷·| ( Eblasakimab °£¤FTREK-AD »Pdupilumab¥¿±¹ï¨M¥~ ,¨Ï¥Î¹Ldupilumab Àø®Ä¤í¨ÎªÌªº¥«³õ¤]«ÜÃe¤j, ¥i¥H¤j¤O·m§ð ¥t¥~ÁÙ¦³¦Ê»õ¬ü¤¸¥«³õªº fast-AA COPD )
¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2024/3/13 ¤W¤È 11:52:30
²Ä 6588 ½g¦^À³
|
±±½L©ó§_¹ï§b·à¦Ó¨¥¡A¬Oµu½u½Ä®ö«ÈªºÃöª`¡FµM³o¤½¥qY¨S¦³¨ÖÁʪº°Ê¦V¬O¨S¦³ªø»·¤U¤@¨Bªº¡A¤j®an²`«×«ä¼{¦p¤T´Ánªá¦h¤Ö¿ú?´Nª¾¹Dªü·à¥¼¨Ón«ç»ò¿ì¤F?
¤j®a°Ñ¦Ò¡A¬ÕÁ«¦Ût~ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GROGER588910148151 |
µoªí®É¶¡:2024/3/13 ¤W¤È 09:35:39
²Ä 6587 ½g¦^À³
|
5M ªÑADS¨p¶Ò¡A¬ù¦ûÁ`ªÑ¥»16.7M ¤§3¦¨¡A¤ñ¨Ò«Ü°ª ---------------------------------------------------------------
ÉÜ®a¤£±±盘
ÉÜ®a¤£±±盘¤@¥uªÑ²¼·N¨ýþÓÉÜ®a§C¤_这²¼ªº10%ªº¬y³q筹码¡AÉÜ®a¤â¤¤¤£¨¬10%ªº¬y³q筹码谈¤£¤W±±盘状态¡A¥u¯à说¬O¤@个¤¤¤j户¦Ó¤w!
轻«×±±盘
ÉÜ®a¯à轻«×±±盘¤@¥u个ªÑªº话¤â¤¤个ªÑ³Ì°_码¦³20%¦Ü30%¥ª¥kªº¬y³q筹码¡A这30%ªº¬y³q筹码³£¬O随Éó·t¤¤§C§lªº;³£¬O¾a´²户卖¥XªÑ²¼¡AÉÜ®a¬Ý¦n这²¼¡A³v渐§C§l¦Ó来ªº¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2024/3/13 ¤W¤È 08:57:25
²Ä 6586 ½g¦^À³
|
5M ªÑADS¨p¶Ò¡A¬ù¦ûÁ`ªÑ¥»16.7M ¤§3¦¨¡A¤ñ¨Ò«Ü°ª
¦Ó¥Bq»ù1¬üª÷¡AÁ`¶Ò¸ê¤~500¸U¬üª÷¡AÁÙnµ¹¥N²z°Ó¶Äª÷¡A
¹ê®³¤£¨ì500¸U¬üª÷¡A¦p¦¹¾Þ§@¥i¯à¤w¤s½a¤ôºÉ¡A«æ»Ý¥Î¿ú¤S§ä¤£¨ì¿ú¡A
³oªü¤TCEO±q¦b¥xÆW´NJ§@«D¬°¡A±q¤£¦Ò¼{ªÑªF§Q¯q¡A
¦pªG®Ä¥Î¤ñ§ù¥²ª¢¦n¡A¦ÛµM·|¦³¤H¶R³æ¡A¨º¤S¬°¦ó¤~º¦¤@ÂI´N«æµÛ½æ¿ú¡A
¦A¥Í¤¸ªÑ»ù²{¤w9¦Ê¦h¬üª÷¡A
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GROGER588910148151 |
µoªí®É¶¡:2024/3/13 ¤W¤È 08:47:36
²Ä 6585 ½g¦^À³
|
§ë¸ê·sÃĥͧÞÁÙ¬OÃöª`¦b¨ä¦¨¥\²v»PÃÄ«~¥«³õ. ¤pªÑªF¦h¤£³ßÅw§CªÑ»ù¡A¤£¹L§CªÑ»ù¦³§Q©ó²ø®a! 1.¤@ª÷¿Ä¤k³Õ¤h说¯}ªÑ¥«¡G为¤°¤\ÉÜ®a´±¥´压ªÑɲ¡AúÒ¤£©È别¤H抢·Gɲ筹码¡H xueqiu.com/6895810792/146076771
2.¨p¶Ò¾Þ½L¤â³zÅS¡G²ø®a«Øܤâªk¥þ§ð²¤ news.cnyes.com/news/id/1154883 |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GªL®õ10030886 |
µoªí®É¶¡:2024/3/13 ¤W¤È 08:06:04
²Ä 6584 ½g¦^À³
|
·í®É004 ¦b¤@´Áªì
³o¦¸¤G´Á¤w°µ§¹ ·Ç³Æ¤T´Á ÁÙ¦h°µ¤F¦³«Ø³]©Êªº¸ÕÅç
·íªì4 ¤¸¨p¶Ò ªÑ»ù«æ©Ô¨ì8 ¤¸ »¤¾É¾÷ºc°Ñ¥[¨p¶Ò
³o¦¸ªÑ»ù¼ÆÓ¤ë¤@ª½¦b 1 ¤¸¥H¤U °Ñ¥[ªÌÄ@·N¥H 1 ¤¸ÁʤJ
¨p¶ÒÀ³¸Ó¬O«æ©Ô¨ì2 ¤¸ ¤§«e´N½Í¦n¤F ¤½¥¬¨p¶Ò®ø®§«á «æ®À¦^°_ötÂI¡]0.62¡^¤W¤@ÂIÂI
À£¦^¤~¬O¹ïªº ¤£µM ª½öt¤W¥h °Z¤£¬O¦³¤º½u¥æ©ö¤§¶û
500 ¸U¬ü¤¸ªº¨p¶Ò¤£ºâ¤jµ§ ¬°¦ó¦³¾÷ºcn¥Î1 ¤¸°Ñ¥[³o¨p¶Ò
«áÄò ªÑ»ù¦p¨S¦A¤U¦æ ÅuµP®ÉÔ¨ì¤F
@¤H´M¨ý
@¤H´M¨ý
@¤H´M¨ý
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gªoºj·Æ±¼10153108 |
µoªí®É¶¡:2024/3/13 ¤W¤È 04:34:51
²Ä 6583 ½g¦^À³
|
ªGµM³Q§Ú§¹¥þ©R¤¤¡A¸òaslan004¤@´Áµo¥¬ªì´Á¼Æ¾Úªº®ÉÔ§¹¥þ¤@¼Ë¡A´N¥u¬O¬°¤F¨p¶Ò½Ä°ª»ù®æ¦Ó¤w¡]¤§«eµo¥¬«á½L«e½Ä°ª¨ìUSD8¤¸¡AµM«á¤]¬Oª½±µUSD4¤¸¥ª¥k¨p¶Ò¡AªÑ»ùª½±µ±YÄê¡^¡A³o¦¸¤]¬OµoÓªì´Á¥¼¸Ñª¼¼Æ¾Ú¡A½Ä°ª»ù®æ«á¥ß¨è§C»ù¨p¶Ò¡AµM«áªÑ»ùª½±µ±YÄê¡A¾ú¥vÁ`¬OÅå¤Hªº¬Û¦ü¡A¤w¸g¤Wºt³o»ò¦h¦¸¤F¡AÁÙ¬O¦³¤H¿ï¾ÜµLµø¡A¦³¤HÁ`¬O¤@ª½¦b»¡carl firth¬O¨ÖÁÊ°ª¤â¡A½Ð°Ý¥i¥H§ä¥X¤@Ó¨Ò¤lµ¹¤j®aÁ@Á@¡A¨Ó¬Ý¬Ý¨ì©³¦h·|¨ÖÁÊ¡H§Ú¥uª¾¹D¬OÓ°é¿ú°ª¤â¦Ó¤w¡A«ö·Ó¤W¦¸¸gÅç¡A±µ¤U¨ÓªÑ²¼·|«ùÄò½w¶^«Üªø¤@¬q®É¶¡¡A¦Ó¥BªÑ¥»¤]¶}©lºCºC¿±µÈ¤¤¤F¡A¦Ñ·à¤Í̽ЫO«¡A§O¦A¬Û«H¨º¨Ç¼ÖÆ[¥J¤F¡A¤j®a¥i¥H¥h½½Â¤å¡A´N¥i¥Hª¾¹D¼ÖÆ[¥Jªº¤ÀªR°ò¥»¤W¨S¦³·Ç¹LRRR¡AˬO§Úµo¤å´£¿ô¤j®aª`·N¡A¼ÖÆ[¥JÁÙ¤£¼Ö¨£¡A¨ì©³¬O½Ö©~¤ß¥r´ú©O¡H |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gªoºj·Æ±¼10153108 |
µoªí®É¶¡:2024/3/12 ¤U¤È 11:41:05
²Ä 6582 ½g¦^À³
|
ªGµM¤@¦p¬J©¹¡A¬Q¤Ñ¤£ºÞ¬O½Ö©Ô°ªªº¡A¤W2¤¸«áª½±µ¤@®Ú¤j¶ÂK¥X³f¡A¥u³Ñ°l°ªªº®M¦b¤s³»¡A¬Ý¬Ý±q2¤¸¨º¤@®Ú±þ¤U¨Ó¤§«á¡A¦¨¥æ¶q¾ãÓµäÁY¡A´Nª¾¹D¬Q¤Ñ©Ô°ªªº¥D¤O¦¶]¤F¡A¥u³Ñ´²¤áú·w¦b´Z©Ò¡AµM«á´N¥u¯àÄ~Äò½w¶^¤F¡A¨C¦¸Aslan¦³´Á¤¤¼Æ¾Ú¤½¥¬³£·|¨Ó³o¤@©Û¡A¯uªº¼Æ¾ÚÀu¨q¡A«ç»ò·|¬Q¤Ñ½L«e´X¥G¨S¤ÏÀ³¡Aª½¨ì½L¤¤¤~¶}©l©Ô¡A´N¬O·íµu½uª£¤@ªi¡A¶¶«KÅý¼ÖÆ[¥J¦í®M©Ð¡A¦Ñ·à¤ÍÀ³¸Ó³£«Ü¼ô±x³o®M¸ô¤F..... |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GªL®õ10030886 |
µoªí®É¶¡:2024/3/12 ¤U¤È 10:00:55
²Ä 6581 ½g¦^À³
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2024/3/12 ¤U¤È 09:28:06
²Ä 6580 ½g¦^À³
|
ASLAN Pharmaceuticals ¸g¾ú³sÄòÁ{§É¥¢§Q¦p¤µWºÉ¥Ì¨Ó¡A°t¦Xªñ´ÁÁ{§É¼Æ¾Úªºµo§G¡A ªÑ»ù§Þ³N½u«¬§Î¦¨¦hÀY±Æ¦Cªº±j¯P¶R¶i°T¸¹¡A ªÑ»ù·|»¡¸Ü¡Aªñ´XÓ¤ë¥kÃä¤j¶q¦Y±¼¥ªÃä¶q¡A ³oºØ¼Qµo¤Wº¦¤è¦¡¨M«D´²¤á©Ò¬°¡AÁÙ¨S¤W¨® ªº¤j¤jµ¥®É¾÷¤W¨®¡A¤£¥Î¦Ç¤ß¡C ²Ö¿n¨ÖÁʽͧP¹ê¤O : TREK-DX :(ªñ¤é¤wµo§G22¤H´¿¨Ï¥Î¹L dupilumab ªº±wªÌ¤¤Âà¨Ï¥ÎeblasakimabªºÀø®Ä¼Æ¾Ú) 63% ±µ¨ü dupilumab ªvÀøªº±wªÌ¦b 16 ¶g«á¥¼¯à¹ê²{³z©ú©Î´X¥G³z©úªº¥Ö½§¡]IGA µû¤À¬° 0 ©Î 1¡^¡Aªí¥Ü¥u¦³37¢Hªº¯f±w¹F¼Ð¡A¹F¼Ð¤¤¤S¦³£¸¥bµLªk¦b±µ¤U¨Ó36¶gºû«ù³z©ú©Î±µªñ³z©úªº¥Ö½§¡A¤]´N¬O»¡¥u¦³¦Ê¤À¤§18.5ªº¯f±w¨Ï¥Îdupilumab¯à¯u¥¿ªº¹F¨ìIGAµû¤À¹F¨ì0©Î1¡A³o¬O£¸Ó«Ü¤j¥¼³Qº¡¨¬ªº»Ý¨D¡A¤]¬Oeblasakimab ¤d¸üÃø³{ªº¾÷·|¡C
TREK-AD : TREK-AD ¬ã¨sªºµ²ªGªí©ú¡Aeblasakimab ¦³¼ç¤O¦b²§¦ì©Ê¥Ö½§ª¢ (AD) ¤¤´£¨Ñ¨C¤ë¤@¦¸ªºµ¹ÃĤè®×¡A¦Ó¤£¼vÅT Àø®Ä¡A¨Ã¦¨¬° AD ªº»â¥ýÀøªk
FAST-AA : (´Á«Ý¦~¤¤µo§G´³¨r¬ã¨sªº´Á¤¤¼Æ¾Ú)
¨ä¥L¦³¼ç¤Oªº»â°ì COPD : (ºC©Êªý¶ë©ÊªÍ¯f ´Á«Ýªñ´Á°ê»Ú´Á¥Z¬ã¨sªº¶i¤@¨B¼Æ¾Ú )
¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gªoºj·Æ±¼10153108 |
µoªí®É¶¡:2024/3/12 ¤U¤È 06:13:49
²Ä 6579 ½g¦^À³
|
¨Ì·ÓAslanªººD¨Ò¡A³£·|¥ý¤½¥¬³¡¤ÀÀø®Ä¬Ý°_¨Ó«ÜÀu¨qªº¼Æ¾Ú¡AµM«á§Q¦h¶}©l¥XÅ¢¡AÀHµÛªÑ»ù¦bµ²ªG¤½¥¬«e¤i¹F¨ì°ªÂI¡AµM«áµ²ªG¥X¨Ó¤£¦p¹w´Á¡Aª½±µ¥´¦^ì§Î¡A¬Ý¬ÝAslan001¡A»¡ªºÃĮĦh¦n¦h¦³«H¤ß¡Aª¼¼Æ¾Ú¤]¬O»¡¦h¦n¦h¦n¡Aµ²ªG¸Ñª¼«á¤£ºÞ¬O¸~½F¤ÏÀ³²vÁÙ¬O¦s¬¡´Á¡A³£¸ò¦w¼¢¾¯²Õ®t¤£¦h¡A¨ì©³þ¸Ì¨Óªº«H¤ß¡HAslan004¤]¬O¤@´Á³¡¤À¼Æ¾Ú«ÜÀu¨q¡Aµ²ªG§¹¾ãµ²ªG¥X¨Ó¤]¬O¾ãÅéÀø®Ä¤£¦p¤@°_ªì´Á¼Æ¾Ú¡A¤G´Á¤]¬Oµ²ªG¥X¨Ó¤~¦A»¡¦w¼¢¾¯²Õ¤ÏÀ³²v¤]«Ü°ª¡A¤§«áªÑ»ù´N±Y½L¤F¡A«e¦¸¶gÂà²v¯}¦Ê´N¬O¤@´Áªì´Á¼Æ¾Ú¥X¨Ó¡AµM«áªÑ»ù¶}°ª«á¤½¥q¥ß¨èµo¥¬¨p¶Ò¡AµM«á¤@¸ô±YÄê¡A·íªì¨p¶Ò¶i¨Óªº¥þ³¡®M¦º¡AAslan¤£¯Êµe¤j»æªº¯à¤O¡A»æµeªº¦A¤j¡A¤´Â¤ñ¤£¤W³Ì«áªº¹êÅçµ²ªG¡A³oºØ´Á¤¤¼Æ¾Ú°Ñ¦Ò´N¦n¡A¦Ñ·à¤ÍÌÀ³¸Ó¤w¸g§K¬Ì¤F..... |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2024/3/12 ¤U¤È 05:27:43
²Ä 6578 ½g¦^À³
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2024/3/12 ¤W¤È 08:15:08
²Ä 6577 ½g¦^À³
|
¬Q±ß¦¨¥æ¶q¬O¾ú¥v¤W³Ì¤j¶q¡A
§CÀÉ¥X¤j¶qÀ³¬O¦n¨Æ¡A
¦ý³o¶q¤]¤ÓÅå¤H¤F¡A ¸Ó¦p¦ó¸ÑŪ¡A
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2024/3/12 ¤W¤È 08:01:12
²Ä 6576 ½g¦^À³
|
¦U¦ì¤j¤j
¨È·à±dªÑ²¼Á`¶q¦³16.7MªÑ¡A
¥i¬O¬Q¤Ñªº¦¨¥æ¶q25.2MªÑ¡A
µ¥©ó¬O©Ò¦³ªÑ²¼³£³Q½æ¹L1¦¸¥H¤W¡A
³o¶q¬O§_¥¿½T©O¡A
´X¥G©Ò¦³ªÑ²¼³£´«¤H©Î¬O¦h¦¸¶R½æ¡A
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2024/3/12 ¤W¤È 12:08:57
²Ä 6575 ½g¦^À³
|
§ó¥¿¸É¥R TREK-DX ±N©Û¶Ò¬ù 75 ¦W¦]¥ô¦óì¦]°±¤î dupilumab ªvÀøªº±wªÌ¡A¥]¬AAD ±±¨î¤£¥R¤À¡BµLªk¶i¤J©Îµo¥Í¤£¨}¨Æ¥ó¡A¨Ã¥H 400 ²@§J eblasakimab ©Î¦w¼¢¾¯ªvÀø¨C¶g¤@¦¸¡A«ùÄò 16 ¶g¡C ¦b¹ï 22 ¦W±wªÌªºª¼ªk¼Æ¾Ú¶i¦æªì¨B¼f¬dªº¼Æ¾ÚºI¤î®É ®Ú¾Ú³Ìªìªº¯Ç¤J¼Ð·Ç¤J²Õ¡A¥H 2:1 ªº¤ñ¨ÒÀH¾÷¤À°t¬¡©ÊÃĪ«²Õ©M¦w¼¢¾¯²Õ¡A17 ¦W±wªÌ§¹¦¨¤F 16¶gªvÀø´Á¡A5 ¦W±wªÌ¦b 16 ¶gªvÀø´Á§¹¦¨«e°±ÃÄ¡C 10 ¦W±wªÌ¡]§Y 45%¡^ªº EASI ¤À¼Æ¤U°¦Ü¤Ö 90¡]EASI-90¡^¡A11 ¦W±wªÌ¡]§Y 50%¡^ Àò±o¸g¹LÅçÃÒªº¬ã¨sªÌ¾ãÅéµû¦ô (vIGA) ¤À¼Æ 0 ©Î 1¡]³z©ú©Î´X¥G³z©úªº¥Ö½§¡^¡C 9¦W±wªÌ¤¤¦b¥ý«e¹ï dupilumab ¤ÏÀ³¤£¨¬ªº±wªÌ¤¤¡A5 ¦W±wªÌ (56%) ¹F¨ì EASI-90¡A5 ¦W±wªÌ (56%) ¹F¨ì vIGA µû¤À¬° 0 ©Î 1¡C¨´¤µ¬°¤î¡AªvÀøªº@¨ü©Ê¨}¦n¡A¨S¦³µo²{·sªº¦w¥þ°T¸¹¡C ¨S¦³µ²½¤ª¢ªº³ø§i¡A¤]¨S¦³µù®g³¡¦ì¤ÏÀ³ªº³ø§i¡C ¨Ó¦Û§¹¾ã¼Æ¾Ú¶°ªº³Ì«nªº«Dª¼¼Æ¾Ú ¹wp2024¦~©³¡C ¡u63% ±µ¨ü dupilumab ªvÀøªº±wªÌ¦b 16 ¶g«á¥¼¯à¹ê²{³z©ú©Î´X¥G³z©úªº¥Ö½§¡]IGA µû¤À¬° 0 ©Î 1¡^2 ¡A ©M¤j¬ù¤@¥bªº±wªÌ½T¹ê¹F¨ì¤F³oºØ¤ÏÀ³¡A¦ý¦b±µ¤U¨Óªº 36 ¶g«á¨Ã¨S¦³ºû«ù³oºØ¤ÏÀ³ ¡A©Ò¥H¦³¢¤Á»ÝnÃB¥~ªº¥Íª«Àøªk¨Ó´£¨Ñ¦w¥þ¦³®Äªºªø´ÁªvÀø¥¼¹F¨ì¨¬°÷¤ÏÀ³ªº±wªÌªº¿ï¾Ü¡C
Ó¤Hµû½× 63% ±µ¨ü dupilumab ªvÀøªº±wªÌ¦b 16 ¶g«á¥¼¯à¹ê²{³z©ú©Î´X¥G³z©úªº¥Ö½§¡]IGA µû¤À¬° 0 ©Î 1¡^¡Aªí¥Ü¥u¦³37¢Hªº¯f±w¹F¼Ð¡A¹F¼Ð¤¤¤S¦³£¸¥bµLªk¦b±µ¤U¨Ó36¶gºû«ù³z©ú©Î±µªñ³z©úªº¥Ö½§¡A¤]´N¬O»¡¥u¦³¦Ê¤À¤§18.5ªº¯f±w¨Ï¥Îdupilumab¯à¯u¥¿ªº¹F¨ìIGAµû¤À ¹F¨ì0©Î1¡A³o¬O£¸Ó«Ü¤j¥¼³Qº¡¨¬ªº»Ý¨D¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2024/3/11 ¤U¤È 11:13:41
²Ä 6574 ½g¦^À³
|
Dupilumab experienced 22¤Hªì¨B¼Æ¾Ú ¶W¥G¹w´Áªº¦n ( Dupilumab Àø®Õ ¤í¨Î¤¤¤S±Ï¤F45%-50 % ªº¤H )
(10¤H/22¤H 45% ¹F¨ì EASI 90 11¤H/22¤H 50% ¹F¨ì vIGA¤À¼Æ 0 ©Î 1 (EASI 75 ¼Æ¾Ú·|¤ñEASI 90 §ó¦n)
(¨ÖÁÊ»ù®æ´£¤É 1 AD ¤G B¼Æ¾Ú 2 ¦~¤¤AA ¼Æ¾Ú 3 TREK-DX¼Æ¾Ú ( ´£¦¤½§i75¤H¤¤ªº22¤H )
¤µ¤é°T®§«Üªø «ÂI¦p¤U TREK-DX ¯Ç¤J¼Ð·Ç¤w¦¬ºò¼Ð·Ç¡A©Û¶Ò°ò½uÀã¯l±¿n©MÄY«µ{«×«ü¼Æ (EASI) µû¤À¦Ü¤Ö¬° 18 ¤À ¡]¦Ó¤£¬O 16 ¤À¡^ªº±wªÌ¡C¦P®É¡A¤]¹ê¬I¤F¿W¥ßµû¼fû¹ï°ò½u EASI ¤À¼Æªº½T»{¡C ¬ü°êºô¯¸¥Ø«e¥¿¦b®Ú¾Ú§ó·sªº¼Ð·Ç©Û¶Ò±wªÌ¡A¼Ú¬wªº¨ä¥L¯¸ÂI¤]¹wp¦b¼Ú¬w¶}©ñ2024 ¦~¤W¥b¦~¡C TREK-DX ±N©Û¶Ò¬ù 75 ¦W¦]¥ô¦óì¦]°±¤î dupilumab ªvÀøªº±wªÌ¡A¥]¬AAD ±±¨î¤£¥R¤À¡BµLªk¶i¤J©Îµo¥Í¤£¨}¨Æ¥ó¡A¨Ã¥H 400 ²@§J eblasakimab ©Î¦w¼¢¾¯ªvÀø¨C¶g¤@¦¸¡A«ùÄò 16 ¶g¡C ¦b¹ï 22 ¦W±wªÌªºª¼ªk¼Æ¾Ú¶i¦æªì¨B¼f¬dªº¼Æ¾ÚºI¤î®É®Ú¾Ú³Ìªìªº¯Ç¤J¼Ð·Ç¤J²Õ¡A¥H 2:1 ªº¤ñ¨ÒÀH¾÷¤À°t¬¡©ÊÃĪ«²Õ©M¦w¼¢¾¯²Õ¡A17 ¦W±wªÌ§¹¦¨¤F 16¶gªvÀø´Á¡A5 ¦W±wªÌ¦b 16 ¶gªvÀø´Á§¹¦¨«e°±ÃÄ
10 ¦W±wªÌ¡]§Y 45%¡^ªº EASI µû¤À¤U°¦Ü¤Ö 90%¡]EASI-90¡^
11 ¦W±wªÌ¡]§Y 50%¡^Àò±o¸g¹LÅçÃÒªº¬ã¨sªÌ¾ãÅéµû¦ô (vIGA) ¤À¼Æ 0 ©Î 1
¨´¤µ¬°¤î¡AªvÀøªº@¨ü©Ê¨}¦n¡A¨S¦³µo²{·sªº¦w¥þ°T¸¹¡C
Dupilumab experienced(½Õ¾ã¦¬®×µ¦²¤ ¥H®É¶¡´«¨ú§ó¨ÎÀø®ÄªºªÅ¶¡ (¨Ï¥ÎDupilumab®ÄªG¤í¨Îªº¯f±w) ¤j®a·Q¤@·Q TREX-DX ¹êÅç¼Æ¾Ú¬OÀø®Ä¤ñ¸û«n ÁÙ¬O¦¤@ÂI¤½§i¼Æ¾Ú¤ñ¸û«n ? ¤½¥q½Õ¾ã¦¬®×µ¦²¤ ¥H®É¶¡´«¨ú§ó¨ÎÀø®ÄªºªÅ¶¡¬O¥¿½Tªº¿ï¾Ü
¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò ¦p¦³¿ù»~½Ð§ó¥¿ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2024/3/11 ¤U¤È 08:23:31
²Ä 6573 ½g¦^À³
|
TREK-DX ¬O²Ä¤@Ó¦b¸g¾ú dupilumab ªº²§¦ì©Ê¥Ö½§ª¢ (AD) ±wªÌ¸sÅ餤¶i¦æªºÀH¾÷¡BÂùª¼¡B¦w¼¢¾¯¹ï·Ó¬ã¨s¡A¤w¶}©l®Ú¾Ú§ó·sªº¤è®×¦b¬ü°ê©Û¶Ò±wªÌ¡F ·sªº¼Ú¬w¯¸ÂI¹wp©ó 2024 ¦~¤W¥b¦~¶}·~ ¦b¹ï¨´¤µ¬°¤î±µ¨üªvÀøªº22 ¦W±wªÌªºª¼ªk¼Æ¾Ú¶i¦æªºªì¨B¼f¬d¤¤¡A45% (10/22) ªº±wªÌªºEASI µû¤À(EASI-90) ¦Ü¤Ö°§C¤F90%¡A50% (11/22)ªº±wªÌ¹F¨ì¤F16 ¶g«á vIGA µû¤À¬° 0 ©Î 1¡]¥Ö½§³z©ú©Î´X¥G³z©ú¡^¡C ¹wp§¹¾ã¸ê®Æ¶°¤¤ªº«Dª¼¸ê®Æ±N©ó 2024 ¦~©³µo¥¬ Âà¤Æ¼Æ¾Úªí©ú¡A¹v¦VIL-13R »PIL-4R ªº®ÄªG¦s¦b®t²§¡Aªí©úeblasakimab ¦³¥i¯à¹ïDupilumab ¥¼¹F¨ì¨¬°÷¤ÏÀ³ªºAD ±wªÌ¦³®Ä¡A³o¬O¤@Ó«n¥BªA°È¤£¨¬ªº±wªÌ¸sÅé¡A«Ü¤Ö¦³¦w¥þ©Mªø´ÁªºªvÀø¿ï¶µ¡A
¥[¦{¸t°¨¯S¶ø©M·s¥[©Y¡A2024 ¦~3 ¤ë11 ¤é¡]Àô²y³q°TªÀ¡^¡XASLAN Pharmaceuticals Ltd.¡]¯Ç´µ¹F§J¥N½X¡GASLN¡^¬O¤@®aÁ{§É¶¥¬q¡B±Mª`©ó§K¬Ì¾Çªº¥Íª«»sÃĤ½¥q¡AP¤O©ó¶}µo³Ð·sÀøªk¥H§ïÅܱwªÌªº¥Í¬¡¡A¤µ¤Ñ«Å¥¬¡G¸Ó¤½¥q¤w¶}©l¦b¬ü°ê®Ú¾Ú¥¿¦b¶i¦æªºTREK-DX ¸ÕÅ窺§ó·s¤è®×©Û¶Ò±wªÌ¡A¦b¨Ï¥Î¹Ldupilumab ªº¤¤«×¦Ü««×²§¦ì©Ê¥Ö½§ª¢(AD) ±wªÌ¤¤¬ã¨seblasakimab¡C
TREK-DX ¬O²Ä¤@Ó¦b¬J©¹±µ¨ü¹L dupilumab ªvÀøªº AD ±wªÌ¤¤¶i¦æªºÀH¾÷¡BÂùª¼¡B¦w¼¢¾¯¹ï·Ó¸ÕÅç¡A¸Ó¥«³õ¹wp¨ì 20291 ¦~±N¹F¨ì 100 »õ¬ü¤¸¡C±j½Õ¤F¬ü°êAD ±wªÌ¸sÅ骺ÅܤơA TREK-DX ¯Ç¤J¼Ð·Ç¤w¦¬ºò¡A¥H©Û¶Ò°ò½uÀã¯l±¿n©MÄY«µ{«×«ü¼Æ(EASI) µû¤À¦Ü¤Ö¬°18¡]¦Ó¤£¬O16¡^ªº±wªÌ¡C»P¦¹¬Ûµ²¦X¡A¿W¥ßµû¼fû°ò½u EASI ¤À¼Æªº½T»{¤]¤w¹ê¬I¡C ¬ü°êªº¯¸ÂI¥Ø«e¥¿¦b®Ú¾Ú§ó·sªº¼Ð·Ç©Û¶Ò±wªÌ¡A¼Ú¬wªº¨ä¥L¯¸ÂI¹wp±N©ó 2024 ¦~¤W¥b¦~¶}©ñ¡C
TREK-DX ±N©Û¶Ò¬ù 75 ¦W¦]¥ô¦óì¦]¡]¥]¬A AD ±±¨î¤£¥R¤À¡BµLªk¶i¤J©Î¤£¨}¨Æ¥ó¡^°±¤î dupilumab ªvÀøªº±wªÌ¡A¨Ã¨C¶g¨Ï¥Î 400 ²@§J eblasakimab ©Î¦w¼¢¾¯ªvÀø¥LÌ¡A«ùÄò 16 ¶g¡C ¦b¹ï®Ú¾Úì©l¯Ç¤J¼Ð·Ç¤J²Õªº22 ¦W±wªÌªºª¼ªk¼Æ¾Ú¶i¦æªì¨B¼f¬d®É¡A³o¨Ç±wªÌ«ö2:1 ªº¤ñ¨ÒÀH¾÷¤À¬°¬¡©ÊÃĪ«²Õ©M¦w¼¢¾¯²Õ¡A¦b¼Æ¾ÚºI¤î®É¡A17 ¦W±wªÌ§¹¦¨¤F16 ¶gªºªvÀø´Á¡A5 ¦W±wªÌ¦b§¹¦¨«e°±ÃÄ16¶gªºªvÀø´Á¡C ¦b²Ä16 ¶g©Î³Ì«á¤@¦¸´N¶E®É¡A10 ¦W±wªÌ¡]§Y45%¡^ªºEASI µû¤À¤U°¤F¦Ü¤Ö90%¡]EASI-90¡^¡A11 ¦W±wªÌ¡]§Y50%¡^¹F¨ì¤F0 ©Î1 ¤Àªº¸g¹LÅçÃÒªº¬ã¨sªÌ¾ãÅéµû¦ô(vIGA) µû¤À¡]³z©ú©Î´X¥G³z©úªº¥Ö½§¡^¡C ¦b¥ý«e¹ïdupilumab ¤ÏÀ³¤£¨¬ªº9 ¦W±wªÌ¤¤¡A5 ¦W±wªÌ(56%) ¹F¨ìEASI-90¡A5 ¦W±wªÌ(56%) vIGA µû¤À¬°0 ©Î1¡C¨´¤µ¬°¤î¡AªvÀø@¨ü©Ê¨}¦n¡A¨S¦³·sªº¦w¥þ©Ê°T¸¹³QÃѧO¡C ¥Ø«eÁÙ¨S¦³µ²½¤ª¢ªº³ø§i¡A¤]¨S¦³µù®g³¡¦ì¤ÏÀ³ªº³ø§i¡C ¹wp§¹¾ã¸ê®Æ¶°¤¤ªº«Dª¼¸ê®Æ±N©ó 2024 ¦~©³µo¥¬¡C
¡u63% ±µ¨üdupilumab ªvÀøªº±wªÌ¦b16 ¶g«á¥¼¯à¹F¨ì³z©ú©Î´X¥G³z©úªº¥Ö½§¡]IGA µû¤À¬°0 ©Î1¡^2¡A¨Ã¥B¦b¹F¨ì³oºØ¤ÏÀ³ªº±wªÌ¤¤¡A¤j¬ù¤@¥b¦bÀH«áªº36 ¶g«á¨S¦³ºû«ù³oºØ¤ÏÀ³3¡A¦]¦¹¢¤Á»ÝnÃB¥~ªº¥Íª«Àøªk¡A¬°¹ï dupilumab ¨S¦³¨¬°÷¤ÏÀ³ªº±wªÌ´£¨Ñ¦w¥þ¦³®Äªºªø´ÁªvÀø¿ï¾Ü¡C EASI-90 ©M vIGA ¬O AD ¬ã¨s¤¤³ÌÄY®æªº²×ÂI¤§¤@¡C ¾¨ºÞ³o¬O°ò©ó¹ïª¼ªk¼Æ¾Úªºªì¨B¼f¬d¡A¦ý§Ú̹ªÀyÆ[¹î¨ì TREK-DX ¬ã¨s¤¤¨´¤µ¬°¤î¹F¨ì³o¨Ç²×ÂIªº±wªÌ¤ñ¨Ò«Ü°ª¡C §Ú̪º¥«³õ¬ã¨sµo²{¡A¤j¦h¼Æ AD ±wªÌ¹ï¥Ø«eªºªvÀø¶È·P¨ì¤¤µ¥º¡·N«×¡C ³o»P§Ú̲£¥ÍªºÂà¤Æ¼Æ¾Ú¤@°_¤ä«ù¤F eblasakimab §@¬°³o¨Ç±wªÌªvÀøªº¼ç¦b§@¥Î¡A¨Ã¥B§Ú̦b TREK-DX ¬ã¨s¤¤²£¥Íªº¼Æ¾Ú¥i¥HÃÒ©ú¡A¹ï©ó³\¦h±wªÌ¨Ó»¡¡Aeblasakimab ¬Æ¦Ü¥i¥H±±¨î¥L̪º¯e¯fdupilumab «o¨S¦³¡A ¡vASLAN »sÃĤ½¥q°õ¦æªøCarl Firth ³Õ¤h»¡¡C
Âà¤Æ¼Æ¾Úªí©ú¡A¹v¦V IL-13R »P IL-4R ªº®ÄªG¦s¦b®t²§¡A³oªí©ú§Y¨Ï¦b dupilumab µL®Äªº±¡ªp¤U¡Aeblasakimab ¤]¦³¥i¯à¦³®Ä¡C Eblasakimab °w¹ï 2 «¬¨üÅ骺 IL-13 ¨üÅé (IL-13R) ¨È°ò¡Aªý¤î³z¹L¥Õ¦å²y¤¶¯À 4 (IL-4) ©M¥Õ¦å²y¤¶¯À 13 (IL-13) ªº°T¸¹¶Ç¾É¡C ¨âªÌ³£¬OAD µoª¢ªºÃöÁäÅX°Ê¦]¯À¡AµM¦Ó¡A³ÌªñµoªíªºÂà¤Æ¼Æ¾Ú±j½Õ¤F¦bAD ±wªÌ¥~©P¦å³æ®Ö²ÓM¤¤¡Aeblasakimab ¹v¦VIL-13R ¬Û¹ï©ódupilumab ¹v¼ÐIL-4 ¨üÅé(IL-4R)ªºÀu¶Õ4¡C »P IL-4R ªýÂ_¬Û¤ñ¡AIL-13R ªýÂ_¥i§ó¦³®Ä¦a´î¤Ö»P 2 «¬ÅX°Ê¡]¹L±Ó©Ê¡^µoª¢¦³Ãöªº²ÓM¦]¤l¡A¨Ã°§C 1 «¬«Pª¢²ÓM¦]¤lªº¤ô¥¡C ¨Ó¦Û AD ±wªÌ¥Ö½§¬¡Àˤ¤ eblasakimab ©M dupilumab ªºÀY¹ïÀY¬ã¨sªº¨ä¥L¼Æ¾ÚÃÒ¹ê¤F¹v¦V IL-13R »P IL-4R5 ªº®t²§¤Æ®ÄªG¡C ¦b³o¶µ¬ã¨s¤¤¡Aeblasakimab ¤ñ dupilumab §ó¦³®Ä¦a´î¤Ö¤F¥Ö½§²Õ´«Pª¢ 2 «¬²ÓM¦]¤lªº§½³¡¤Àªc¡A³oªí©ú eblasakimab ¥i¯à¹ï dupilumab ¥¼²£¥Í¨¬°÷¤ÏÀ³ªº AD ±wªÌ¦³®Ä¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2024/3/11 ¤U¤È 08:16:04
²Ä 6572 ½g¦^À³
|
TREK-DX ¬O²Ä¤@Ó¦b¸g¾ú dupilumab ªº²§¦ì©Ê¥Ö½§ª¢ (AD) ±wªÌ¸sÅ餤¶i¦æªºÀH¾÷¡BÂùª¼¡B¦w¼¢¾¯¹ï·Ó¬ã¨s¡A¤w¶}©l®Ú¾Ú§ó·sªº¤è®×¦b¬ü°ê©Û¶Ò±wªÌ¡F ·sªº¼Ú¬w¯¸ÂI¹wp©ó 2024 ¦~¤W¥b¦~¶}·~ ¦b¹ï¨´¤µ¬°¤î±µ¨üªvÀøªº22 ¦W±wªÌªºª¼ªk¼Æ¾Ú¶i¦æªºªì¨B¼f¬d¤¤¡A45% (10/22) ªº±wªÌªºEASI µû¤À(EASI-90) ¦Ü¤Ö°§C¤F90%¡A50% (11/22)ªº±wªÌ¹F¨ì¤F16 ¶g«á vIGA µû¤À¬° 0 ©Î 1¡]¥Ö½§³z©ú©Î´X¥G³z©ú¡^¡C ¹wp§¹¾ã¸ê®Æ¶°¤¤ªº«Dª¼¸ê®Æ±N©ó 2024 ¦~©³µo¥¬ Âà¤Æ¼Æ¾Úªí©ú¡A¹v¦VIL-13R »PIL-4R ªº®ÄªG¦s¦b®t²§¡Aªí©úeblasakimab ¦³¥i¯à¹ïDupilumab ¥¼¹F¨ì¨¬°÷¤ÏÀ³ªºAD ±wªÌ¦³®Ä¡A³o¬O¤@Ó«n¥BªA°È¤£¨¬ªº±wªÌ¸sÅé¡A«Ü¤Ö¦³¦w¥þ©Mªø´ÁªºªvÀø¿ï¶µ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2024/3/7 ¤U¤È 11:34:33
²Ä 6571 ½g¦^À³
|
¤½¥q¤T¤ë¤»¤é«n°T®§¡A¨â¦ì¬ì¾ÇÅU°Ý¾Ç¸g¾ú
2024 ¦~ 3 ¤ë 6 ¤é ªü´µÄõ»sÃĤ½¥q (ASLAN Pharmaceuticals) ¤½§G Eblasakimab ªvÀøºC©Êªý¶ë©ÊªÍ¯f (COPD) ªº·sÂà¤Æ¼Æ¾Ú¡A¨Ã¥ô©R»â¥ýªº©I§l¨t²Î±M®a¬°¬ì¾ÇÅU°Ý ¦b COPD ¤HÅé²Õ´¼Ò«¬¤¤¹ïeblasakimab©Mdupilumab¶i¦æªºÀY¹ïÀY¬ã¨sªº·sÂà¤Æ¼Æ¾ÚÅã¥Ü¡A¦b¬Û¦P¿@«×¤U¡Aeblasakimab¦b§ïµ½®ð¹D¥\¯à©M¼W±j¤ä®ðºÞÂX±i¤è±Àu©ódupilumab »â¥ýªº©I§l¨t²Î±M®a Ramaswamy Krishnan ³Õ¤h©M Reynold Panettieri Âå¾Ç³Õ¤h³Q¥ô©R¬°¬ì¾ÇÅU°Ý¡A¬°eblasakimabªº®t²§¤Æ¥H¤Î¥¼¨Ó COPDÁ{§É¶}µo´£¨Ñµ¦²¤«Øij ¥[¦{¸t°¨¯S¶ø©M·s¥[©Y¡A 2024 ¦~ 3 ¤ë 6 ¤é¡V ASLAN Pharmaceuticals Ltd.¡]¯Ç´µ¹F§JªÑ²¼¥N½X¡GASLN¡^¬O¤@®aÁ{§É¶¥¬q¡B±Mª`©ó§K¬Ì¾Çªº¥Íª«»sÃĤ½¥q¡AP¤O©ó¶}µo³Ð·sÀøªk¥H§ïÅܱwªÌªº¥Í¬¡¡A¤µ¤Ñ«Å¥¬¤F¨Ó¦Û¤@®a¤½¥qªº·sªº¿n·¥Âà¤Æ¼Æ¾Ú¡C¦bºC©Êªý¶ë©ÊªÍ³¡¯e¯f (COPD) ¤HÅé²Õ´¼Ò«¬¤¤¹ïdupilumab»PeblasakimabCOPD¥Íª«Àøªkªº¼ç¤O´£¨Ñ¤F¶i¤@¨B¤ä«ù¡C¦¹¥~¡A¸Ó¤½¥qÁÙ«Å¥¬¥ô©R©I§l¨t²Î±M®a Ramaswamy Krishnan ³Õ¤h¡B«¢¦òÂå¾Ç°|«æ¶EÂå¾Ç°Æ±Ð±Â¡BÂå¾Ç³Õ¤h¡Bù®æ´µ¤j¾ÇÂà¤ÆÂå¾Ç»P¬ì¾Ç°Æ®Õªø Reynold Panettieri Jr ³Õ¤h¬° ASLAN ¬ì¾Ç¹Î¶¤¦¨û¡C¿Ô¸ß©eû·|¥¿¦bµû¦ôeblasakimab§@¬°ªvÀøºC©Êªý¶ë©ÊªÍ¯f¥H¤Î²§¦ì©Ê¥Ö½§ª¢(AD) ªº¼ç¦bÀøªk¡C
¡u¦b»P ASLAN ¹Î¶¤¦X§@¡A±qeblasakimab©Mdupilumab¦b COPD ±wªÌ²Õ´¤¤ªºÀY¹ïÀY¬ã¨s¤¤Àò±o¥O¤H¦L¶H²`¨èªºÂà¤Æ¼Æ¾Ú«á¡A§Ú«Ü°ª¿³¥¿¦¡¥[¤J¬ì¾ÇÅU°Ý©eû·|¡A¶i¤@¨B±´¯Áeblasakimab¦b COPD ¤¤ªº¼ç¤O¡A¡¨³Õ¤h»¡
¡u§Ú«Ü°ª¿³¯à»P ASLAN ¹Î¶¤¦X§@¡A§Q¥Î³oÓ¥O¤H¿³¾Äªº¾÷·|¨Óµû¦ôeblasakimab¦b COPD¡]¤@ºØ 2 «¬ÅX°Ê¯e¯f¡^¤¤ªº¶}µo¸ô®|¡C§Ú¬Û«H¥Íª«»s¾¯¦³«Ü¤jªº¾÷·|§ïÅܳoºØºC©Ê¯fªºªvÀø®æ§½¡A´N¹³§Ú̦b¨ä¥L©I§l¨t²Î¯e¯f¦pÄY«®ð³ÝªºªvÀø¤¤©ÒÆ[¹î¨ìªº¡C³o¨Ç·s¼Æ¾Úªí©úeblasakimab¦³¼ç¤O¦¨¬° COPD ªº¤@¬y¥Íª«ÀøªkÃĪ«¡A§Ú´Á«Ý§Ú̪º¦X§@¹Ù¦ñÃö«Y¡A¡vù®æ´µ¤j¾ÇÂà¤ÆÂå¾Ç»P¬ì¾Ç°Æ®Õªø Reynold Panettieri Jr ³Õ¤h»¡¡C
2023 ¦~ 11 ¤ë¡AASLAN «Å¥¬¤F¨Ó¦Û°·±d®½Ãت̲Õ´ªºÂà¤Æ¼Æ¾Ú¡AÅã¥Üeblasakimab§@¬° COPD ªvÀøÃĪ«§í¨î 2 «¬µoª¢ªº¼ç¤O¡C¨Ï¥Î COPD ±wªÌªºªÍ²Õ´¶i¦æ¤F¶i¤@¨Bªº¬ã¨s¡A¤ñ¸û¤F¬Û¦P¿@«×ªºeblasakimab©Mdupilumab¡C¨CºØªvÀø±ø¥ó§¡¦b¦Ü¤Ö 6 Óºë½T¤Á³ÎªºªÍ¤Á¤ù¤¤¶i¦æ´ú¸Õ¡C¦b COPD ±wªÌ²Õ´¤¤¡Aeblasakimab¥i¦³®Ä«ì´_¦¬ÁY¡A¥HÀ³¹ï IL-4 ©M IL-13 ªº¬D¾Ô¡A¨Ã¦b¦¬ÁYªº®ð¹D¤¤ªí²{¥XºÖ²ö¯Sù»¤¾Éªº§Ö³t®ð¹DÂX±i¡CºÖ²ö¯Sù¬O¤@ºØªø®Ä£]¨üÅé¿E°Ê¾¯¡A¬O®ð³Ý©MºC©Êªý¶ë©ÊªÍ¯f±wªÌ±`¥Îªº¤@ÃþÃĪ«¡Cȱoª`·Nªº¬O¡Aªì¨B¼Æ¾ÚÅã¥Ü¡A¦b¬Û¦P¿@«×¤U¡A eblasakimab¦b¦hÓ»â°ìªºªí²{Àu©ódupilumab¡A¥]¬A IL-4 ©M IL-13 §ðÀ»«á®ð¹D¥\¯àªº«ì´_ ¡C
¡u§Ú̬۫Heblasakimab¦³¼ç¤O¦¨¬°»â¥ýªºªvÀø¿ï¾Ü¡A¦]¬°§ÚÌ¥¿¦b±´¯Á¨ä¦b AD ¥H¥~ªº¨ä¥L¯e¯f¤¤ªº¾A¥Î©Ê¡A¨Ò¦p COPD¡A³o¬O¤@Ó©|¥¼Àò±o§å㪺¥Íª«»s¾¯ªº¤j«¬¥«³õ¡C§ÚÌ´Á«Ý»P Krishnan ³Õ¤h©M Panettieri ³Õ¤h¥H¤Î¼ç¦b¦X§@¹Ù¦ñ¦X§@¡A¦Ò¼{ COPD ªº¼ç¦b·§©ÀÅçÃÒ²Ä 2 ´Á¬ã¨s³]p¡A¨Ã±´¯Á³Ìªñ¶i¦æªº¥Íª«¾Ç¬ã¨s¤¤ªº·s²×ÂI¡A¡vASLAN º®u°õ¦æ©x Carl Firth ³Õ¤h»¡
¦³ÃöeblasakimabªvÀøºC©Êªý¶ë©ÊªÍ¯fªº§ó¦hÂà¤Æ¼Æ¾Ú±N¦b§Y±N¥l¶}ªº¬ì¾Ç¤j·|¤W´£¥æµoªí¡C
Ãö©ó Ramaswamy Krishnan¡A«¢¦òÂå¾Ç°|«æ¶EÂå¾Ç°Æ±Ð±Â¡Bõ¾ÇºÓ¤h¡B³Õ¤h
Ramaswamy Krishnan³Õ¤h¬O«¢¦òÂå¾Ç°|«æ¶EÂå¾Ç°Æ±Ð±Â¡C¥Lªº¹êÅç«Ç±Mª`©óªÍ¤O¾Ç©M¾÷±ñ¶Ç¾É¡A±Mª`©ó®ð¹D¦p¦ó¦¬ÁY©M©ñÃP¡C¬°¦¹¡A¥Lµo©ú¤F¤@®M§Þ³N¨Ó´ú¶q®ð¹D²ÓM©M²Õ´ªº¦¬ÁY¡BÃP¦¢¡B¤O¶Ç»¼©M¤O¶Ç¾É¡C³o¨Ç§Þ³N¤£¶È¨Ï¥L¦Û¤vªº¹êÅç«Ç¯à°÷µo²{ªvÀøºC©Êªý¶ë©ÊªÍ¯f©M®ð³Ýªº·sÔ¿ïÃĪ«¡A¦Ó¥BÁÙ¦b¥þ²y½d³ò¤º³Q¥Î§@µû¦ô«Ý©wÔ¿ïÃĪ«ªº¤ä®ðºÞ«OÅ@©M¤ä®ðºÞÂX±i¥\¯àªºÂà¤Æ¤èªk¡CKrishnan ³Õ¤h¦bôÛ¤ñ¨È¤j¾ÇÀò±o¾÷±ñ¤uµ{³Õ¤h¾Ç¦ì¡A¨Ã¦b«¢¦ò¤j¾Ç¶i¦æªÍ¥Í²z¾Ç³Õ¤h«á¬ã¨s¡C¥Lµoªí¤F¶W¹L 75 ½g¤å³¹¡Bµû½×¡BªÀ½×©M³¹¸`¡A¨ä¤¤³\¦hµoªí¦b¡m¦ÛµM²ÓM¥Íª«¾Ç¡n©M¡m¦ÛµM§÷®Æ¡nµ¥µÛ¦W¦P¦æµû¼f´Á¥Z¤W¡C
Ãö©ó Reynold Panettieri Jr ³Õ¤h¡]Âå¾Ç³Õ¤h¡^ ù®æ´µ¤j¾ÇÂà¤ÆÂå¾Ç»P¬ì¾Ç°Æ®Õªø
Reynold A Panettieri Jr Âå¾Ç³Õ¤h¬Où®æ´µ¤j¾ÇÂà¤ÆÂå¾Ç»P¬ì¾Ç¬ã¨s©Òªºº¥ô©Òªø©MÂà¤ÆÂå¾Ç»P¬ì¾Ç°Æ®Õªø¡A¦¹«e´¿¾á¥ô»«¦{¤j¾Ç®ð¹D¥Íª«¾Çp¹º¥D¥ô¡CPanettieri ³Õ¤hªº¹êÅç«Ç±Mª`©ó®ð¹D¥·Æ¦Ùªº§K¬Ì¥Íª«¾Ç¡BÀô¹Ò¬r¯À¹ï®ð¹D°ª¤ÏÀ³©Êªº¼vÅT¥H¤Î®ð³Ý©MºC©Êªý¶ë©ÊªÍ¯fªvÀø¤èªkªº·s¼Ð¹v©M¥¥xªºÃѧO¡C°£¤F¥Lªº¬ã¨s©MÁ{§É¿³½ì¤§¥~¡APanettieri ³Õ¤hÁÙ¾á¥ô NIH ªÍ²ÓM¡B¤À¤l©M§K¬Ì¥Íª«¾Ç¬ã¨s³¡ªùªº¥D®u¡A¨Ã¥B¬O NIH ³Ç¥X½s¿è¤p²Õªº¦¨û¡CPanettieri ³Õ¤hµoªí¤F¬ù 450 ½g¥Xª©ª«¡A¨Ã¦b»«¦{¤j¾Ç±µ¨ü¤FÂå¾Ç°ö°V¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2024/3/7 ¤U¤È 10:28:28
²Ä 6570 ½g¦^À³
|
A ¤j®a§Ñ¤F¶}µo¤@ºØÃĪ«¥i¥H¦³«Ü¦h¾AÀ³¯g ( eblasakimab ¶}µo²§¦ì©Ê¥Ö½§ª¢AD , ®ð³Ý»PºC©Êªý¶ë©ÊªÍ¯f COPD , Farudodstat ¶}µo Alopecia areata ¯ë¨r )
B Dupilumab experienced(½Õ¾ã¦¬®×µ¦²¤ ¥H®É¶¡´«¨ú§ó¨ÎÀø®ÄªºªÅ¶¡ (¨Ï¥ÎDupilumab®ÄªG¤í¨Îªº¯f±w) ¤j®a·Q¤@·Q TREX-DX ¹êÅç¼Æ¾Ú¬OÀø®Ä¤ñ¸û«n ÁÙ¬O¦¤@ÂI¤½§i¼Æ¾Ú¤ñ¸û«n ? ¤½¥q½Õ¾ã¦¬®×µ¦²¤ ¥H®É¶¡´«¨ú§ó¨ÎÀø®ÄªºªÅ¶¡¬O¥¿½Tªº¿ï¾Ü
C Eblasakimab¬O¤@ºØ·s«¬¥þ¤H·½³æ®è IgG4 §ÜÅé¡A¥i¯S²§©Êµ²¦X¥Õ¦å²y¤¶¯À (IL)-13 ¨üÅé (IL-13R)¡A ªý¤î³z¹L 2 «¬¨üÅé¶Ç»¼ IL-4 ©M IL-13 °T¸¹¡C 2 «¬¨üÅé¬O¥]§tIL-4¨üÅé(IL-4R)©MIL-13¨üÅé(IL-13R) ªº²§¤G»EÅé¡C²ÓM¿E¯À IL-4 ©M IL-13 ³z¹L 2 «¬¨üÅéµo¥X°T¸¹¡A¬Oµoª¢ªºÃöÁäÅX°Ê¦]¯À¡A¬O¤Þµo AD¡B®ð³Ý ©M COPD µ¥ 2 «¬¯e¯fªº¹L±Ó¯gª¬ªºÃöÁä
D 2024 ¦~ 3 ¤ë 6 ¤éªü´µÄõ»sÃĤ½¥q (ASLAN Pharmaceuticals) ¤½§G Eblasakimab ªvÀøºC©Êªý¶ë©ÊªÍ¯f (COPD) ªº·sÂà¤Æ¼Æ¾Ú¡A¦b COPD ¤HÅé²Õ´¼Ò«¬¤¤¹ïeblasakimab©Mdupilumab¶i¦æªºÀY¹ïÀY¬ã¨sªº·sÂà¤Æ ¼Æ¾ÚÅã¥Ü¡A¦b¬Û¦P¿@«×¤U¡Aeblasakimab¦b§ïµ½®ð¹D¥\¯à©M¼W±j¤ä®ðºÞÂX±i¤è±Àu©ódupilumab
E »â¥ýªº©I§l¨t²Î±M®a Ramaswamy Krishnan ³Õ¤h©M Reynold Panettieri Âå¾Ç³Õ¤h³Q¥ô©R¬°¬ì¾ÇÅU°Ý¡A¬°eblasakimabªº®t²§¤Æ¥H¤Î¥¼¨Ó COPDÁ{§É¶}µo´£¨Ñµ¦²¤«Øij (¹ï¤S¤@Ӧʻõ¬ü¤¸ªº¾AÀ³¯g °Ê§@¶W§Ö¬O¥i²z¸Ñªº)
Dupilumab¤]¬O¤@¼Ë¶}µo«Ü¦h¾AÀ³¯g Dupilumab¾A¥Î©óªvÀø¤¤«×¦Ü««×²§¦ì©Ê¥Ö½§ª¢(2017 FDA )¡B¤¤«×¦Ü««×®ð³Ý(2018 FDA) ¡A ¥H¤ÎªvÀø¦ñÀH»ó®§¦×ªººC©Ê»óÄuª¢
2022 ¦~ 5 ¤ë¡Adupilumab ªº·s¾AÀ³¯gªvÀø12 ·³¤Î¥H¤W¡BÅé«¦Ü¤Ö 40 ¤½¤ç¡]88 ½S¡^ªº¤Hªº ¶Ý»Ä©Ê²É²ÓM©Ê¹¹Dª¢
2022 ¦~ 9 ¤ë¡Adupilumab ªº·s¾AÀ³¯g¬°¥]¬AªvÀø¦¨¤Hµ²¸`©ÊÄo¯l¡]PN¡^
¬ã¨s¤¤ COPD 2023 ¦~ 3 ¤ë¡AÁɿյ᤽§G¤F¤@¶µ 3 ´Á¸ÕÅ窺µ²ªG¡A¸Ó¸ÕÅçÀˬd dupilumab ªvÀø ºC©Êªý¶ë©ÊªÍ¯f(COPD) ªºÀø®Ä¡C¦b³o¶µÀH¾÷¡BÂùª¼¡B¦w¼¢¾¯¹ï·Ó¸ÕÅ礤¡Adupilumab ÃÒ©ú COPD ¤¤«×©Î««×«æ©Ê´c¤Æ´î¤Ö 30%¡A¥B COPD ±wªÌªºªÍ¥\¯à©M¥Í¬¡«~½èÅãµÛ§ïµ½
¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2024/3/7 ¤U¤È 12:28:16
²Ä 6569 ½g¦^À³
|
§Úı±oÀ³¬OTREX-DX¸ÕÅç¼Æ¾Ú¤£¦n¡A
©Ò¥H¤~Åܧ󦬮׹ï¶H¤§¼Ð·Ç¡A
²{ªp¤S¨S¸g¶O°µ004 3´Á¸ÕÅç¡A
¥ý§äÓ±µÄò´À¥NpµeÄ~Äò©¿巄¤j®a¡A ¬Ý¯à¤£¯à¦bÄFÂI¸g¶Oª¯©µ´Ý³Ý¡A
¤£ºÞ¬O¨rÀYÃĩάOCOPDÃÄ¡A
³£¬Oªü¤TÄF¿ú¥Îªº¤â¬q¡A µL¸Û«Hªº¤½¥q¡A |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2024/3/7 ¤W¤È 08:56:36
²Ä 6568 ½g¦^À³
|
«æº¦¤Å³ß¡A«æ¶^¤Å¼~¡F±o¤§§Ú©¯¡A¥¢¤§§Ú©R¡F¬Ýºò²ü¥]¡A¬ÕÁ«¦Ût! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥d¦b¥b¤s¸y10153098 |
µoªí®É¶¡:2024/3/6 ¤U¤È 10:38:33
²Ä 6567 ½g¦^À³
|
3h«eªº·s»D
¤§«e°µ¥Ö½§¹L±Ó ²{¦b§ïÅÜ·s¤è¦V¥h°µ©I§l¹DªÍ¯f?
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2024/3/1 ¤U¤È 10:32:44
²Ä 6566 ½g¦^À³
|
¤½¥qªº¬ãµo²£«~¥Dn¥H¤jÃĬ°¥D ¨âÁû¤jÃÄ©è¹L¤QÁû¤pÃÄ
§Ú̪º²£«~²Õ¦X¥H eblasakimab ¬°¥D¾É¡A³o¬O°w¹ï IL-13 ¨üÅ骺¼ç¦b¤@¬y§ÜÅé¡A¦³¥i¯à §ï¶i¥Ø«e¥Î©óªvÀø¹L±Ó©Ê¯e¯fªº¥Íª«»s¾¯¡C §Ṳ́]¥¿¦b¶}µo Farudodstat¡A¤@ºØ DHODH 酶 ªº¦³®Ä¤fªA§í¨î¾¯¡A§@¬°ªvÀø´³¨rªº¼ç¦b¤@¬yÀøªk¡C
1 Eblasakimab IL-13R£\1 Atopic dermatitis ¬O¤@ºØ¥¿¦b¶}µoªº¥Î©ó¤¤««× AD ªº·s«¬¥Íª«»s¾¯¡A¦³¥i¯à±q¤@¶}©l´N´£¨Ñ¨C¤ë¤@¦¸ªºµ¹ÃĤè®×¡A¥B¤£¼vÅTÀø®Ä
¨Ì¾Ú¤½¥q2024¦~¤@¤ë²³ø ¨ì2029¦~ ²§¦ì©Ê¥Ö½§ª¢¥þ²y¥«³õ190»õ¬ü¤¸ 2 Dupilumab experienced ½Õ¾ã¦¬®×µ¦²¤ ¥H®É¶¡´«¨ú§ó¨ÎÀø®ÄªºªÅ¶¡ (¨Ï¥ÎDupilumab®ÄªG¤í¨Îªº¯f±w)
T 3 Type 2-driven disease (¤G«¬ª¢¯g) 81% ²§¦ì©Ê¥Ö½§ª¢¯f±w¦³¤G«¬¬ÛÃöª¢¯g( ¦p¹L±Ó ®ð³Ý)
4 ¨ä¥L¦³¼ç¤O¾AÀ³¯g COPD ºC©Êªý¶ë©ÊªÍ¯f 5 Farudodstat DHODH Alopecia areata Phase 2a interim topline data mid-2024 2022 ¦~¬ü°ê´³¨r¡]²æ¾v¡^ªvÀø¥«³õ¦ôȬ° 34.44 »õ¬ü¤¸¡A¹wp 2023 ¦~¦Ü 2030 ¦~½Æ¦X¦~¼W ªø²v¬° 5.50%¡A¨ì 2030 ¦~¹F¨ì 52.85 »õ¬ü¤¸¡C(¥þ²y¥«³õ2030¦~ 137»õ¬ü¤¸) ¨Ì¾Ú¤½¥q2024¦~¤@¤ë²³ø´³¨r²×¥Íµo¯f²v¦Ê¤À¤§2.1% 2020¦~¬ü°ê¯f±w70¸U¤H ¨ä¤¤¦Ê¤À¤§25 ÄÝ©óÄY«±¡ªp 62%´³¨r¯f±w·|±µ¨üÃĪ«ªvÀø
¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥d¦b¥b¤s¸y10153098 |
µoªí®É¶¡:2024/3/1 ¤W¤È 01:56:33
²Ä 6565 ½g¦^À³
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2024/2/29 ¤U¤È 10:23:10
²Ä 6564 ½g¦^À³
|
2024 ¦~ 2 ¤ë 29 ¤é ªü´µÄõ»sÃĤ½¥q Farudodstat ªºª«½è²Õ¦Xª«±M§Q¥Ó½Ð¼Ú¬w±M§Q§½ªº¦nµû farudodstatªº·sª«½è²Õ¦X±M§Q±N¥[±j´¼¼z°]²£Åv«OÅ@¡A¨Ã¬°farudodstat´£¨Ñ°Ó·~¿W¦ûÅv¡A ¦Ü¤Ö«ùÄò¨ì 2043 ¦~¥[¦{¸t°¨¯S¶ø©M·s¥[©Y¡A2024 ¦~ 2 ¤ë 29 ¤é¡V ASLAN Pharmaceuticals Ltd. ¬O¤@®aÁ{§É¶¥¬q¡B±Mª`©ó§K¬Ì¾Çªº¥Íª«»sÃĤ½¥q¡AP¤O©ó¶}µo³Ð·sÀøªk¥H§ïÅܱwªÌªº¥Í¬¡¡A¤µ¤Ñ«Å¥¬¨ä ¤wÀò±o¦³§Qªº±M§QÅv§@¬°°ê»Ú¼f¬dûªº¼Ú¬w±M§Q§½ (EPO) ¹ïFarudodstatªº¦h´¹«¬±M§Q¥Ó½Ðµoªí¤F·N¨£¡A ¦pªG¦b°ê®a¶¥¬qÀò±o§åã¡A±N§âFarudodstatªº¦³®Ä±M§Q«OÅ@©µªø¦Ü¦Ü¤Ö 2043 ¦~¡C
Farudodstat¬O¤@ºØ¦³®Äªº¤fªA¤G²B¨Å²M»Ä²æ²B酶 (DHODH) §í¨î¾¯¡A¦³¥i¯à¦¨¬°´³¨r (AA) ªº¤@¬yªvÀø ¿ï¾Ü¡CASLAN ¥Ø«e¥¿¦b AA ¤¤¶i¦æ 2a ´Á·§©ÀÅçÃÒ¸ÕÅç¡]¡uFAST-AA ¬ã¨s¡v¡^¡A¹wp¸Ó¬ã¨sªº¤¤´Áµ²ªG ±N©ó 2024 ¦~¤¤´Á¤½§G¡C
ASLAN Pharmaceuticals °õ¦æªø Carl Firth ³Õ¤h»¡¡C ¡u§ÚÌ«Ü°ª¿³¦¬¨ì¼Ú¬w±M§Q§½Ãö©ófarudodstatª«½è²Õ¦¨±M§Q¥Ó½Ðªº¥¿±ªì¨B·N¨£¡A¨Ã»{¥i§ÚÌ©Ò¦³ ªºÅv§Qn¨D§¡¨ã¦³·s¿o©Ê©M³Ð³y©Ê¡C¦pªG¦b°ê®a¶¥¬qÀò±o±ÂÅv¡A·s±M§Q±N§âfarudodstatªº±M§Q«OÅ@ ©µªø¦Ü¦Ü¤Ö2043¦~¡C³o±NÅãµÛ¼W±jfarudodstatªº°Ó·~¿W¦û©Ê¡A¬O§Ú̦b©Ò¦³ÃöÁä°Ó·~»â°ìfarudodstat ¥[±j ¥Ñ©ó´³¨r±wªÌ¥i¥ÎªºªvÀø¿ï¾Ü«Ü¤Ö¡A§Ú̪º¥Ø¼Ð¬O¬°±wªÌ´£¨Ñ¦w¥þ¦³®ÄªºªvÀø¿ï¾Ü¡C
Ãö©ó Farudodstat
Farudodstat ¬O¤@ºØ¦³®Äªº¤fªA DHODH §í¨î¾¯¡A¥i³z¹LªýÂ_ DNA ½Æ»s©Ò»ÝªºáGÔr±qÀY ²£¥Í¨Ó §í¨î§K¬Ì²ÓM¼W´Þ©M IFN-£^ ¤Àªc¡C»P²Ä¤@¥N DHODH §í¨î¾¯¬Û¤ñ¡A farudodstat ¹ï DHODH ©M T ²ÓM¬¡©Êªº§í¨î®ÄªG¬ù¬° 30 ¿¡A¨Ã¥B¨ã¦³¨}¦nªº@¨ü©Ê¦w¥þ©Ê¡CASLAN ²£¥Íªº¼Æ¾ÚÅã¥Ü¡A farudodstat ¥i¥H¼ç¦b¦a¨¾¤î¤òÅn§K¬Ì¯SÅv³à¥¢¡A¤ä«ù¨ä§@¬° AA ¤@¬yªvÀø¿ï¾Üªº¼ç¤O¡C AA ªº 2a ´Á·§©ÀÅçÃÒ¸ÕÅç¡]FAST-AA ¬ã¨s¡^¥Ø«e¥¿¦b¶i¦æ¤¤¡A¹wp±N©ó 2024 ¦~¤¤´Á¤½§G¤¤´Áµ²ªG¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2024/2/27 ¤U¤È 09:20:32
²Ä 6563 ½g¦^À³
|
NVIDIA(½÷¹F) 22¤é¤½¥¬°]³ø¡Aªí²{¶W¥G·Q¹³ªº¦n¡A¬Q¤éªÑ»ù790.92 USD ¡I ¯¸¦bAI®ö¼é¦yºÝªº¥L¡A¶À¤¯¾±ªñ¤é«o¶}¥Ü¥Í©R¬ì¾Ç¤~¬O¥¼¨ÓÅã¾Ç |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gªoºj·Æ±¼10153108 |
µoªí®É¶¡:2024/2/27 ¤U¤È 06:36:11
²Ä 6562 ½g¦^À³
|
1.§ÚÁöµM¤£¬Ý¦nASLAN¡A¦ý¤]¤£±Æ°£³Ì«áµ²ªG¥´Áy§Ú¡A¤£¹L¦³¤@説¤@¡A°ò¥»¤W13F¤£¥i¯à´¦ÅS«ù¦³³¡¦ìªº¶R¶i»ù®æ¡A´N¹³¤Úµá¯S¤§«e¶R¶i¥x¿n¹q¡A¤j®a¤]¥u¯àÂÇ¥Ñ13F¥h§PÂ_¶R¶iªº®É¶¡ÂI¬O²Ä´X©u¶i¦Ó¥h¦ôºâ§¡»ù¡Awhalewisdom.com¤W±ªº»ù®æ¤]¥u¬O°Ñ¦Ò¡Awhalewisdom.com¨Ã¤£·|³qÆF¡A©Ò¥H§Ú¤~»¡ºô¯¸¸ê®Æ¦³À°¦£¾ã²z«ùªÑ¸ê®Æ½T¹ê¤è«K¡A¦ý¦³¨Ç¸ê°T°Ñ¦Ò§Y¥i¡A¤£¥Î¹L«×Ár´ú¡A»{¯un¬ÝÁÙ¬O¥h¬ÝSECªºì©l¸ê®Æ¤ñ¸û¦n¡C 2.¸Û¦p¸Ø±i¤j©Ò»¡¡AASLAN¨Ã¤£¬O¼öªùªÑ²¼¡A©Ò¥H³o1.2¤¸«ç»ò¦ô¥X¨Óªº§Ú¤£ª¾¹D¡A¦ý«Ü©úÅãwhalewisdomªººô¯¸¸ê®Æ´N¬O2023Q4²Ä¤@¦¸¶R¶iªº«ùªÑ³£¬O1.2¤¸¡A¥h¥J²Ó¬Ý´NÆZ©úÅ㪺¡A¨Ò¦pBVF,Parkman Healthcare,Rhumbline³£¬O2023Q2²Ä¤@¦¸¶R¶i¡A¶R¶i»ù®æ¤]³£¬O3.65¡ASchonfieldÁöµM¬O3.24¡A¦ý¬O¬O¦]¬°«áÄò¦³¼W«ù¼vÅT¨ìwhalewisdomªº¦¨¥»pºâ¡A©Ô¦^¥hwhalewisdom¸ÌASLANªº2023Q2«ùªÑ¸ê®Æ¡A¥i¥H¬Ý¨ìSchonfied¶R¶i»ù®æ¤]¬O3.65¡A©Ò¥H¨ä¹ê¤£¦s¦b©Ò¿×¤º½uªº°ÝÃD°Õ¡A³»¦h´N¬O¦³7®a§ë¸ê¾÷ºc¶i¨Ó¦Ó¤w¡A¨ä¤¤¦³UBS³o¤j©@¡A´N¥u¬O³o»ò²³æ¡A¦pªG¯uªº¦³¤º½u¡AASLAN¥«È¤~¦h¤Ö¡Aª½±µ¶R¤U¨Ó³£¥i¥H¤F¡A7®a¦Xp¤~¶R¤J¤£¨ì150¸UªÑ¡A¥H0.5¤¸¨Óºâ¤]¤~75¸U¬ü¡A¸òªk¤Hªº§ë¸ê³¡¦ì¤ñ°_¨Ó¡A´N¬OªáÂI¤p¿ú¶RÓ¼Ö³z¦Ó¤w..... |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GªL®õ10030886 |
µoªí®É¶¡:2024/2/26 ¤U¤È 05:04:26
²Ä 6561 ½g¦^À³
|
¯u§Æ±æ¸Ø±i¤j©Ò¼gªº ¬O ¯«µo²{
¨È·à³oÓ»ù ½æ¤F ½ßÓª¯¦Y«Ë£½
¥u¯à§Ñ¤F¥¦ ¬ß°]¯«·Ý²²ÅU
ÁÂÁ¸رi¤j¡I¡I¡I |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2024/2/26 ¤W¤È 08:40:51
²Ä 6560 ½g¦^À³
|
whalewisdom.com/stock/asln ¥h¦~²Ä¤T©uºI¤î¡A¦³22®a§ë¸ê¾÷ºc«ù¦³¨È·à±dªºªÑ²¼ ¦Ó¦Ü112/12/31(112¦~²Ä¥|©u)µ²§ô §ï¥Ñ23®a§ë¸ê¾÷ºc«ù¦³¨È·à±dªºªÑ²¼(6®a¥X²M¡B7®a·s¶i) (23®aºâ«Ü¤Ö¤F) ¦Ó23®aùر¦³7®a¬O¥h¦~²Ä¥|©u¤~è·s¶iªº§ë¸ê¾÷ºc 7®a¾÷ºc¦p¤U
1. UBS GROUP AG¶R¶i625,000ªÑ 2. SHAY CAPITAL LLC¶R¶i400,000ªÑ 3. LANDSCAPE CAPITAL MANAGEMENT, L.L.C.¶R¶i83,259ªÑ 4. XTX TOPCO LTD¶R¶i27,666ªÑ 5. JANE STREET GROUP, LLC¶R¶i23,093ªÑ 6. ONYX BRIDGE WEALTH GROUP LLC¶R¶i22,727ªÑ 7. CUTLER GROUP LLC¶R¶i1,000ªÑ
·s¶iªº7®a¥þ³¡³£¬O²Ä¤@¦¸¶R¶i¡A¤]³£¦P¤@»ù¦ì¡A¶R¶iªº»ù¦ì³£¬O1.2¤¸/ªÑ¡A³o»ò¥© (¦³¤º½u¤~´±¶i¨Ó¶R§a) ¥h¦~²Ä¥|©uªÑ»ù°ªÂI1.92¤¸¡AªÑ»ù§CÂI0.392¤¸ ½Ð¤j¤jÀ°¦£ºâ¤@¤U7®a³£¶R¦P¤@»ù¦ìªº¾÷²v¬O¦h¤Ö? (Y¤À§å¶R¡A³Ì«á¥§¡¬O1.2¤¸¤]¤£Â²³æ~~~¦ý½Ð¤£n³o»ò·Q) ¨È·à±d¤£¬O¼öªùªÑ§a(¼öªùªÑ(¥x¿n¹q-ADR)§Ú´N¬Û«H¬O¥©¦X)(´N¥ý¥H¤º½u¸ÑŪ)
¨ä¤¤112¦~Q4ªº·ç»È§Q¥ÎªÑªF¨¤À©ó113¦~1¤ë ¶i¦æ¡G 1.¸ò¨È·à±d°ª¼h°Q½×´M§ä¦X§@¹Ù¦ñ¶i«× 2.§ä¨ìªÑ²¼½æ®a(½æ®a¬°¦ón½æ?) 3.½Í¦n¥æ©ö»ù¦ì «á 113/2/6¦A¥[½X¥Ó³ø¶R¶i16,292,600ªÑ
ÁÙ¦³2/1~2/13ªº½L¤¤¨C¤ÀÄÁ¥æ©ö¤Î2/15¨C¤Q¤ÀÄÁ¥æ©ö1000ªÑªº¸ê°T¡A³£n¨ì5/15¤~ª¾¹D¡C³oÓ¤~¼F®`¡C (Y¨È·à±d5/15«e³Q¨Ö¡A§A´Nª¾¹Dþ¨Ç¤½¥q¦³¤º½u¤F)
¸ò¦U¦ì¤À¨É ¨Ã½Ð«ü¥¿(7®a³£¶R¦P¤@»ù¦ì¡A¦U¦ì¤j¤j¬Û«H¬O¥©¦Xªº½Ð»¡©ú¤@¤U¡A§ÚÅ¥¬Ý¬Ý¦X¤£¦XÅÞ¿è¡AÁÂÁÂ)(§ë¸ê·ÀI½Ð¦Û¦æµû¦ô)
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gªoºj·Æ±¼10153108 |
µoªí®É¶¡:2024/2/24 ¤U¤È 10:22:29
²Ä 6559 ½g¦^À³
|
1.Dupilumab¾P°âÃB°ª¡A°£¤FAD¥~¡A³o´X¦~«ùÄò§ð§J¤F¦h¶µ¾AÀ³¯g¸ò¥i¨Ï¥Î±Ú¸s¡ACOPD¤]¬OFDAª½±µµ¹Àu¥ý¼f¬dÅv¥[³t¼f®Ö³q¹L¡A¦³³o¨Ç¤~³y´N¤F¦Ê»õ¤jÃÄ¡AEblasakimab¤G´Á¤w¸g¹L¤F¤j¥b¦~¡A¹ï¤@Ó«ùÄò¿N¿úªº·sÃĤ½¥q¨Ó»¡¡A³o®ö¶Oªº®É¶¡¦¨¥»¥N»ù«D±`°ª©ù¡A¦pªGEblasakimab¯uªº¥«³õ¼ç¤O¦p¦¹Àu¨q¡A«ç·|©ì¤F³o»ò¤[ÁÙ¥d¦b³o¸Ì¡H¤@°ï¤jÃļt¦£µÛ©ï»ù¦X§@³£¨Ó¤£¤Î¤F¡A²{¦b´Nºâ¦³¦X§@¹ï¶H¥i¥H¿ï¾Ü¡A¤j·§²v³£¬O¦X§@±ø¥ó¤£¬Æ²z·Q¡A¤~·|¥d³o»ò¤[¡A²¦³º³o¤j¥b¦~´X¥G¬ãµo¨SÔ£¶i®i¡A¯uªº¦³¤jÃļt·P¿³½ìªº¸Ü¡AÀ³¸Ó¤G´Á«e´N¶}©l³W¹º¬¢½Í¡A¤G´Áµ²ªG¥X¨Ó´N«æµÛ±ÂÅv©Î¨ÖÁʤF¡AµoÓ¤G´Á¸ÕÅ窺¶i¤@¨B¥Íª«¼Ð°O¸ò¦¸±Ú¸s¤ÀªR´N§O»¡¬OÔ£¶i®i¤F¡A´N¬O¨S¿ú°µ¤T´Á¡A¥u¯à²`¤J¤ÀªR¤@¤U¤G´Á¼Æ¾Ú¡A¤£µMÁÙ¯à«ç»ò¿ì¡HCOPD¤]¥u¬O¤Á¤ù¹êÅç¡A³£ÁÙ¦bªì´Á±´¯Á´N¤£n¦n°ªÄE»·¤F¡A¥ý·Q¿ìªk±À¶iAD¤T´Á§a.... 2.whalewisdom.comªº¸ê®Æ§Ú¬O»{¬°°Ñ¦Ò§Y¥i¡A¦pªGn»{¯u¬ã¨s¬üªÑ¡AÁÙ¬O¥h¬Ý¤½¥qªºSEC¸ê®Æ¤ñ¸û·Ç½T¡A¥u³æ¾aºô¯¸¾ã²zªº¸ê®Æ¨ä¹ê¦³·ÀI¡A¦]¬°¸Ì±ªº¸ê®Æ¨ä¹ê¦³¨Ç¸Óµù©ú¨Sµù©úªº¡A¨Ò¦p¦³¨ÇªÑªFªº«ùªÑ³æ¦ì¬O¥ÎADS¡]25ªÑì©lªÑ¡^¡A¦³¨ÇªÑªFªº«ùªÑ³æ¦ì¬O¥Îì©lªÑ¡ABVF.K2³æ¦ì³£¬Oì©lªÑ¡AÀ³¸Ó¬O¦]¬°2023¦~¨p¶Ò¸ò»{ªÑÅvªº³æ¦ì³£¬Oì©lªÑªº½t¬G¡A©Ò¥HSEC¤å¥ó¤W¥Ó³øªº³æ¦ì¤]³£¬Oì©lªÑ¡Awhalewisdom.com¶È¶È¥u¬O§â¼Æ¦r¦C¤W¥h¦Ó¤w¡ABVF¹ê»Ú¤W«ùªÑ¼W¥[¡A¨Ã«D¬O±q¥«³õ¤W¶R¶i¡A¬O¥Ñ¤§«e¨p¶Ò»{ªÑÅv»{ªÑ¦Ó¨Ó¡A³o¦bSEC¤å¥ó¤¤³£¦³µù©ú¡A¦Ówhalewisdom.com¤W¨Ã¤£·|´¦ÅS¨ì³o»ò¸Ô²Ó¡C 3.¥H§ë¸ê¨Ó»¡¡AªÑ»ù²×¨s·|¦^Âk°ò¥»±¡A±q2018¦~ADS¾ú¥v³Ì°ª»ù52.195¨ì2024¦~ªÑ»ù¤£¨ì0.5¡A§O¦Aè¤ß¦k·Q¬O¥«³õ¨Sµo²{ASLANªº»ùȤF¡A¦Ó¬OASLAN¹ê»Ú¤W´N¥uȳo¼Ë¡A´L«¥«³õok? 4.½Ð¦Ñ·à¤Í̦ò¨t¬Ý«Ý«ùªÑ¡A¨S½ß´NºâÁȨì¤F¡A§O«ü±æ·|¤jÁÈ¡A²¦³º«ù¦³¦¨¥»À³¸Ó³£¤£§C¡A¤]§O·Q¤p¿ú¤jÅu¥¡A¨S¥²n¬°¤F¥W³æ·d¨ì³s¤p¿ú³£½ß¶i¥h¡A¤ñ°_¯{¿ú¦bASLAN¡A®³¥h§ë§Oªº¤ñ¸û¹ê»Ú........ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GªL®õ10030886 |
µoªí®É¶¡:2024/2/24 ¤U¤È 05:48:12
²Ä 6558 ½g¦^À³
|
µ¥¸ó±i¤jªº
¾÷ºc«ùªÑ ¦³¦ó¥©¦X¤§¨Æ
ÁÂÁ±z¡I¡I¡I |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2024/2/23 ¤W¤È 09:42:52
²Ä 6557 ½g¦^À³
|
³o³¾Âû¦ØªÑ¡A
©ñ±ó§a¡A
©{¦p¶BÄF¶°¹Î¡A
³s¤@ª½¹ª§jªº¤H¡A ¤]»{©R°h¥X¤£¨£¤F¡A
©ú¤Ñ¹L«á¤j¡A¤~¬O¥ýª¾¡A |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¦N10151329 |
µoªí®É¶¡:2024/2/23 ¤W¤È 09:35:26
²Ä 6556 ½g¦^À³
|
ÁÙ¥H¬°¤µ¦~·|ºCºC¤W¥h, µ²ªG¤S³oºØ¶^ªk ¤Ó§é¿i |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GªL®õ10030886 |
µoªí®É¶¡:2024/2/23 ¤W¤È 05:29:52
²Ä 6555 ½g¦^À³
|
¶ã©I«s«v¡I¡I¡I ªÑ»ù¤£µ¹¤O
³oºØ¶^ªk ¤Ó§é¿i¤H¤F |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2024/2/17 ¤U¤È 10:57:15
²Ä 6554 ½g¦^À³
|
¥h¦~²Ä¥|©u,¾÷ºc«ùªÑÁÙ¦³§ó¥©ªº¨Æ,¤U¶g¤À¾å. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2024/2/17 ¤U¤È 09:51:47
²Ä 6553 ½g¦^À³
|
·ç»È·s¼W«ùªÑ¨Ó¨ì16,917,600ªÑ ( ¸ê°T¦b Page2 ) whalewisdom.com/stock/asln ·ç»È¦X¨Ö·ç«H«áÅD¤É¥þ²y²Ä¤G¤j°]´IºÞ²z¾÷ºc ¼W¥[ ASLN «ùªÑ ¥²¦³¨ä±M·~§PÂ_ªº²z¥Ñ
112/12/31¤î «ùªÑ²Ä1¦WBVF ì«ùªÑ8,488,000 ªÑ ·s¼W«ùªÑ34,856,975ªÑ Á`p43,344,975ªÑ «ùªÑ²Ä2¦WK2 ì«ùªÑ5,293,226 ªÑ ·s¼W«ùªÑ17,174,449ªÑ Á`p22,467,675ªÑ «ùªÑ²Ä3¦W·ç»È ì«ùªÑ625,000 ªÑ ·s¼W«ùªÑ16,292,000ªÑ Á`p16,917,600ªÑ
Phase 2b Study of ASLAN004 in Adults With Moderate-to-Severe Atopic Dermatitis ¨ü¸Õ¨Ó¦Û¤£¦P°ê®a ¤£¦P¸~±Ú( ¬ü°ê ¥[®³¤j ¯Ã¦èÄõ ¿D¦{ ¦L«× ·s¥[©Y ªiÄõ) ( ¬ü¦{ ¿D¦{ ¨È¦{ ¼Ú¦{ )
CNTBªºCBP-201 ¤G´ÁÁ{§É ¬d¸ß ClinicalTrials.gov ¨ü¸Õ§½¦b¦Û¤v°ê®a ¦P¤@ºØ±Ú
®æ§½¤£¦P ¥ø¹Ï¤ß¤£¦P Àø®Ä»P¦w¥þ©Ê¤£¦P ¥@¬É¯Å¤jªÑªF«ùªÑ¤£¦P ---- »ùÈ·íµM¤£¦P
¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò ¦p¦³¿ù»~½Ð§ó¥¿ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2024/2/17 ¤U¤È 05:04:41
²Ä 6552 ½g¦^À³
|
¦³¾÷ºc½æ¥X¡A·íµM´N¦³¾÷ºc¶R¤J¡C (¦ý´N¬O³o»ò¥©¦X) ºI¦Ü112/12/31´N¦³6®a¾÷ºc¶R¦b¦P¤@»ù¦ì
1. UBS GROUP AG¶R¶i625,000ªÑ 2. SHAY CAPITAL LLC¶R¶i400,000ªÑ 3. LANDSCAPE CAPITAL MANAGEMENT, L.L.C.¶R¶i83,259ªÑ 4. XTX TOPCO LTD¶R¶i27,666ªÑ 5. JANE STREET GROUP, LLC¶R¶i23,093ªÑ 6. ONYX BRIDGE WEALTH GROUP LLC¶R¶i22,727ªÑ
¤Wz6®a³£¬O²Ä¤@¦¸¶R¶i¡A¶R¶iªº»ù¦ì³£¬O1.2¤¸/ªÑ¡A³o»ò¥© (¦U¦ì¥i¥H¥h¬d¥L̪ºt³d¤H) ¨È·à±d¤£¬O¼öªùªÑ§a(¼öªùªÑ§Ú´N¬Û«H¬O¥©¦X) (´N¥ý¥H¤º½u¸ÑŪ)
¨ä¤¤·ç»È113/2/6¦A¥[½X¶R¶i16,292,600ªÑ
¸ò¦U¦ì¤À¨É³oÓ´¡¦± (§ë¸ê·ÀI½Ð¦Û¦æµû¦ô)
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gªoºj·Æ±¼10153108 |
µoªí®É¶¡:2024/2/17 ¤U¤È 03:17:52
²Ä 6551 ½g¦^À³
|
1.Dupilumabªº¦¨ÁZ¦³¥Ø¦@¸@¡A§âEblasakimab®³¨Ó¤ñ¸û¡A·íµM¬Ý°_¨Ó«e³~¤@ ¤ù¥ú©ú¡A¦pªG¯uªº¯à¸òDupilumab¤À®x§Ü§¡A¨º¦Ñ·à¤ÍÌ´N¦³ºÖ¤F¡A¦ý¤ñ°_ ¸òDupilumab¬Û¤ñ¡AASLAN¥Ø«eªºª¬ªp§ÚˬOı±o¸òCNTB¤ñ¸û¬Ûªñ¡A¤@¼Ë¬O ¬D¾ÔDupilumab¡A¦ý¤G´Á¸ÕÅçµ²ªG³£¦]¦w¼¢¾¯²Õ¤ÏÀ³²v¤]°ª¡A»P¹êÅç²ÕÀø®Ä ®t²§¨S¦³·Q¹³¤¤¤j¡A¾ÉPªÑ»ù§C°g¤£®¶¡AASLAN¸òCNTB¤]³£ÁnºÙ¦¸±Ú¸s¤ÀªR ªí¥ÜAD¸û¬°ÄY«ªÌ¡A¦w¼¢¾¯²Õ»P¹êÅç²Õ®t¶Z§¡¦³®Ä´£°ª¡ACNTBªºCBP-201±q 2022¦~¤G´Á¸Ñª¼µ²§ô¨ì²{¦b³£¥¼Äw¨ì¤T´Á¸êª÷¡A2023¦~11¤ëµo¥¬CBP-201©µ ¦ù¨ì52¶gªºªvÀøµ²ªG¡A즳16¶g¦³®Ä±wªÌ«ùÄòªvÀø¨ì52¶g«á¬ù¦³8.9¦¨¯àºû «ùÀø®Ä¡AµM«áñq±ÂÅv¦X¬ù¡A¦¬¨ú«eª÷¤j¬ùUSD2100¸U¡AÁ`±ÂÅvª÷¬ù USD1.25»õ¡A²{¦bAD¤T´Á¤]¬OÄw¤£¨ì¸êª÷¿ð¿ðµLªk¶}©l¡A¶ZÂ÷¸Ñª¼¦Ü¤µ¤w ¹L1¦~¥H¤W¡A¥u¯à´Âý³Ý¥tÅP³~®|¡A¤£Ä±±o³o¸òASLAN¤ñ¸û±µªñ?¶Z¸Ñª¼¦Ü¤µ ¤]¤w¹L¤F¤j¥b¦~¡ATREK-DX¹wp¦³µ²ªG¤]¬O2024¦~©³¤F.......
2.³o¤@ªi°h³õªºªÑªFÌ°£¤FTANG¡A²H°¨¿üµ¥µ¥¸û¦´ÁªºªÑªF¤]³£¤@°_ºM¤F ¡AÁöµM«ùªÑ³°Äò¦³ªk¤H±µ¤â¡A¦ý©Ò¿×ªº¤º½uÃø¹D¨¬°³Ì¤jªÑªFªºTANG¤]¤£ ª¾¹D¡A¼ÝµM¨MµM¥X°â¤j¶q«ùªÑ?³o§Ú«ù«O¯dºA«×¡A¤£¹L¦³¤HªÖ±µªº½T¤]¬O¦n ¨Æ¤@¼Î¡C
3.²{¦b°ò¥»¤W´N¬O¤@½¤GÀü²´¡A¼ÖÆ[ªÌı±o¤ñªÓDupilumab¡A´dÆ[ªÌı±o¸ò CBP-201®t¤£¤F¦h¤Ö¡AÁ`¤§°µ¦n¤ß²z·Ç³Æ§Y¥i¡AŤ§§Ú©¯¡A¿é¤§§Ú©R¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2024/2/17 ¤W¤È 10:02:52
²Ä 6550 ½g¦^À³
|
(·s¼W§ùÁת¢2023¦~¾P°âÃB)
¨È·à±d¨ÖÁʪ÷ÃBºâªk¦p¤U¡G °Ñ¦Ò·|û¡G¤Ñ©R¤j10141925 µoªí®É¶¡:2023/6/22 ¤U¤È 08:20:52 ASLAN004 ¥þ²y±ÂÅv+§Q¼í¤§¹w¦ô ¤é¥»¦û¥þ²y¾P°â¬ù5%.,±ÂÅvª÷1.385 »õ¬ü¤¸. ¥þ²y±ÂÅvª÷¦ô 1.385/5%=27.7»õ¬ü¤¸ 27.7-7.8(CSL¦¨¥»)=19.9»õ¬ü¤¸(¦©°£CSL¦¨¥»¤§§Q¯q) ASLN004 ¤§»ùÈ:¥þ²y±ÂÅvª÷ 19.9»õ¬ü¤¸ + 10% ¾P°â¤À¼í ¾P°â¤À¼í: 20%- 10%=10%(¦©°£CSL¦¨¥»¤§§Q¯q) ¥H¤W¥¼§t003°Ó¥Î«á¤§¨ÖÁÊ»ù¡C ¥[003°Ó¥Î«á¤§¨ÖÁÊ»ù¦ô¬ù¬üª÷25»õ¤¸³Q¨ÖÁÊ(©¹«áªº20¦~¡C¨C¤@¦~ªº10% ¾P°â¤À¼í¥¼ºâ¶i¥h)¡C
¥tÃö©ó¾P°â¤À¼í¨C¦~10%¡G ¥H§ùÁת¢2023¦~Á`¾P°âÃB115.9»õpºâ¡A ·sÃĤò§Q¥H8¦¨pºâ¡G115.9*0.8=92.72»õ¬ü¤¸¬OÁÉ¿Õµá³æ³æ2023¦~½æ§ùÁת¢²bÁÈÈ 115.9*10%=11.59»õ¬ü¤¸´N¬O·í(¥h)¦~¾P°â¤À¼í10%ªºÈ
§ùÁת¢¦~«×¾P¦¬ª÷ÃB¦p¤U¡G(·PÁ¤ѩR¤j´£¨Ñ) 2017¦~/2.279»õ¬ü¤¸ 2018¦~/9.22»õ¬ü¤¸ 2019¦~/23.156»õ¬ü¤¸ 2020¦~/40.448»õ¬ü¤¸ 2021¦~/61.988»õ¬ü¤¸ 2022¦~/86.811»õ¬ü¤¸ 2023¦~/115.9»õ¬ü¤¸ §ùÁת¢¦Ü2023¦~¤î¦@¾P°â339.8»õ¬ü¤¸ ¾P°â¤À¼í10%=33.98»õ¬ü¤¸(´«ºâ¾P°â¤À¼í15¦~§Y¶W¹L150»õ)( Eblasakimab¦p¥xÁÞ¤j©Ò»¡ªGµM¬O¶W¯Å¤jÃÄ)
ASLN ¦¨¾À¯È¾÷²v¬Û·í§C¡D ¦ý¶W°ªÀø®Ä¤£¥i¯à¡D ¥unÀø®Ä¡B¥ÎÃÄÀW²vĹ¹L§ùÁת¢§Y¥i
Eblasakimab¦b©¹«á20¦~ªº¾P°â¹w¦ôȤ@©w°Ñ¦Ò§ùÁת¢q©w ³o20¦~ªº¾P°â¤À¼í¥[Á`(¾P°â¤À¼í¨C¦~10%)¤]·|¨Ö¤J¨È·à±d³Q¨Öª÷ÃB¸Ì±¡C
(¥H¤W³¡¤À¯ÂÄÝÁr´ú¡BÁr´ú¦p¦³¹p¦P¡B¹êÄÝ¥©¦X) ¥H¤W½Ð«ü¥¿ (§ë¸ê¦³·ÀI¡B½Ð¦Ût¬ÕÁ«)
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GªL®õ10030886 |
µoªí®É¶¡:2024/2/16 ¤U¤È 05:09:19
²Ä 6549 ½g¦^À³
|
·PÁ¸ó±i¤j
¦pªG¬O³o¼Ëªº¸Ü
Aslan ÁÙ¦³À¸
§Æ±æ ±µ¤U¨Ó ¦nÀ¸³s¥x |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2024/2/16 ¤U¤È 04:38:48
²Ä 6548 ½g¦^À³
|
½Ð¬d¥H¤Uºô¯¸ whalewisdom.com/stock/asln (½Ð°O¤U¨Ó¡A113/5/15ÁÙ·|¦A¬d¤@¦¸)
112/12/31¤î «ùªÑ²Ä1¦WBVF ·s¼W«ùªÑ34,856,975ªÑ¨Ó¨ì43,344,975ªÑ «ùªÑ²Ä2¦WK2 ·s¼W«ùªÑ17,174,449ªÑ¨Ó¨ì22,467,675ªÑ «ùªÑ²Ä3¦W·ç»È ·s¼W«ùªÑ16,292,600ªÑ¨Ó¨ì16,917,600ªÑ
𤽥q´î«ù39,020,205ªÑ³Ñ6,134,975ªÑ ð¸ê¥»¥X²M1,901,552ªÑ
(ªoºj·Æ±¼¤j¤j¦b2024/1/3 ¤W¤È 10:36¦³µoªí¤F) (§Ú¬Q¤Ñ¥u·Q½T»{¬y¦V¡A¦]¬°¶q¤j¡An¦³¤H¥i¥H±µ¤U¨Ó¡Cì¨Ó¬OBVF¡BK2±µ¨«)
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GªL®õ10030886 |
µoªí®É¶¡:2024/2/16 ¤U¤È 02:33:39
²Ä 6547 ½g¦^À³
|
¬O¦b»¡¹Ú¸Ü¶Ü¡H
½Ð°Ý¸ó±i¤j ðªºÄw½X³Q³o¨â®a±µ¨«ªº¸ê®Æ þ¸Ì§ä±o¨ì¡H |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2024/2/16 ¤U¤È 12:40:16
²Ä 6546 ½g¦^À³
|
¬Q±ß(2/15)ªº½L§ó©úÅã ¨C¹j¬ù10¤ÀÄÁ¥æ©ö900~1000ªÑ ¥D¤O¦b¸Ì±
¥t 𤽥qªºÄw½X¥þ³QBVF¡BK2±µ¨« BVF¡BK2¬O¥h¦~2¤ëªº¶U´Ú»È¦æ (ª¾¹D¨È·à±d·|Ë¡AÁÙ¶U´Úµ¹¥¦¡AÁÙ±µ¥¦ªºªÑ²¼???) (ÁÙ´ÚÁÙ®i©µ¨ì114¦~1¤ë1¤é)
¥t ¤µ¦~2/1~2/13¤Î2/15ªº½L¤¤¥æ©ö¹ï¶H ¦]Äݤµ¦~Q1¡An¤µ¦~5¤ë15¤é¤~·|ª¾¹D ½L¤¤¥æ©ö¹ï¶H¤~¬O«ÂI ¦]¨È·à±d³Q¨Öªº¤º³¡¸ê°T¤w¸g©ú®Ô ³o´N¬O¤º½u
5¤ë15¤é«e³Q¨Ö¾÷·|¤j ³Q¨Ö«á µ¥¨ì5/15§ÚÌ´Nª¾¹D¤µ¦~2/1~2/13¤Î2/15ªº½L¤¤¥æ©ö¹ï¶H¬O½Ö¤F ³o´N¬O¤º½u
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2024/2/14 ¤U¤È 11:06:17
²Ä 6545 ½g¦^À³
|
2/1~2/13(¬Q¤Ñ),¨C¤ÀÄÁ³£¦³¦¨¥æ°O¿ý,¬O¤£¥¿±`ªº¡C¥u¯àÃÒ©ú¦³¥D¤O¦bùر¡C
²{¦b(2/14), 10:30(¶}½L)¦¨¥æ134ªÑ 10:42¦¨¥æ6000ªÑ 10:45¦¨¥æ100ªÑ 10:46~11:00¨S¦¨¥æ¶q¡C ¤µ¤Ñ½L¶Õ«ì´_¥¿±`(¨S¦³¨C¤ÀÄÁ³£¦³¦¨¥æ¶q)¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2024/2/9 ¤U¤È 10:44:14
²Ä 6544 ½g¦^À³
|
´N½u½×½u ªñ´Á©³³¡¥X¶q¡A¶}§C¨«°ª¦h¤é¯dªø¤U¼v½u¡A ¤ë½u¦¤w¬ð¯}©u½u½u§e²{¤¤´Á¦hÀY±Æ¦C¡A¤µ¤é¦A¶}§C¨«°ª ¤Q¤é½u±N¬ð¯}¤ë½u¡Aµu´Á¦hÀY±Æ¦C§Î¦¨¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2024/2/9 ¤W¤È 10:06:18
²Ä 6543 ½g¦^À³
|
·Pı¦³¤H³s3¤Ñ¦b0.55ªþªñ¦Y³f¡A
ªÑ»ù¤w¸gÄê«Ü¦h¦~¤F¡A
§Æ±æ¯àÀs¦~·s¦~·s®ð¶H¡A
¯¬ºÖ¤j®a |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥d¦b¥b¤s¸y10153098 |
µoªí®É¶¡:2024/2/8 ¤W¤È 12:14:35
²Ä 6542 ½g¦^À³
|
¤S½M¤SÄê §j³£¤£·| ªÑ»ù¤]¼µ¤£°_¨Ó=_= |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gblessyiche10143957 |
µoªí®É¶¡:2024/1/19 ¤U¤È 11:58:58
²Ä 6541 ½g¦^À³
|
½Ð°ÝFirstrade «ç»ò²{¦b¤£¯à¶R¡A¥u¯à½æ°Ú¡H ¥X²{¡¨¡¨Illiquid,Opening Position Trades Not Accepted ¡¨ »Ýnñ¸p¤°»ò¸ê®Æ¶Ü |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2024/1/17 ¤W¤È 11:39:26
²Ä 6540 ½g¦^À³
|
¬Q¤Ñ©M¥h¦~7¤ë6¤éII´Á¸Ñª¼«®À¤@¼Ë¡A
¤U¶^ªñ4¦¨¡A¤S±N¶}±Òªø´Á¤U¶^ÁͶաA
½Ð°Ý¦U¦ì¤j¤j¡A
¹wq1¤ë24¤éªÑªF·|±ÂÅv¤½¥q¸ê¥»¼W¥[¡A
¬O¤£¬O¦³¤H¤£·Q°Ñ¥[¥ý¨«¡A©Î¬Oµu´ÁÀò§Q¤Fµ²¡A
·Pı³oªÑ¦h¨a¦hÃø¡A±q¥¼À°ªÑªF¿Ñ¤@ÂIÂIçħQ¡A
¤Ñ©R¤j±zªº¬Ýªk©O
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2024/1/16 ¤U¤È 09:14:11
²Ä 6539 ½g¦^À³
|
·íAslan pharmaceutical ADR ¹L¤F1¬ü¤¸¡A¤U¥«ºÃ¼{¸Ñ°£¡A´N¬O²¢»e»ùªº¶}©l¡A°²¦p§ë¸ê¾÷ºcµû¦ô¤½¥q¦³16¬ü¤¸¡A¶V±ß¦^¸É²¢»e«×¶V§C,¶V¦¦^¸É²¢»e«×¶V°ª¡A§C»ù´N¬O³Ì¤jªº»¤¦]¡C ¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò ²`¤Jµû¦ô ¦A°µ¨Mµ¦
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥d¦b¥b¤s¸y10153098 |
µoªí®É¶¡:2024/1/12 ¤U¤È 11:43:30
²Ä 6538 ½g¦^À³
|
¤w¸g0.86 §CÂI¹L¤F¶R¤£¨ì²¢²¢»ù¤F |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2024/1/12 ¤U¤È 09:04:41
²Ä 6537 ½g¦^À³
|
³¡¥÷§ë¸ê¾÷ºc°ªÂI½æ¥X«ùªÑ,À£§CÀ~¥XÄw½X,¥Ø«e²{ª÷º¡º¡¥i¥H±q§CÂI¦^¸É,¤]¥i¥H»{ªÑÂX¤j«ùªÑ¤ñ²v «ç»ò¤U¨Ó«ç»ò¤W¥h, «ùªÑ¦¨¥»°ª¨S¦³½æ¥X©Î¤w½æ¥X¦³»ù®t, ¦pªG¦Û¤vµû¦ô¥Ø«e¤½¥q¬ãµoÃĪ«¦³¼ç¤O¡A ¨S¦³·Q¹³ªº¨º»ò®t,±©¤@ªº«Øij°Ê§@´N¬O¶q¤O¦Ó¬°ºÉ§Ö¦^¸É,¤p¿ú¤jÅu¥,§Ö³t°§C¦¨¥»
¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò |
|
¡@ |
¦^°Q½×°Ï1¶ |
³Ì·s100«h¦^ÂÐ >> |